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Abstract
Early detection of breast cancer is critical for improved survival. Currently, breast
abnormalities are diagnosed based on a histopathological evaluation of tissue removed during
core needle biopsy. Microcalcifications are used as targets to position biopsy devices, as they
may indicate the presence of malignancy. Despite stereotactic guidance, needle biopsy fails to
retrieve target microcalcifications in up to 15% of patients. Optical techniques may help
clinicians accurately diagnose and treat patients by providing important diagnostic
information in real time in a minimally invasive manner. This thesis describes the results of
several studies we performed to evaluate the potential of Raman, reflectance, and intrinsic
fluorescence spectroscopy to provide biochemical and morphological information for
discriminating breast lesions. Each modality was evaluated individually, as well as in
combination, using a technique known as multimodal spectroscopy (MMS). For the first part
of this project we conducted a clinical study in which spectra were acquired from excised
tissue in 99 patients and physically meaningful parameters were extracted by modeling the
data. The goals of the study were as follows: 1) To prospectively validate previously
developed diagnostic algorithms on the data from these patients; 2) To develop a new
algorithm to evaluate additional histopathology diagnoses. Diffuse reflectance (DRS) spectra
were modeled using diffusion theory and provided information about tissue absorbers and
scatterers. Intrinsic fluorescence (IFS) spectra were extracted from the combined fluorescence
and DRS spectra and analyzed using multivariate curve resolution. Raman spectroscopy data
were fit using a linear combination of Raman active components (e.g. collagen, calcium,
adipose) found in breast tissue. Prospective validation of Raman spectroscopy resulted in
sensitivity and specificity and negative predictive value (NPV) of 78%, 98%, and 98%,
respectively. An MMS system was developed to evaluate the benefit of combining
information from all three spectroscopic modalities. We found that using new 3D Raman
algorithm we could discriminate among 6 histopathology categories as compared to 4
categories previously diagnosed with Raman spectroscopy. For the second part of this
project, we designed and developed a portable, miniature Raman clinical spectroscopy system
to evaluate the potential of spectroscopy to guide the retrieval of microcalcifications during
core needle biopsies. We focused specifically on the use of Raman spectroscopy for this
application, as it is particularly sensitive to calcium-containing minerals. The system employs
a side-viewing Raman probe that can be used in conjunction with commercial stereotactic
needle biopsy devices. Prior to core needle excision, the Raman probe was inserted into the
core needle biopsy device and spectra were acquired and analyzed in real time (<Is).
The results from our work indicate that spectroscopy has the potential to accurately diagnose
breast lesions and enable targeted biopsies of diseased tissue and retrieval of
microcalcifications.
Thesis supervisor: Michael S. Feld
Title: Professor of Physics and Director of G. R. Harrison Spectroscopy Laboratory
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CHAPTER 1: Introduction
CHAPTER 1
Introduction
The work in this thesis describes the development and evaluation of Raman
spectroscopy, diffuse reflectance spectroscopy and intrinsic fluorescence
spectroscopy, as well as combination of the three methods, as techniques for the
diagnosis of breast cancer. Here we introduce the motivation and the overall goal of
the work that was done in this dissertation. This chapter describes the goals of this
thesis as well as provides information about thesis content.
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CHAPTER 1: Introduction
1.1 Motivation
1.1.1 Mortality and survival
Breast cancer is the leading cause of non-preventable cancer death among
American women. More than 175,000 new cases are diagnosed each year, and more
than 40,000 women die annually from breast malignancy. An American woman has a
one in eight (12.3%) chance of developing breast cancer during her lifetime
[American Cancer Society Breast Cancer Facts and Figures 2007-2008]. However,
numerous studies have shown that survival from breast cancer can be improved
through early detection and intervention [1].
1.1.2 Current diagnostic procedures and their challenges
The current management of breast cancer involves periodic screening
(either by self palpation or mammography) followed by a diagnostic procedure (core
needle biopsy or surgical biopsy) in the event that an abnormality is detected.
1.1.2.1 Mammography
Women over the age of 40 should have a clinical breast exam and
mammogram annually. Mammography is the current gold standard for screening for
non-palpable, highly curable breast cancer [2, 3]. This X-ray technique images tissue
based on differences in tissue density either with or without the aid of a contrast
agent. This technique is widely used for anatomic (structural) imaging, but provides
no biochemical information. Because anatomic changes do not uniquely correlate
with breast cancer, abnormalities identified with mammography must be further
investigated with biopsy. Therefore, while valuable for screening, it is not diagnostic,
and a definitive diagnosis must be rendered by pathologic examination of a biopsied
tissue specimen. Thus each year, a large number of breast biopsies are performed on
benign lesions. Only 10 to 25 percent of suspicious lesions found during
mammography are diagnosed as malignant upon biopsy [4]. Independent of the
biopsy procedure employed, the biopsy and wait for diagnosis is a stressful
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experience, both physically and mentally, even for those who are not diagnosed with
breast cancer.
1.1.2.2 Core needle biopsy
If the radiologist identifies an abnormality during mammography, the patient
is then scheduled to undergo breast biopsy in order to diagnose the suspicious lesion.
Diagnostic breast biopsy is performed by biopsy procedures such as stereotactic and
ultrasound guided core needle biopsy [5]. In order to correctly diagnose a suspicious
lesion, five to ten cores of different sizes (depending on the choice of needle devices)
are extracted during biopsy. Unfortunately, a significant percentage of core needle
biopsies are non-diagnostic and require follow up surgical biopsy [6]. Therefore,
there is a clinical need for improved core needle biopsy procedures to minimize
patient trauma and expedite diagnosis of the suspicious lesion.
1.1.2.3 Surgical biopsy
Breast cancer surgery has changed dramatically over the past several
decades, and continues to evolve. With the emergence of partial mastectomy (also
known as lumpectomy or breast conservation surgery), during which a tumor is
surgically removed, women may now preserve their breast without compromising
survival [7]. To ensure that all malignant tissue is removed, a small margin of non-
cancerous breast tissue surrounding the lesion is excised. In order to verify that the
surgeon has removed the entire malignant lesion, the margins are examined by a
pathologist [8-11]. Negative resection margins, typically defined as the absence of
either invasive or intraductal cancer at the tissue margin - within 1 -2 mm from the
edge of the tumor, are associated with lower rates of local recurrence following
partial mastectomy [12-16]. Positive or unknown margins usually prompt re-excision
surgery, since they are associated with a higher risk of local recurrence, even when
radiation therapy is administered to the surgical cavity post-operatively [7, 17].
Determining the status of the margins based on a histopathological assessment can
take several hours or even longer. Furthermore, in the case of positive margins, the
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patient has to undergo a second surgery. In clinical practice, as many as 20-60% of
patients undergoing partial mastectomy require a second surgical procedure due to
positive margins (incomplete cancer resection) [18]. The complete diagnostic work
up, from start to finish, may take weeks and include multiple biopsies. Thus, there is a
clinical need for techniques that can accurately assess margins intra-operatively and
provide real-time feedback to enable immediate re-excision of positive margins.
Reducing the number of unnecessary biopsies and re-excision surgeries will
significantly lower the cost associated with breast cancer diagnosis and treatment.
1.2 Thesis goals
Spectroscopic techniques can noninvasively provide information about tissue
composition, such as the presence and amount of microcalcification, collagen, fat,
and blood. Therefore, spectroscopy has the potential to provide clinically
relevant information for diagnosing breast lesions. The goal of this thesis is to
develop a real-time clinical diagnostic tool based on reflectance, fluorescence and
Raman spectroscopy, as well as combination of these techniques, which accurately
classifies breast lesions. The specific aims are as follows:
1) To perform clinical studies to evaluate the diagnostic capabilities of individual
modalities (listed above) and the combination of all three - multimodal spectroscopy
(MMS);
2) To design and develop a new MMS system (instrument and probe);
3) To evaluate the performance of the MMS system in identifying breast lesions;
4) To prospectively evaluate Raman and DRS/IFS diagnostic algorithms;
5) To expand and improve the capabilities of MMS-based diagnostic algorithms to
diagnose additional benign and malignant lesions, discriminate between tumor
grades, identify calcifications and correlate with biomarkers; and
6) To design, and test a side-viewing Raman probe that can be used during core
needle biopsies.
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1.3 Thesis overview
This dissertation is organized as follows:
Chapter 2: This chapter provides the necessary background information on breast
anatomy and breast cancer.
Chapter 3: This chapter describes different optical approaches that are currently being
investigated to detect breast cancer. It provides extensive background information on
the spectroscopic modalities and instrumentation that were used during the course of
the work presented in this thesis.
Chapter 4: This chapter focuses on the application of Raman spectroscopy to
diagnose breast lesions during ex vivo and in vivo clinical studies. It describes the
development of a Raman diagnostic algorithm, as well as the prospective application
of the algorithm. It concludes with the application of this spectroscopic-based
diagnostic technique to assess the status of surgical margins. This final study is
significant in that it is the first ever in vivo study of Raman spectroscopy for this
application.
Chapter 5: This chapter gives an overview of the clinical ex vivo work that was done
using diffuse reflectance and intrinsic fluorescence spectroscopy. After presenting
these results, we describe the motivation for combining the three spectroscopic
modalities (diffuse reflectance, intrinsic fluorescence and Raman spectroscopy).
Chapter 6: In this chapter, we give a detailed description of the MMS clinical
instrument and the probe, as well as explain changes in the modeling of the data.
Chapter 7: The results of an ex vivo clinical study performed using the MMS
instrument are presented in this chapter. Prospective validation of a previously
developed algorithm and the development of a new algorithm is also described.
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Chapter 8: In this chapter we describe the results of a pilot feasibility study in which
we use the diagnostic algorithm developed using the MMS instrument to assess
malignancy grade. We also correlate the spectroscopic findings with the results of
molecular biomarkers used to assess the disease status of the tissue.
Chapter 9: In this chapter, we begin by providing the motivation for switching from
the front-viewing probe design to a side-viewing probe design, for clinical studies in
which Raman spectroscopy is used to guide the acquisition of tissue samples during
core needle biopsies. We then summarize several probe designs that are under
consideration for this application. Finally we include the results of the proof-of-
principle ex vivo study, during which we used the first prototype of Raman side-
viewing probe in conjunction with a commercial vacuum- assisted biopsy device.
Chapter 10: In this final chapter we summarize the findings and conclusions of our
investigations and discuss future directions for the project. We conclude with the
summary of all accomplishments of this dissertation.
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Breast and breast pathology
The development of new methodologies to diagnose breast lesions must be based on a
clear understanding of both the disease and the current medical procedures. This
insures that the achieved results will provide relevant information for patients and
clinicians and can be easily integrated into the clinical setting as a new standard. This
chapter contains an overview of the macroscopic and microscopic structure of the
breast. Both breast anatomy and pathology are described, including details on breast
cancer staging and prognosis. Finally, a description of the current screening and
treatment for breast cancer is provided, including the strengths and limitations of each
method. This chapter provides the necessary foundation for interpreting the
spectroscopic data described in the later chapters. Knowledge of the current biopsy
and surgery procedures - areas that will benefit from the spectroscopic approach - is
essential for designing studies in which spectroscopic approaches will be applied.
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2.1 Breast anatomy
Development of the human breast is a process that starts in the embryo. Full
breast differentiation is achieved with pregnancy and lactation. Breast development
from puberty to adulthood can be defined by volume, number of structures present in
the mammary gland, and the degree of differentiation of the individual structures. The
female breast lies on top of the major pectoralis muscles between the second and sixth
rib of the chest. Chest muscles located under the breast include the major and minor
pectoralis, the serratus magnus, and the rectus abdominus. The main functional
purpose of the adult female breast is milk production and secretion [1]. The female
breast is composed of six to ten major duct systems, each of which is subdivided into
lobules. Successive branching of the large ducts leads to the terminal ducts. The
lobules are arranged around ducts that direct milk to the nipples. Each breast contains
15 to 20 lobes arranged in a
circular fashion. The nipple and chestwal
areola are covered by squamous pectoralis
epithelium and are located in the
center of the breast. The stroma, lobules
which accounts for the majority
of the breast volume in the non-
lactating state, is composed of
adipose (fat) and fibrous
connective tissue. Figure 2.1
(modified from areola
http://commons.wikimedia.org/w adipose
iki/File:Breastanatomynormal_ skssue
scheme.png) shows a schematic Figure 2.1. Diagram of anatomic sites of breast
of the female breast.
The breast's blood supply is derived from the internal mammary artery. Breast
tissue is drained by lymphatic vessels that lead to axillary nodes and internal
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mammary nodes. Most lymphatic vessels in the breast drain into a network of lymph
nodes located around the breast's edges, in the underarm, and near the collarbone.
Axillary lymph nodes are often the first site of breast cancer metastasis. Because the
long thoracic nerve innervates the muscles that helps move the upper arm, surgeons
must be careful not to injure this nerve when operating near the axillary lymph nodes.
2.1.1 Normal breast
As previously mentioned, breast tissue is composed of adipose tissue, fibrous
tissue and glands. A microscopic image of a thin (5 um) section of normal breast
tissue stained with hematoxylin and eosin (H&E) is depicted in Fig. 2.2. The basic
dye hematoxylin, stains basophilic structures (ribosomes, cell nucleus) with a blue-
purple hue, while the alcohol-based
acidic eosin Y, colors acidophilic
structures (cytoplasm, fibrous tissue)
bright pink. Fig. 2.2 clearly shows
ducts and lobules that are lined with
glandular epithelium. Adipose tissue
can be seen as clear spaces, as fat is
washed away during the tissue
processing. The fatty tissue contains Figure 2.2. H&E slide of normal breast
cells, adipocytes, which harbor
copious amounts of cytoplasmic fat. The fibrous tissue is mainly composed of
collagen and a small amount of glycosaminoglycans. The stroma also contains
fibroblasts, cells that synthesize the extracellular matrix and collagen, and blood
vessels [2]. The glandular tissue is comprised of lobes connected to ducts that carry
milk to the nipple. The lobular units and the ducts are separated from the stroma by a
basement membrane, which is composed of collagen, predominantly type IV. The
basement membrane, which follows the contour of skin, ducts, and ductules, serves as
a scaffold for regeneration of the epithelium and influences cell proliferation and
growth. Fibrous connective tissue lies between the breast tissue and the skin and
separates breast tissue from the chest muscles [3].
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2.1.2 Benign lesions
Figure 2.3 shows the
typical distribution of findings
in women seeking evaluation
of breast lumps (modified from
[1]). Most of the suspected
breast lesions are found to be
benign upon biopsy. About
66% of all breast lesions are
diagnosed as benign lesions, Figure 2.3. Distribution of findings in women
seeking evaluation of breast lumps.
predominately fibrocystic
change (FCC) and 12% as fibroadenoma. It is important to note that during screening
procedures a large portion (30%) of women are noted as having irregularities which
are actually due to the normal variations in breast tissue.
Based on the degree of cellular proliferation, benign breast lesions can be
classified as either non-proliferative or proliferative lesions. Non-proliferative lesions,
such as FCC, do not increase a woman's risk for developing breast cancer.
Fibroadenoma, on another hand, modestly increases the risk of developing breast
cancer. Because of the differences in
the risk for breast cancer, it is
necessary to distinguish among
different types of benign lesions as
the treatment for them is different.
FCC is common in
adolescents as well as 50% of women
of reproductive age. Patients with
FCC can palpate lumps, which are Figure 2.4. H&E stain of fibrocystic change.
generally found in the upper outer quadrants of the breast. FCC can manifest as:
fibrosis, formation of fibrous tissue; adenosis, increase in the numbers of ductules; or
cyst formation, dilation of ducts and lobules by semi-transparent fluid. There is
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considerable variation in the degree to which each of these changes occur and the
precise change or combination of changes that can manifest. Cysts are more frequent
in women between the ages of 30 and 40. An H&E stained tissue specimen with FCC
is shown in Fig. 2.4.
Fibroadenomas, the second most
common benign breast lesions, are
characterized by the presence of
glandular tissue in addition to fibrous
tissue as depicted on Fig. 2.5. It can
occur at any age, but is most common in
women under 30 years of age. The lesion
is well-defined and mobile. Most Figure 2.5. H&E stain of fibroadenoma
fibroadenomas are 2-3cm in size. Fibroadenomas show an accumulation of collagen
due to fibroblast proliferation, which results in expansion of the stroma. Therefore,
fibroadenomas often grow rapidly resulting in significant morbidity unless excised
[4]. For this reason, it is important to evaluate the tissue surrounding fibroadenomas
to determine the extent of disease and determine the appropriate treatment.
There are other benign conditions, such as fat necrosis, and intraductal
papilloma, which are less common. Our spectroscopic work will focus on identifying
the most common benign and malignant lesions, thus descriptions of such lesions are
beyond the scope of this dissertation.
2.1.3 Malignant lesions
The incidence of breast carcinoma increases with age, with 85% of cases
arising in women older than 30 years. Cancer is characterized by abnormal cell
proliferation as well as abnormal maturation of cells. Genetic mutations often
override the normal cell signaling system allowing cellular proliferation and growth
to occur in the absence of any external stimulus. Thus, unlike normal cells, malignant
cells do not stop proliferating after they have doubled 50 or 60 times. They may also
become more resistant to the maturation of cells into a form adapted to a specific
function. A fully mature cell of any particular cell line is described as highly
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differentiated, whereas stem cells are relatively undifferentiated. Cancerous cells
exhibit variable states of differentiation and often fail to achieve a highly
differentiated state. Poorly differentiated cancers typically confer a worse prognosis.
Most malignant lesions (50%) occur in the upper outer quadrant of the breast.
Breast cancers commonly develop in glandular tissue, and thus are classified as
adenocarcinomas. The two major types of breast cancers, in situ and invasive
carcinoma, arise in ducts or lobules. In situ carcinoma is defined by the absence of
invasion of surrounding tissues (i.e. malignant cells are confined by the basement
membrane). Approximately 80% of all non-invasive cancers are classified as ductal
carcinoma in situ (DCIS), while 80% of all invasive cancers represent invasive ductal
carcinoma (IDC). It is now believed that many cases of low-grade DCIS and most of
the cases of high-grade DCIS progress to invasive carcinoma [5]. IDC by definition
spreads through the duct walls, and invades the surrounding breast tissue. These
findings once again emphasize the importance of accurate early diagnosis to ensure
successful treatment.
A gross and microscopic view of an IDC tissue specimen are shown in Fig 2.6.
Figure 2.6. Invasive ductal carcinoma. a) Gross and b) Histopathology slide
The central white area (Fig. 2.6A) of the tumor (arrow) shown in the gross
photograph is very hard and gritty because the neoplasm is producing a desmoplastic
(formation of fibrosis) reaction with significant collagen deposition. This is often
referred to as a "scirrhous" appearance. There is also focal dystrophic calcification
leading to the gritty areas. Lesions diagnosed as IDC exhibit significant hyperplasia
and often increased collagen content due to fibroblast proliferation in response to
stromal invasion by the malignant epithelial cells.
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Lobular carcinoma in situ (LCIS) consists of hyperplasia in the terminal breast
ducts and acini. The cells are small and round. Invasive lobular carcinoma (ILC)
accounts for 5-15 percent of invasive breast cancers. ILCs often have a diffusely
invasive pattern making tumors difficult to detect by either physical examination or
mammography.
2.1.4 Stages and grades of malignancy
Breast cancer has been divided into smaller groups in order to standardize
comparisons of results of various therapeutic modalities among clinics and guide
treatment. The American Joint Committee on Cancer Staging divides the clinical
stages as shown in Table 2.1 [5]:
Stage Description 5-yr
survival
Stage 0 Cancerous lesions diagnosed as DCIS or LCIS 92%
Stage I Invasive carcinoma with a size of 2 cm or less without nodal involvement and without 87%
any distant metastases
Stage IH Invasive cancerthat is less than 5 cm in size; involvement of movable axillary 75%
nodes; no metastases
Stage ill A lesion is greater than 5 cm in size; breast cancerwith fixed axillary nodes or that 46%
involves ipsilateral mammary lymph nodes; any breast cancer with skin involvement,
pectoral and chest wall fixation,edema, or clinical inflammatory carcinoma.
Stage IV Breast cancerwith distant metastases 13%
Table 2.1. Stages of breast cancer with the corresponding 5-year survival rate.
For a single breast lesion, older patients are more likely to have malignant
lesions. Tumor size is another important prognostic factor used in staging a lesion, as
a larger tumor increases the risk of axillary and systemic metastasis [6]. Although
rare, very small tumors are capable of distant metastasis. The course of treatment
depends on both the stage of the disease and the patient's preference. Treatment
options include surgery, radiation therapy, chemotherapy, hormone therapy, and
immunotherapy. If no axillary metastases are present, some patients may not receive
systemic therapy, depending on the characteristics of the tumor. Almost all women
with one to three positive axillary nodes receive some form of standard systemic
treatment, either hormonal therapy or chemotherapy. Women with four to nine
Page 37
CHAPTER 2: Breast and breast pathology
positive axillary nodes are eligible for high-dose chemotherapy. If ten or more nodes
are positive, patients are eligible for other experimental treatments [1].
The cell types themselves, along with the invasiveness of the cancer, help to
predict the natural history of the cancer. As a general rule, all histologic types of
invasive breast cancer (lobular, tubular, etc.) except ductal carcinoma tend to have a
favorable prognosis, with the exception of the so-called "inflammatory" variant of
invasive breast cancer, which has a worse prognosis [7]. Pathologists often assign a
histologic grade to a patient's cancerous breast tumor to help determine the patient's
prognosis. A completely uniform system of grading for breast cancers is not possible
because of the wide variety of histologic cell types. The Scarff-Bloom-Richardson
system [8, 9] is the most common type of cancer grading system used today and is
presented in Table 2.2.
Tubule Formation (% of carcinoma composed of tubular structures) Score
>75% 1
10-75% 2
less than 10% 3
Nuclear Pleomorphism Score
Small, uniform cells 1
Moderate increase in size and variation 2
Marked variation 3
Mitotic Count (per 10 high power fields) Score
Up to 7 1
8 to 14 2
15 or more 3
Table 2.2. The Scarff-Bloom-Richardson system
Histologic grading of all types of invasive breast cancer takes into account
growth pattern (tubule formation), nuclear pleomorphism and mitotic rate and is
usually expressed as grade I (well differentiated), grade II (moderately differentiated)
or grade III (poorly differentiated). The grade is calculated by adding the above
scores. Histologic grade has been shown to be a significant predictor of both survival
and likelihood of local recurrence and/or metastasis in breast cancers. It has also been
shown to correlate with prognosis [9].
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The grade correlates with survival as shown in Table 2.3 [1] :
Grade Description Score 5 yr. survival 7 yr. survival
Grade I Well-differentiated breast cells; cells generally appear 3,4,5 95% 90%(lowest) normal and are not growing rapidly
Grade 11 Moderately-differentiated breast cells; have 6,7 75% 63%G characteristics between Grade I and Grade 11 tumors
Grade IlIl Poorly differentiated breast cells; cells do not appear 8,9 50% 45%(highest) normal and tend to grow and spread more aggressively
Table 2.3. Correlation of grade and survival
2.2 Diagnostic Procedures: biopsy
Biopsy
Biopsy is the standard procedure for removing tissue from a potentially
abnormal site previously found by mammography, ultrasound, or by a physician for
further investigation and diagnosis. Traditionally, open excisional biopsies are
performed under general anesthesia in the operating room. A surgeon removes the
entire lesion, which can vary in size from a few centimeters to the entire breast
(mastectomy). After removal, the tissue is sectioned, stained, and examined by a
pathologist. Currently, a diagnosis by pathology is considered the gold standard for
diagnosing breast lesions.
Needle Biopsy
In recent years, less invasive techniques
than excisional biopsies for extracting
tissue specimens have been developed,
such as needle biopsy. Needle biopsies
are less intrusive than excisional biopsies
yet they provide the same diagnostic
accuracy. In the case of stereotactic core
needle biopsy a woman lies face down on
a special table, as shown in Fig. 2.7.
stereotactic table
Figure 2.7. Instrumentation used in
stereotactic biopsy procedures
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Breast lumps are localized with the aid of mammography and ultrasound. Needle
biopsies are performed in a radiologist's office on an outpatient basis under local
anesthesia. The entire procedure can be performed in just a few minutes.
Fine Needle Aspiration (FNA)
Needles of various sizes are used to perform fine needle aspiration. In cases
where the doctor wants to extract fluid from a cyst or cells from a solid lesion, they
utilize very small 20-25 gauge (0.89-0.51 mm) needles. The procedure is performed
under local anesthesia and requires a small incision. The procedure takes a few
minutes and typically leaves no scarring and does not require stitches. FNA is the
easiest method to provide pathologists with a breast biopsy. Due to the small size of
the needle used for FNA, the healing process will be quick, but as a result, the cell
sample is small and so evaluation of the suspicious lesion can be incomplete. A study
of fine needle aspiration found that 34 percent of patients were insufficiently sampled
and required repeat procedures.
Core Needle Biopsy
Core needle biopsies are similar to fine needle aspiration with the exception of
the larger size of the needle (14-18 gauge, 2.11-1.25 mm). Increasing the size of the
needle enables the doctor to obtain a larger sample that can lead to a better diagnostic
accuracy and decrease the need for repeat procedures. During the core biopsy breast
tissue is removed while under FNA only cells and fluids are removed.
2.3 Treatment
Surgical (excisional) biopsy
The combination of surgery with radiation and/or chemotherapy is the most
common treatment for breast cancer. Lumpectomy and mastectomy are both
commonly performed surgical procedures for removing (excision) breast tumors. A
lumpectomy is a partial mastectomy, in that only part of the breast is removed.
Depending on the case, lymph nodes may also be removed during this procedure. To
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make sure that all of the cancerous cells are excised from the patient, a small amount
of normal tissue surrounding the lesion (1-4mm, depending on policy of a particular
hospital) is also excised (margins). The removed tissue is inked with different colors
on all faces. Margins and the excised tissue samples are examined by a pathologist. If
cancer cells are found touching or near the inked regions, margins are called positive,
and it is assumed that malignant cells are likely still present in the patient. The color
of the ink identifies the region of the surgical cavity which still has malignant cells. In
cases where cancer cells are found at margins, the doctor recommends the patient
undergo a re-excision. Generally, lumpectomy procedures take 60 to 90 minutes.
Even in the case of negative margins (no cancerous cells have been found at margins)
women receive 6 to 7 weeks of radiation therapy in order to eliminate any potentially
remaining cancer cells.
There are three types of mastectomies: simple, modified radical and radical
mastectomies. A simple mastectomy is the procedure, during which the entire breast
tissue is removed, but axillary contents are undisturbed. The most common form of
mastectomy is a modified radical mastectomy, under which the entire breast is
removed along with the axillary contents, which is one reason for the limited range of
motion in the arm and shoulder on the operative side after the surgery. The radical
mastectomy procedure involves removing the entire breast, the axillary lymph nodes,
and the pectoralis major and minor muscles behind the breast. This type of
mastectomy is more disfiguring than a modified radical mastectomy. It is done in the
case of tumors involving the pectoralis major muscle. Mastectomies require general
anesthesia and must be done in the hospital. Patients have a choice of getting breast
reconstruction immediately following the mastectomy as a part of the same surgery,
or receiving it afterwards.
Radiation Therapy
Radiation therapy uses high-energy x-rays to destroy cancer cells. It is
performed externally or by radioactive "seeds" that are placed directly into the tumor
(brachytherapy). The patient may be asked to undergo radiation therapy in order to
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shrink the tumor before surgery (neoadjuvant therapy) or after surgery to destroy all
the cancerous cells remaining in the breast, underarm, or chest wall (adjuvant
therapy). Radiation therapy is performed in a hospital or outpatient center. Radiation
treatment lasts for 6 to 7 weeks, and each treatment session takes a few minutes.
Chemotherapy
Chemotherapy is a systemic treatment in which the patient takes a
combination of drugs that circulates through the entire body via the bloodstream. The
goal of this treatment is to slow tumor growth and destroy cancer cells. Drugs may be
given to a patient orally or injected into the venous system. Chemotherapy can be
used before and after the surgery similar to radiation therapy.
Hormone Therapy
The most effective and least toxic therapy currently available is endocrine
manipulations. Estrogen, a hormone produced by the ovaries, promotes the growth of
some breast cancers, particularly those with detectable amounts of estrogen receptor
protein. The goal of hormone therapy is to block the effect of estrogen or lower
estrogen levels. Tamoxifen is a SERM (selective estrogen receptor modulator). It is
the most prescribed SERM. It works by competing with estrogen to bind to estrogen
receptors in breast cancer cells. By blocking estrogen in the breast it helps slow the
growth and reproduction of breast cancer cells. Tamoxifen is used for the treatment of
ER (estrogen receptor) positive breast cancer in pre- and post-menopausal women. It
can be prescribed to a patient before and/or after biopsy, as well as to treat cancer that
has spread or regenerated after a previous treatment. It is also approved by the FDA
for the prevention of breast cancer in women at high risk of developing breast cancer.
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2.4 Summary
Breast cancer is the most common female cancer. The survival rate depends
on early diagnosis and effective treatment. Pathology is the gold standard for
diagnosis, but it is subject to human error, inconsistency, need of different stains and
time consuming. Owing to the heterogeneity and complexity of the breast, a good
understanding of breast pathology is necessary for the correct development of a
diagnostic algorithm.
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CHAPTER 3
Current technologies:
Imaging and spectroscopy
This chapter describes different imaging and spectroscopic technologies used in
clinical and research practice for identification of breast lesions. The first part of the
chapter is devoted to the imaging technologies, such as MRI, PET, DOT and OCT.
This part of the chapter is focused on the strengths and weaknesses of these
techniques. In the second part of the chapter, different spectroscopic modalities are
depicted. The main focus of this topic is Raman, diffuse reflectance and intrinsic
fluorescence spectroscopy. The theory behind these phenomena is introduced.
Previously developed instruments to obtain spectroscopic signal as well as calibration
and fitting data are provided in great details.
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3.1 Introduction
The history of light application for diagnosing breast lesions can be traced to 1929,
when Cutler applied light for monitoring status of breast lesions [1].
3.2 Strengths and weaknesses
3.2.1 MRI
Magnetic resonance imaging (MRI) is an imaging technique that uses radio
waves to induce spin flips of protons, which are part of water molecules, while a
person is placed inside a high magnetic field. By applying a spatial field gradient,
MRI provides information about tissue density.
Unlike the other techniques, magnetic resonance (MR) imaging can non-
invasively analyze molecular structure and composition in addition to anatomy. In
forming images, however, conventional proton MR imaging techniques largely ignore
and often suppress chemical shift information. As a result, as currently used
clinically, they also mainly provide anatomic images. New high-resolution MR
techniques may be able to identify breast lesions smaller than those currently detected
with mammography [2], but will still require biopsy for diagnosis [3]. The most
useful MRI technique for breast imaging uses a contrast agent, Gadolinium DTPA,
which is injected into a vein in the arm prior or during the exam to improve the
quality of the images. This contrast agent helps produce stronger and clearer images
in order to highlight any abnormalities. However, one of the weaknesses of MRI is
that it has been unable to effectively image microcalcifications, small calcium
deposits that can be associated with breast cancer, as it will be discussed later, see
Chapter 9 [4].
3.2.2 PET
Positron emission tomography (PET) detects pairs of gamma rays emitted
indirectly by a positron-emitting radionuclide, which is introduced in to the body on a
biologically active molecule. The vast majority of the work in breast tissue using PET
has utilized a fluorodeoxyglucose labeled with Fluorine-18 (18FDG). This technique
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produces a three-dimensional image with a resolution of 5-8mm range in all three
planes [5-8].
3.2.3 DOT
Diffuse optical tomography (DOT), an optical imaging technique to identify
suspect lesions, is currently under study [9]. Similar to current screening techniques,
it is noninvasive and can detect lesions deep within the breast. It employs light of a
number of near-IR wavelengths. Contrast, provided by scattering and absorption,
measures relative concentrations of oxy- and deoxyhemoglobin, as well as the
presence of lipids and water content [10]. However, this technique has a low
resolution [11, 12], due to which lesions of small size go undetected; a resolution of 4
to 13 mm has been reported, and the sources of contrast are limited [9, 10, 13].
Despite these challenges, DOT has been utilized in several reported breast cancer
studies [14, 15].
3.2.4 OCT
Optical coherence tomography (OCT) is another promising imaging technique
that is rapidly developing. OCT is based on low-coherence interferometry to produce
a 2-dimentional cross-sectional image of tissue microstructure. OCT can provide a
micrometer resolution [16, 17]. The imaging depth of OCT is about 2-3 mm and it
can be incorporated into a endoscopic imaging devices [18]. Hsiung et al had studied
OCT for evaluation of breast lesions during an ex vivo study [19]. Scientists observed
structural changes associated with different histopathology diagnoses on the limited
set of specimens. However, even though OCT images can be acquired rapidly,
visualization and interpretation of the image takes a long time. The disadvantage of
OCT is the fact that it can provide only structural information, and it does not provide
biochemical information about tissue composition. In addition, the information is not
quantitative and it is subject to interpretation.
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3.3 Spectroscopy
3.3.1 Raman spectroscopy
Raman spectroscopy detects molecules by exciting vibrations amongst bonds
which uniquely correspond to each molecule, and thus has been extensively studied in
biomedical research [20-23]. Raman spectroscopy is a tool that can be used for
studying the structure and biochemical changes in biological tissue; it has been used
extensively for monitoring and diagnosis of disease in vivo and in vitro, for example
in atherosclerosis, malignant lesions, and bone and teeth [24-26].
3.3.1.1 Theory
The Raman effect was discovered by C.V. Raman in 1928 [27]. It is an
inelastic scattering process, during which photon of incident transfers energy to
(Stokes) and from (anti-Stokes) the sample's vibrational or rotational modes. The
frequency shift is equal to the molecular vibration frequency, and usually measured in
wave numbers (cm'). The Stokes scattering is more intense than the anti-Stokes,
because the Raman scattering is proportional to the population of the initial state.
Individual bands in the Raman spectrum are characteristic of specific molecular
motions. By measuring the energy of the emitted photon after the scattering event,
and knowing the energy of the incident photon, the structure of the interrogated
molecule can be analyzed.
Biological tissue, such as breast tissue, has a number of molecules that have
vibrations, characterized by wavelength (frequency) and Raman scattering cross
section; and the Raman spectrum of a particular molecule has a distinct pattern, which
can be easily recognized. However, the Raman effect is a weak effect (as only 1 in
107 of incident photons cause Raman effect [28]), thus the intense Rayleigh light must
be removed so it does not overwhelm the Raman scattering. In addition, it is
important to remember, that the Raman frequency shifts are independent of the
wavelength of the incident light. Thus, the frequency of the excitation light can be
chosen for a specific application. In the case of biological samples, near infrared
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(NIR) light is optimal because of a reduction of background fluorescence and deeper
sampling depth.
Alfano et al acquired the first Raman spectra from breast tissue [20]. Since
then, several other groups have investigated usage of Raman spectroscopy to
diagnose breast cancer [23, 29-32]. Our laboratory has been involved in the research
of applying Raman spectroscopy for diagnosing breast lesions [21, 23, 33-37]. We
found out that usage of the 830 nm excitation wavelength is appropriate for biological
tissue. Due to heterogeneity and complexity of breast disease (as described in Chapter
2), it is important to accurately detect a number of different molecules. Previously,
our laboratory identified and collected eight Raman active morphological components
of the breast tissue using 830 nm excitation light: calcium oxalate dehydrate, calcium
hydroxyapatite, p-carotene, fat, collagen, cell nucleus, and cell cytoplasm [38].
Spectra are depicted in the Figure 3.1. In addition to these 8 Raman components, we
Calclimoxalat dihydrat
--- calclimhydroxyaete
- -Cholestero~keCA
Fat
Collagen
--- Cell cytoplasm
7W 10 9W  1100 12W 1300 14W 17 1i 17W 1 8W
Raman shift (cm")
Figure 3.1. Raman spectra of morphological Raman active molecules found in the breast.
collected Raman spectra from water, as well as sapphire and epoxy - components that
were used in the manufacturing of the probe (spectra not shown).
3.3.1.2 Clinical Raman system
The original spectra depicted on Figure 3.1. were collected using a laboratory
based Raman microscope system [37]. In order to apply Raman spectroscopy
technique as a valuable medical tool, the clinical Raman system was constructed.
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Note, throughout the thesis we will refer to "system" as a combination of a clinical
instrument and an appropriate probe that delivers light from the instrument to the
tissue site that is under investigation.
3.3.1.2.1 Clinical Raman instrument
The clinical Raman instrument, developed in the Spectroscopy laboratory, is
illustrated in Figure 3.2a [39]. Light from an 830-nm InGaAs diode (Process
Instruments, Salt Lake City, UT) is collimated by two cylindrical lenses and passed
through a bandpass filter centered at 830 nm (Kaiser Optical Systems, Inc., Ann
Arbor, MI). Then, the light is focused into the 200pm core diameter excitation fiber
of the Raman probe using a lOx microscope objective. Illumination of the sample is
gated by a high-speed computer-controlled external shutter (LS6ZM2, Vincent
Associates, Rochester, NY) redirected by a gold-coated mirror and focused onto the
Raman probe excitation fiber by a lOxmicroscope objective. The Raman probe is
terminated with an FC connector in order to provide day-to-day reproducibility of
alignment. This vertical array serves as an entrance slit to the spectrograph (Holospec
f/1.8i, Kaiser Optical Systems) attached via modified BNC connector. The collection
light passes through a notch-filter and then it is dispersed onto a back-illuminated,
deep-depletion CCD detector with a 1340x400 array of pixels (Spec-10:256 BR,
Princeton Instruments, Trenton, NJ). The CCD detector has a 16 bit dynamic range
and is liquid nitrogen cooled to -110*C. Instrument is controlled by a laptop
computer. The Raman probe, depicted in Figure 3.2.b has a total diameter of 2mm a
length of about 4m.
3.3.1.2.2 Front-viewing Raman probe
Clinical application of Raman spectroscopy requires an optical fiber probe for
minimally invasive acquisition of Raman signal. The important aspect of the probe is
the ability to collect Raman light in a clinically relevant time frame with a safe level
of light exposure. Our Raman optical fiber probe provides an optimal collection
efficiency probe that is capable of collecting high-quality data in seconds [40].
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In order to efficiently transmit NIR light, fused silica optical fibers were
employed [41]. However, even with a low laser excitation power the fused silica fiber
background is intense and saturates the detector. The fiber background consists of
Raman light from the fused silica core, fluorescence from impurities and dopants
used to produce fibers of a particular numerical aperture (NA), and signal from jacket
materials. This fiber background would overwhelm and mask the tissue Raman
signal, thus it has to be removed. In addition, backscattering laser light generated in
the tissue needs to be separated and removed from Raman signal generated in the
tissue.
Our lab designed a set of dielectric filters at the distal end of the probe. The
delivery fiber is terminated with a short-pass filter that is centered at 830nm
wavelength. It transmits the laser excitation light while blocking the background
generated in the delivery fiber. The distal end of the collection fibers are terminated
with a long-pass filter, which transmits the tissue Raman signal to the spectrograph,
while blocking Rayleigh-scattered light.
Diode Laser b)
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oC 830 nm holographic
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Figure 3.2. a) Schematic of Raman instrument; b) Schematic of Raman front-viewing
probe
In addition, in order to efficiently collect Raman signal, the probe design
contains 1 delivery fiber surrounded by 15 collection fibers. The central excitation
fiber has a 200mm core diameter and 0.22 NA. The collection fibers have 200 mm
core diameter and 0.27 NA, which is matched to the NA of the spectrograph. Also,
the distal tip of the probe contains an anti-reflection coated sapphire ball lens
(MKPhotonics, Albuquerque, NM) secured to the fiber bundle and filter unit in a
stainless steel tube. All components of the probe are constructed using medical grade
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materials that can withstand standard cold gas ethylene oxide sterilization for surgical
procedures.
3.3.1.3 Calibration and data modeling
The Raman acquired spectra have to be post processed to configure them into
the form that will be diagnostically useful. The calibration process ensures a day-to-
day, system-to-system, and user-to-user reproducibility of the data.
A wavenumber calibration needs to be performed for determination of Raman
band frequencies. Given small changes in the instrumentation alignment, changes
may occur in the pixel position of a particular Raman band. Tylenol 4-
acetaminophenol is used as a standard for wavenumber calibration. In order to correct
Raman spectra for the system wavelength response, collection of the light from a
wavelength-calibrated tungsten halogen lamp (LS-1, Ocean Optics, FL) diffusely
scattered from a reflectance standard, BaSO4, that has a flat response, is performed.
The remaining probe background generated in the optical fibers is characterized by
collecting the excitation light scattered from a roughened aluminum surface.
All of the data modeling is based on the assumption that the Raman spectrum
of a mixture can be viewed as a linear combination of the spectra of its constituents
(basis spectra), P, a d that the signal intensity, S, at a specific wavenumber (w)
and chemico-morphological concentration, Cj, are related as follows:
S(w) = Ci -Pi(w) Eq 3.1
Non-negativity constrained ordinary least squares minimization is used for
model fitting, yielding the relative contribution of the basis spectrum of each
component, given in Fig 3.1, to the observed spectrum of the mixture. The accuracy
of a given model can be qualitatively determined by observing the residual of the
model that was calculated by subtracting model fit from the observed tissue spectrum.
The smaller the structureless residual, the more completely the model has accounted
for the observed spectral features, and thus the better the model. One of the biggest
advantages of our modeling procedure over that of other groups' one is that the basis
spectra can be correlated with the presence or absence of a specific chemical or a
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morphological feature providing both quantitative and qualitative information about
tissue composition. All constructed algorithms that are based on fit coefficients -
relative concentrations of different chemico-morphological constitute - that are
physically meaningful, and thus will be easier to explain and can lead to deeper
knowledge of cancer development. In addition, this type of algorithm is believed to
be more robust provided that it is constructed on an adequate set of data.
Logistic regression is used to generate decision algorithms. Logistic
regression is a method that classifies points in a space that we used throughout the
dissertation. Logistic regression is a method for classifying a sample according to
discrete categories. Specifically in our study, lesions are characterized by vectors,
whose elements are spectral parameters - fit coefficients, and the labels indicate
disease classification provided by a pathologist, for example IDC - infiltrating ductal
carcinoma. Pathological diagnoses are used as a gold standard in all of our diagnostic
algorithms. Thus, it used to correlate fit coefficients, obtained by modeling Raman
spectra, with disease diagnoses. Logistic regression is a linear technique, which
assumes that a discriminant score, Rm6, for the mth sample to be in class 6, can be
determined from the relative fit contributions (Cmj) of the j basis spectra, such that
R,,5 =a5 +X C,,,3. 3.2
where a is a constant offset and P is an adjustable coefficient for each
morphological structure in each diagnostic class [42]. This method is preferred over
traditional discriminant analysis because logistic regression does not make any
assumptions about the fit-coefficients being normally distributed, and it allows
discrete variables as inputs. A maximum likelihood estimation is the core
manipulation involved in logistic regression [43].
An analytical error formula that estimates the uncertainty in spectral
contributions predicted by linear multivariate calibration has been also derived [44,
45]. The formula provides the standard deviation of the predicted contribution of a
tissue component for a given signal to noise ratio and spectral model overlap. The
overlap factor accounts for the similarity between the Raman spectrum of the tissue
Page |53
CHAPTER 3: Current technologies: imaging and spectroscopy
component of interest and the spectra of all the other tissue components. This
standard deviation, termed Ac, for the kh model component of interest can be
expressed as:
0-
Ack = -* ofk 3.3
Sk
In the above equation, a is the standard deviation of the noise in the system, Sk
is the signal strength of the kh model component, and the olfk is the spectral overlap
factor between the k model component and the rest of the model spectra.
Thus, prior to developing or prospectively applying diagnostic Raman
algorithms, the fluorescence background from each spectrum was removed by means
of a sixth-order polynomial. Following spectral correction, the basis spectra of the
Raman spectral model were fit to the spectrum obtained from the breast tissue via
non-negatively constrained least-squares minimization. In addition, Raman spectra of
epoxy and sapphire - two probe components - were added to the model, to correctly
model the data. Following the procedure used in the calibration study, the fit
coefficients for each Raman spectrum of the data set were normalized to sum to unity.
An example of a raw and processed Raman spectrum is illustrated in Fig 3.3.
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Figure 3.3. Example of Raman a) raw and b) processed data.
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3.3.2 DRS/IFS spectroscopy
3.3.2.1 Theory
Diffuse reflectance spectroscopy (DRS)
Diffuse reflectance spectroscopy (DRS), an elastic scattering spectroscopy, is
a non-invasive technique that uses the interaction of light with a sample through
absorption and scattering phenomena to produce a characteristic reflectance spectrum
that provides information about the structure and composition of the medium.
Diffusion theory is appropriate in a medium dominated by scattering rather than
absorption so that each photon undergoes many scattering events before being
terminated by an absorption event.
Elastic scattering is the most prominent optical property of tissue. The
scattering coefficient, ts, which represents an average number of scattering events per
unit length, is in the range of ps=10-100mm4 for soft tissue. Scattering arises from
the microscopic variations and inhomogeneities of the refractive index that
correspond to various scattering centers [46]. The angular distribution of the
scattering is described by the scattering phase function, p(0), which provides the
probability of a photon to be scattered at an angle, 0, with respect to the initial
direction. The scattering coefficient is essentially the cross-sectional area per unit
volume of tissue. The reduced scattering coefficient is a lumped property
incorporating the scattering coefficient ps, and the anisotropy parameter g:
ps'= ps(l - g), where g = 2rfp()cos Osin OdO 3.4
Anisotropy, g, is used to indicate how strongly forward-directed the scattering
is. Typical values for tissue are g = 0.8 - 0.95, which corresponds to average
scattering angles between 45 and 20 degrees, respectively.
Mie theory provides an exact solution for scattering of light with wavelength
k by a spherical object with diameter d and refractive index n that is located in a
surrounding medium with refractive index n. In this study Is' was modeled using a
power law in the following way:
p,'V= Al-B 3.5
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where A can be interpreted as the amount (or concentration) of Mie scatterers, B is
related to the sizes of the scatterers.
Absorption is measured by means of the absorption coefficient, pa, which is
defined as the amount of absorption present in units of inverse length. Water, being
the major component of soft tissue has negligible absorption in the visible range
(<104 mm-1). Tissue absorption, which depends on wavelength, is due to a number of
characteristic biochemical molecules.
Hemoglobin is a major absorber in the blue region of the visible spectrum.
Other biochemical compounds with characteristic light absorption in the visible range
include p-carotene, bilirubin, and in the skin, melanin. Many other absorbers are
present in the tissue at much smaller concentrations and can be ignored. Several other
research groups have applied DRS for separating malignant breast lesions from non-
malignant lesions [47-49]. In this study, oxyhemoglobin, deoxyhemoglobin and p-
carotene will be treated as the major absorbers of light in breast tissue. Their
absorption spectra are illustrated in Figure 3.4. The total absorption coefficient, pa,
can be expressed as a linear combination of the extinction spectra of the two
absorbers as follows:
J a =C co 2 *emo 2 (A)+c, -IO ()) 3.6
1.2 where cp is the concentration of
-- p-carotene
- Oxyhemoglobin P-carotene and is theDeoxyhemoglobin
o /~0.8 cnetaino
F0.6 oxyhemoglobm. Note, if the
0.4 excised tissue is under study,
0.2. i.e. ex vivo study, the tissue is
o 0exposed to air, thus
-. 2 deoxyhemoglobin is not used as
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Wavelength (nm) one of the absorbers.
Figure 3.4. Absorption spectra of oxyhemoglobin
deoxyhemoglobin, and J-carotene.
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Intrinsic fluorescence spectroscopy (IFS)
Fluorescence is one of the categories of luminescence and occurs from
electronically excited states. Fluorescence is more dominant in the UV than in the IR
range. Autofluorescence from tissue can be observed from reduced nicotinamide
adenine dinucleotide (NADH), collagen, oxidized flavins (FAD, the adenine
dinucleotide, and FMN, the mononucleotide), elastin and pyridoxal phosphate.
Fluorescence excitation and emission spectra in tissue can be used to identify
fluorophores and monitor their concentrations. In biological tissue, with the
progression of a disease the relative concentration of fluorophores can change, thus
leading to changes in the observed fluorescence intensity and its lineshape.
Autofluorescence spectroscopy has been used to explore diagnosing different
diseases, such as atherosclerosis, oral cancer, cervical dysplasia, and breast cancer.
Alfano et al. were the first to measure the fluorescence spectra of malignant and
nonmalignant breast tissue [50]. Several groups [51-53] showed promising results in
separation malignant lesions from non-malignant using empirical algorithms. Such
empirical algorithms do not emphaze the importance of biochemical and
morphological information contained in the spectra.
However, fluorescence spectra acquired from a bulk tissue are distorted by
absorption and scattering, thereby limiting the accuracy of the extracted information.
To overcome this problem, DRS can be used in conjunction with the measured
fluorescence spectrum to extract the intrinsic (undistorted) fluorescence [46, 54]. This
process is called intrinsic fluorescence spectroscopy (IFS).
3.3.2.2 DRS/IFS system
DRS and IFS spectra can be collected by means of a FastEEM system
previously developed by our laboratory [55].
3.3.2.2.1 DRS/IFS instrument
The FastEEM instrument collects white light reflectance and fluorescence
excitation-emission matrices (EEM's) within a fraction of a second in order to collect
diffuse reflectance and intrinsic fluorescence spectra [56]. A schematic of the
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FastEEM instrument, that is capable of collection of white light reflectance and
fluorescence spectra in fraction of seconds, is presented in Fig. 3.5. It delivers a
sequence of ten laser pulses (308 - 480 nm) and two white light pulses to the tissue
via an optical fiber probe (see below for details of the probe design). The XeCl laser
(Lambda Physik Optex, Ft. Lauderdale, FL, 308 nm, 8 mJ per pulse, FWHM 8 ns)
excited fluorescence at 308nm wavelengths as well as pumped 10 dyes circularly
arranged on the dye-wheel providing an additional 10 excitation wavelengths in the
308-480nm range. When the wheel spins, the individual dye cells are consecutively
pumped by the XeC1 excimer laser. The Xe arc flashlamp (Hamamatsu L7684,
Bridgewater, NJ, 1 J per pulse, FWHM 2 ps) was used to excite tissue reflectance.
The same probe collects the white light reflectance and fluorescence and delivers it to
the entrance slit of a diffraction grating spectrometer where it is dispersed onto an
intensified CCD detector. All ten laser-induced emission spectra and the two white
light reflectance spectra can be collected in approximately 0.3 s. Several of these
acquisitions can be averaged together to increase the signal-to-noise ratio (SNR).
a) Xe Excimer
Flashlamp Laser
Dye cell
wheel
I
Spectrograph
White light Fluorescence
s e citation fiber excitation fiber CCD
Collectioin
| xcitation fiber
Figure 3.5. a) Simplified schematic of the FastEEM instrumentation; b) a photograph of
developed FastEEM instrument
Previously, we found that the acquisition of five measurements provides
sufficient SNR in most tissues, making a typical acquisition time on the order of 1.5 s.
Reflectance and fluorescence light was coupled into the optical probe, which is used
for light delivery and collection (illustrated in Figure 3.6). It is in the form of a
flexible catheter, with an overall length of over 3 m and a diameter of approximately
1.2 mm.
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3.3.2.2.2 Front-viewing probe
Front View Side View
a) b
Exciasbon Fiber
Figure 3.6. a) A diagram of the DRS/IFS optical fiber probe showing front and side view;
b) A photograph of the probe.
An optical fiber probe is used to deliver the excitation light from the two
sources (from the flash lamp for DRS and from excimer laser for fluorescence
spectroscopy), as well as to convey light emitted from the tissue to the detection
components [56]. The probe consists of a single central delivery fiber surrounded by
6 collection fibers in a closest-packed configuration. The fiber core is composed of
fused silica and has a diameter of 200 pm (Numerical Aperture (NA) = 0.22). With
the cladding, the diameter of each fiber is 220 pm. The entire 3 m length of the probe
is enclosed in Teflon tubing for protection. At the probe tip, the fibers are exposed
from the cladding, fused, embedded in a protective silver epoxy, and surrounded by a
protective sheath. A 1.5 mm long quartz shield is placed at the very tip to create a
reproducible geometry when in contact with the tissue. With the cladding and
protective sheath, the probe tip has a diameter of approximately 1.2 mm. The tip of
the probe is polished to an angle of approximately 170 to prevent specular reflections
from entering the probe and producing artifacts in the measured signal. At the distal
end of the probe, the 6 collection fibers are separated from the source fiber and
coupled to the detection portion of the instrument via a set of 6 SMA connectors.
Similarly, the distal end of the delivery fiber is coupled to the excitation sources via
another SMA connector.
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3.3.2.3 Calibration and modeling DRS and IFS
Prior of collecting spectroscopic data from tissue specimens, calibration of the
system was performed. Background calibration is used to remove effects of CCD
dark currents and stray light. All data were corrected for background reflectance and
fluorescence by measuring a spectrum from water in a black container and subtracting
these counts from the signal measured from the sample. The wavelength calibration is
performed by recording a spectrum from a mercury argon lamp (HG- 1, Ocean Optics,
Dunedin, FL) each day of data collection. Because the wavelengths of the mercury
peaks are known, we determine the relationship between pixel number and
wavelength by fitting a second-order polynomial to a plot of the wavelength of each
peak versus the pixel number of the peak. White light reflectance calibration is
achieved by dividing the background corrected tissue spectrum by that of a
reflectance standard (20 % reflectance standard, Labsphere Inc., North Sutton, NH).
Calibration of the measured reflectance corrects for the spectral profile of the
flashlamp and the wavelength-dependence of the detector response. Each EEM is
corrected for excitation intensity of the dye lasers by measurement of a standard
Rhodamine B dye mixture (5 g/L in ethylene-glycol). The known quantum yields of
Rhodamine B are then used to correct the intensity of each emission spectrum.
The calibrated diffuse reflectance spectrum were fit over the range of 350 - 750 nm
using a constrained nonlinear least-squares fitting algorithm. First, calibrated diffuse
reflectance spectrum, DRS, is calculated by the following formula:
Spectrum - Background 3.7
Spectralon - Background
All data were corrected to take into account background reflectance and fluorescence
via measuring a spectrum from water in an opaque container, as well as spectralon
spectrum acquired from Spectralon (LabSphere, Inc., North Sutton, NH) 20%
reflectance standard; SpecCal is an intrinsic property of the material and its value
were provided by the manufacturer, and represents a fraction of the light reflected by
the spectralon reflectance standard.
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A non-linear least-squares fitting algorithm was used to fit the calibrated
reflectance data, DRS, to the Zonios model [46]. The best fit is found by minimization
of X2
X2  (DRS(X) - Fit(X) 2 3.8
6(A)
where 6(k) is the error in DRS and calculated using the following formula:
6 IZ SDRS(A) 2 3.9
We obtain several parameters from modeling tissue reflectance: A [mm~'],B, Hb
[mg/ml], p-carotene [mg/ml]. Note, in the case of ex vivo studies, where tissue is
exposed to air, we assume that tissue is oxidized, and Hb presents only oxidized
hemoglobin.
Based on photon
migration theory, light Diffuse Reflectance Fluorescence
propagation in a turbid medium
is described by photons Absorbed Absorbed
traveling in paths with discrete
nodes, at which absorption, Figure 3.7. Photon migration theory
scattering, and fluorescence events occur, Fig. 3.7. Reflectance is related to the
product of albedo, a, which represents the fraction of unabsorbed photons at each
interaction event, and the escape probability of a photon that enters the medium,
undergoes n scattering events, and is collected after exciting, Pn. The reflectance, R,
can de described by a following expression:
R(A)= Z a ~p, where a= , 3.10
n=1 Ps + P
and ps is a scattering coefficient and pa is a absorption coefficient.
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An analytical expression for pn, was derived based on Monte Carlo
simulations by Wu et al [57]., modified by Zhang et al. [46], and given as follows:
p, = a -exp(-# 3 n), where # = S(l - g), a = R -C , and e = exp(#) - 1 3.11
Note, parameter S is a constant related to the probe geometry, g is the anisotropy
parameter of the medium, and Ro is the reflectance in the absence of the absorption.
We assume that g is constant over all wavelengths of the fluorescence spectrum.
In the case when excitation light is absorbed after an initial i scattering events
at the excitation wavelength, the fluorescence occurs at the (i+ 1 )th node, and the
fluorescence photon undergoes n-i-i scattering events at the emission wavelength,
where n is the total number of scattering events. The measured fluorescence can be
found using the following equation:
n10 i+L fxm a -j'1  , 31F,,, n " a,-" a",~ Pi 3.12
n=1 i=0 s
The fluorescence escape probability is derived based on Monte Carlo simulations by
Wu et al. [57]., modified by Zhang et al., and given as follows:
p., = (aa ,)12 exp[-p 5 (i+1)]exp[-,,(n - i -1)]. 3.13
The quantityfx,n is intrinsic fluorescence and is given by:
fx, = ( 5  flo,,hv,.. 3.14hv, )
The subscripts x and m provide dependency of each variable on the excitation and
emission wavelengths, respectively. The intensity of the incident light is denoted by
I, h is Planck's constant, and v is frequency of light. The absorption coefficient of the
fluorophore and its quantum yield are denoted by pf and <i, respectively. The
constant 1 has dimension of length and characterizes a given light delivery-collection
geometry; it is, therefore, probe-specific. Combination of above equations lead to the
formula for the intrinsic fluorescence as follows:
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1 Rox Ro,,, R_ R,, 3.15
pSXl E EMn Rox RO.n
Using this expression we can extract the intrinsic fluorescence spectrum from the
measured fluorescence by use of the diffuse reflectance collected from the same
tissue site with the same probe.
Once intrinsic fluorescence is derived it can be linearly decomposed into its
constituents. The spectrum of tissue intrinsic fluorescence is modeled as a linear
combination of tissue fluorophore basis spectra. The basis spectra were extracted
from the intrinsic fluorescence spectra using multivariate curve resolution (MCR). In
order to reduce patient-to-patient variation in fluorescence spectra, the areas under the
IFS spectra, as well as basis spectra, were normalized to a value of one.
3.4 Summary
In this chapter the theories behind the spectroscopic techniques employed in the
thesis, DRS, IFS and Raman, as well as other optical techniques were explained. Each
modality provides additional information about biochemical composition of tissue,
thus the combination of all three modalities might lead to a superior technique. A
brief overview of the instrumental design and collected data was also presented.
Evaluation of spectroscopic modalities as a tool to diagnose breast lesions is present
in the next chapters.
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CHAPTER 4
Clinical Raman studies: ex vivo and in vivo
In this chapter we describe the clinical application of Raman spectroscopy for the
discrimination of breast lesions. We begin by presenting a description of an in vitro tissue
study (study on tissue that was frozen-thawed for days-weeks) in which we develop a
Raman diagnostic algorithm based on parameters extracted from the Raman spectra.
Raman spectra were collected from freshly excised breast specimens from patients
undergoing excisional biopsy: lumpectomy or mastectomy. After developing the
diagnostic algorithm, we then test it prospectively. First, we applied the algorithm to
assess a new set of tissue samples collected during an ex vivo study (study on a freshly
excised tissue). Lastly, we used the algorithm to prospectively evaluate the status of
margins in an in vivo study. For the in vivo study we implemented Raman spectroscopy in
the operating room setting, which has never been performed in previous studies in the
literature. The success of the study shows that if the Raman technology can be
implemented in real-time to provide the surgeon the information about the disease status
of the margins around a lesion; it could prevent patients from undergoing a second
surgery.
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4.1 Introduction
Our laboratory has studied Raman spectroscopy for a number of years. Raman
spectroscopy is very sensitive to the presence of proteins, fats, etc, which are Raman
active, in the medium. Thus Raman spectroscopy has been extensively studied for
diagnosing breast lesions.
4.2 Development of Raman diagnostic algorithm
The development of the Raman diagnostic algorithm was based on data acquired
from frozen-thawed in vitro specimens collected from 58 patients, who were undergoing
surgical (excisional) breast biopsy, reduction mammoplasties and prophylactic
mastectomies. Additional information can be found in [2, 3]. A total of 130 spectra were
collected using the Raman system [4, 5] using an integration time that varied between 10
and 30 seconds based on the signal intensity. The average laser excitation power
delivered to the tissue was between 100 and 150 mW. Sites of data acquisition were
marked with India ink for future correlation with pathology. All specimens were then
fixed in formalin and routinely processed. The histopathology examination was
performed by an experienced pathologist blinded to the results of the spectroscopy. The
histopathology results for the study samples were as follows: 49 normal tissues, 50
benign lesions (16 fibrocystic change (FCC) lesions and 31 fibroadenoma lesions) and 31
infiltrating ductal carcinoma (IDC) lesions.
Spectroscopic data was processed as described in the Chapter 3.3.2. Model fitting was
performed using a linear combination of basis spectra of biochemical/tissue components
present in the breast tissue with a nonnegativity constraint. The contribution of each basis
spectrum, extracted from the modeled fit to the tissue spectrum was normalized so the
sum of all fit coefficients would sum to one (Chapter 3). Fit coefficients are a function of
both the concentration of the each basis spectrum and its Raman scattering cross section,
which represents the strength of the signal at a unit concentration. The fit coefficients
represent the amount that each model basis spectrum must be weighted to recreate the
tissue spectrum, thereby providing insight into the chemical/morphologic makeup of the
tissue. The Raman diagnostic algorithm is based on physically-meaningful fit
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coefficients. Out of eight fit coefficients there were found two, fat and collagen, fit
coefficients that had the most diagnostic capabilities.
A large fit coefficient for fat for normal breast tissue correctly suggests that
normal breast tissue is primarily composed of fat (adipose tissue). Based on the anatomy
of the breast it is known that breast tissue consists of both glandular and adipose tissue
[7]. Glandular tissue consists of ducts and a supportive collagenous extracellular matrix,
while ducts represent only a small volume of the tissue. The Raman model correctly
characterizes normal breast tissue as a tissue that mostly consists of fat and a small
contribution of collagen. Another important observation was that the amount of collagen
increases in all abnormal tissues. This is also consistent with breast pathology, as the
formation of lesions is associated with fibrosis- a scarring process characterized by
increased accumulation of collagen in the stroma.. FCC lesions demonstrated the largest
collagen composition. Lesions diagnosed as fibroadenoma were also marked by an
increased contribution of collagen. This is consistent with the fact that these lesions are
characterized by the proliferation of fibroblasts, the cells which produce collagen, and as
a result, accumulation of collagen in the stroma [8]. IDC is associated with a fibroblast
proliferation as a response to stromal invasion by the malignant epithelial cells. These
lesions also showed an increased contribution of collagen. The fit coefficients for
collagen varied for different histopathology diagnoses [3].
Logistic regression, + Normal
70 * FCC
a discriminate analysis 0 FA
technique, was used to 5 Change
correlate the normalized fit
40 A
coefficients with the U
*03  Carcinoma
histopathology diagnoses
for all of the eight %
components in the model. 0
A likelihood ratio test was 0 (Fat)
used to determine the Figure 4.1. Raman diagnostic algorithm. This figure is
modified from [3] and reprinted with the permission of the
importance of each of the publisher.
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model components to the correct classification of the lesions at each step in the
algorithm. Leave-one-out cross-validation analysis was used to obtain the most robust
diagnostic algorithm.
Note, the diagnostic algorithm is evaluated based on its performance on the
testing data set. The best way, is to test robustness of the diagnostic algorithm is on an
independent data set, which does not include the data points used for calibration and
development of the algorithm. However, not always it is possible to acquire an
independent data set for validation purposes, as large number of specimens and patients
might be difficult to acquire. In the case of small number of samples, one can perform a
cross-validation. Is allows an efficient use of a data set because only a small number of
samples are reserved, and the spectra of the remaining samples are used for calibration.
The leave-one-out method is one of the cross validation techniques, in which only one
spectrum at a time is left out of the calibration. The diagnostic algorithm is calibrated
using logistic regression excluding that one data point (spectrum). The excluded data
point is used for validation and the prediction made on it, is compared to the diagnosis
provided by a pathologist. The same procedure is repeated sequentially, excluding each
spectrum from calibration set.
The fit coefficients for fat and collagen proved to be most diagnostically relevant
for discrimination among the four pathology categories. Therefore, a diagnostic algorithm
was developed based on the normalized fit coefficients of fat and collagen. A scatter plot
of the fit coefficient (FC) of collagen versus FC of fat for the four histopathology
categories, and the diagnostic decision lines that separate samples are shown in Figure
4.1. Using maximum likelihood estimation, we determined the probability that a breast
sample is normal, FCC, fibroadenoma, or IDC. Receiver operating characteristic (ROC)
curves were generated by changing the probability threshold for assigning a classification
in order to separate malignant lesions (IDC) from non-malignant (normal, FCC and
fibroadenoma) lesions. (Fig 4.2).
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Note, a receiver operating 1
characteristic (ROC) curve is a plot of the 0.
0.7sensitivity vs. specificity for a binary
classifier (two-class prediction) system as > 0.
'7 0.
its discrimination threshold is varied. A 5 0
decision boundary can be associated with 0.
0.
any particular threshold probability from 0.1
the logistic function (not necessarily a 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
50% probability). As the decision 1-SpecificityFigure 4.2. ROC curve demonstrates ability of
boundaries are moved depending on the Raman spectroscopy to diagnose breast lesions.
probbilty tresoldso s a radoff This figure is taken from [3] and reprinted withprobbilty tresoldso s a radoff the permission of the publisher.
between sensitivity and specificity. Thus, ROC curve represents the tradeoff between
sensitivity and specificity. Often, the ROC is used to generate a summary statistic. The
area under the ROC curve, or "AUC", is equal to the probability that a classifier will rank
a randomly chosen positive instance higher than a randomly chosen negative one.
The performance of the algorithm was very promising, yielding a sensitivity,
specificity, positive predictive value (PPV), negative predictive value (NPV) and overall
accuracy of 94%, 96%, 88%, 98%, and 86% respectively. Sensitivity is defined as
probability of correctly diagnosed malignant (IDC) specimens, while specificity is
defined as probability of correctly diagnosed non-malignant specimens. The overall
accuracy is the percentage of correctly classified samples for all pathological categories
(see appendix for more explanations on the sensitivity, specificity, PPV, NPV, and
overall accuracy).
Any newly developed algorithm needs to be tested prospectively on a new set of
data, in order to make sure that the algorithm is robust and also to make sure that the data
that was used for development of the algorithm is representative of the disease spread and
disease prevalence. The next section of this chapter will describe the first study where the
spectroscopic algorithm was applied in a prospective fashion.
Page 173
CHAPTER 4: Clinical Raman studies: ex vivo and in vivo
4.3 Prospective application of Raman diagnostic algorithm
4.3.1 Clinical data collection protocol
In order to validate the Raman diagnostic algorithm, a new clinical ex vivo study
[6] was designed and carried out in the Mather Surgical Pavilion at University Hospitals-
Case Medical Center. The study was approved by the University Hospitals-Case Medical
Center Institutional Review Board and the Massachusetts Institute of Technology
Committee On the Use of Humans as Experimental Subjects. Informed consent was
obtained from all subjects prior to their surgical procedures. Over the span of two months
data was collected from 28 consecutive patients undergoing excisional breast biopsy
(n=20), partial mastectomy (lumpectomy; n=7) or simple mastectomy (n= 1).
Data were collected from freshly excised surgical specimens in the pathology
suite adjacent to the operating rooms, typically within 30 minutes of tissue excision.
Upon removal, the surgical specimens were inked and sectioned following standard
pathology protocol, and Raman spectra were acquired from breast tissue sites (regions of
interest) chosen by the pathologist. Depending on the region of interest identified by
pathologist, the number of spectra taken per patient varied. The data were taken in the
frozen section room (adjacent to the operating rooms), where several pathologists and
residents work simultaneously, thus it was not possible to turn the lights off during data
acquisition. In order to reduce the ambient light, all breast specimens were placed in a
box that was impermeable to light during acquisition of the Raman data. Following
spectral acquisition, the breast specimens were marked with multicolored colloidal inks
to uniquely identify each site sampled and fixed in 10% neutral buffered formalin. The
fixed tissue samples were routinely processed, paraffin embedded, sectioned in 5 pm
thick sections, and stained with H&E. The histology slides were evaluated by an
experienced breast pathologist who was blinded to the outcome of the Raman
spectroscopy analysis.
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4.3.2 Pathology
The pathology results were used as the gold standard against which the Raman
spectral diagnoses were compared. Overall, a total of 220 Raman spectra from the 28
patients were collected. Of these, 129 Raman spectra from 21 patients were analyzed in
the prospective analysis: 41 spectra from normal breast tissue, 82 from benign lesions (73
FCC lesions and 9 fibroadenomas), and 6 from malignant lesions (IDC). Ten spectra
were excluded from the analysis due to contamination from ambient light (6 normal, 1
FCC, 3 IDC). As the purpose of this study was the prospective validation of the
diagnostic algorithm, histopathological categories that were not present in the calibration
data set were excluded from this study. Therefore, twenty spectra acquired from
specimens diagnosed as ductal carcinoma in situ (DCIS) were also excluded. Sixty-one
spectra acquired from two patients with breast cancer who had undergone pre-operative
chemotherapy (16 normal, 9 FCC, 3 IDC) and five patients undergoing re-excision
surgery to ensure negative margins (14 normal, 17 FCC, 2 IDC) were also excluded from
the prospective analysis. Note the original algorithm was constructed on the excised
specimens from patients who were not treated with chemotherapy and did not undergo a
re-excisional biopsy. Thus, the data set for a prospective validation was constructed to
simulate the same conditions, i.e. patients who underwent pre-operative chemotherapy or
re-excisional surgery were excluded from the prospective validation of the algorithm.
4.3.3 Data acquisition and data analysis
Data were collected using the clinical Raman instrument and Raman optical fiber
probe described in Chapter 3. On average, the excitation laser power was 100 mW.
Before data collection, calibration spectra were acquired (Chapter 3).
In the next step of the procedure, the fit coefficients for the 8 components
(calcium oxalate dehydrate, calcium hydroxyapatite, b-carotene, fat, collagen, cell
nucleus, and cell cytoplasm) used to fit the Raman spectra were normalized to sum to
unity. The contributions of calcium I and calcium II spectra were excluded from this
normalization, as these species were not present in the tissue samples used for diagnostic
algorithm development. Increased contributions from cholesterol-like lipid deposits was
observed in this data set, possibly due to differences in the Raman scattering cross-
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section of this component in frozen-thawed and fresh tissue. Thus, the cholesterol-like
component was excluded from normalization.
4.3.4 Results
Each of the 129 Raman spectra from the 21 patients in the prospective data set
was analyzed as described above to obtain the normalized fit coefficients of collagen and
fat. The Raman diagnostic algorithm developed previously was then applied
prospectively to obtain the Raman spectral diagnoses, and subsequently compared to the
histopathology diagnoses. The results of the prospective classification of lesions using
the diagnostic algorithm are shown in Fig 4.3. Prospective application of this algorithm
to excisional biopsy specimens resulted in the correct diagnosis of 5 of 6 cancerous sites
(IDCs) and 114 of 123 non-cancerous sites (normal breast tissues and benign lesions).
Based on these results, a sensitivity of 83% and a specificity of 93% were obtained. The
overall accuracy of correctly classifying each of the four tissue types individually was
78% (101/129). The positive predictive value (PPV) and negative predictive value (NPV)
for this study were 36% and 99%, respectively. A comparison of the Raman spectral
diagnoses and the histopathology is shown in Table 4.1.
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Fibrocystic
0.5, * Change
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Carcinoma =
0.2 +
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Figure 4.3. Prospective application of the Raman diagnostic algorithm. This
figure is taken from [6] and reprinted with the permission of the publisher.
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PathoIogy Normal Fibrocystic Fibroadenoma Infiltrating
Raman Change Ductal Carcinoma
(41 samples) (73 samples) (9 samples) (6 samples)
Normal 38 13 0 0
Fibrocystic Change 3 54 0 0
Fibroadenoma 0 2 4 1
Infiltrating Ductal Carcinoma 0 4 5 5
Table 4.1. Comparison of histopathology diagnoses and Raman spectroscopic
classification of breast disease.
The Raman diagnostic algorithm proved to be successful on the new set of data.
Four factors influenced the performance of the diagnostic algorithm in this prospective
study as compared to the performance in the original study (in vitro study). First, the
internally-validated original data is always expected to give more apparently efficacious
results than those of a prospective study since the cross-validation employed to develop
the algorithm in the original study was optimized only for the calibration data set. It
should be noted that some research groups regard such internal-validation techniques to
be prospective [9, 10]. However, their techniques are not equivalent to a prospective test,
in which an algorithm developed based on one data set is applied to new data set. A
prospective test is the best method for evaluating the efficacy of the diagnostic algorithm
in clinical setting, as was performed in this study. Second, differences in the patient
populations studied affect the findings[ 11]. As discussed below, potential sources of bias
in the patient populations must be properly taken into account to interpret the efficacy of
the diagnostic algorithm in the prospective study. Third, the use of freshly-excised
surgical samples in the prospective study, as opposed to fresh-frozen samples in the
original data set, which was used for calibration, may produce differences in the spectral
properties of the tissue. Past studies have shown that the Raman spectral lineshape is
equivalent in the two types of samples with regard to the eight components that comprise
our diagnostic algorithm, since they are structural rather than metabolic in nature [12].
However, there were a few differences in the contribution of particular model
components (cholesterol-like component) between the calibration and prospective
studies. This may be due to changes in disease spectrum, as discussed below, or
alternatively to changes in the Raman scattering cross-section as a result of freezing and
thawing the tissue. Finally, factors related to the instrumentation, particularly SNR, may
contribute to the differences in the findings [13].
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4.3.5 Significance ofprevalence
Unlike the sensitivity and specificity, the PPV and NPV depend heavily on the
prevalence of the various lesions in the data set. Disease prevalence (or prior probability)
refers to the proportion of individuals with an attribute or disease in a given population.
PPV gives the probability of disease if a test result is positive, while NPV gives the
probability of no disease if a test result is negative. PPV and NPV can be calculated as
follows:
TP p-sePPv = =-TP+FP (p-se+(1-p))-(1 sp)
TN (1 - p) -sp 4.2
TN + FN (1 - p) -sp + p - (1 - se)
where TP/N is true positive/negative and FP/N is false positive/negative. As the disease
prevalence in a particular data set decreases, PPV decreases and NPV increases. Thus,
the lower the disease prevalence the lower the probability that a positive result will be
"correct", regardless of sensitivity and specificity. Therefore, the prevalence of lesions in
each of the studies needs to be taken into account when comparing the predictive values.
Also, according to Bayes' Theorem, the prospective value can be expressed in terms of
prior probability, p (disease prevalence), sensitivity, and specificity see the second part of
Eq. 4.1 and Eq. 4.2. [14].
Tissue samples were obtained by different methods in the calibration and
prospective studies. Our initial calibration study was a case-control study, in which
tissues were procured from 58 patients with grossly visible/palpable lesions and paired
with normal control tissues whenever possible. Thus, the prevalence of cancer was
artificially increased (31/126; 25%) in the calibration data set. In the current prospective
study, 28 consecutive patients were examined. Only 6 of these patients had grossly
visible/palpable lesions; the remainder had mammographically suspect/non-palpable
lesions, the majority of which were non-cancers. This significantly reduced the
prevalence of cancer (IDC) in the prospective study. It should be noted that the decreased
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cancer prevalence (6/129; 5%) in the ex vivo prospective data set better represents the
disease prevalence in the general patient population [15]. An excellent NPV (99%) was
obtained in the prospective test for distinguishing cancerous from non-cancerous tissues.
In the clinical setting, NPV is the most important parameter for making clinical decisions.
In contrast, the NPV remained very high, the PPV was greatly reduced. The decreased
disease prevalence in the ex vivo prospective data set adversely affected the PPV of the
diagnostic algorithm, as discussed below.
The predictive values of our Raman diagnostic algorithm calculated for the
calibration and prospective data sets were based on the disease prevalence in the two data
sets, which differed. The cancer prevalence in the calibration study was 25%, while in
the prospective study it fell to 5%. As a result, PPV decreased and NPV increased in the
prospective study.
By evaluating these equations it was possible to compare effectiveness of the
Raman diagnostic algorithm for both of the data sets as a function of the prevalence. As
shown in Figure 4.4, with a drop in the prevalence of invasive cancer from 25% to 5%,
the PPV is expected to decrease from 88% to 53% while the NPV is expected to increase
from 98% to 99%. This indicates that the decrease in PPV seen in the prospective study
(from 88% to 36%) is due, in large part, to the decrease in cancer prevalence in the
patient cohort, rather than poor performance of the diagnostic algorithm.
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Figure 4.4. Predictive values as a function of prevalence of the disease
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4.3.6 Significance of spectrum of the disease
The sensitivity and specificity of the algorithm, applied prospectively, were lower
than for the original data set. The sensitivity, which is the probability of a positive test
result among patients with the disease, depends only on the distribution of positives
(lesions), while the specificity - the probability of the negative result among patients
without the disease - depends only on the distribution of negatives. At the same time,
both of these probabilistic variables are independent of the relative number of all
positives and negatives in the given data set. For that reason, some investigators suggest
that sensitivity and specificity are the best measures with which to compare diagnostic
algorithm performance from study to study [13]. However, sensitivity and specificity are
affected by the disease spectrum, the variability in severity of disease in the study
population [16]. When the target group - cancer - is distinctly different from the control
group - non-cancer, then the sensitivity and specificity will be high. When the difference
between the two groups is less prominent, the sensitivity and specificity will decrease,
(i.e. the spectrum of disease in the control group lessens the difference between non-
disease group and diseased one) [16].
In the prospective data set, we observed that the FCC specimens demonstrated a
broader diversity in their histological appearance compared to the original calibration
data set. In the original study, the predominant feature observed for FCC lesions was
stromal fibrosis, a pathology characterized by collagen accumulation. In the prospective
study, three different manifestations of FCC were observed: stromal fibrosis, cyst
formation, and adenosis (gland proliferation). In addition to the presence of ductal cysts
and adenosis, there was a marked increase in the amount of fat relative to stromal
fibrosis. This change in the disease spectrum of FCC between the two studies was
reflected in the Raman spectra as well as the fit coefficients for fat and collagen. The
mean fit coefficient of fat increased from 0.32 in the original study to 0.50 in the
prospective study and the mean fit coefficient of collagen decreased from 0.38 in the
original study to 0.29 in the prospective study. These differences likely contribute to the
increased in the rate of misdiagnosis between FCC and IDC in the prospective data set,
which in turn contributes to the observed decrease in both sensitivity and specificity in
the prospective study.
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4.3.7 Instrumentalfactors
Although we have minimized the effects of SNR through our spectral error
analysis, we may not have completely nullified all SNR effects. Any remaining SNR
effects would likely have the greatest effect on the diagnosis of fibroadenoma, as this
diagnostic category occupies the smallest area in our diagnostic plane.
Although it is difficult to quantify the effects of changes in disease spectrum on
algorithm performance due in part to the small size of the relevant subgroups of
fibrocystic change, it is clear that the decrease in sensitivity and specificity in the
prospective study results at least in part from changes in disease spectrum. The changes
in disease spectrum also effect PPV and NPV, which depend not only on disease
prevalence but additionally on sensitivity and specificity. Thus, the change in
performance of the Raman diagnostic algorithm can be largely explained by differences
in the two patient populations in the calibration and prospective studies with respect to
disease spectrum and cancer prevalence.
4.3.8 Significance of the study
The current study has validated a Raman spectroscopic algorithm for the
diagnosis of breast cancer that was developed in vitro on a large prospective ex vivo data
set that closely mimics the target patient population in our in vivo clinical studies,
described below.. It is the first prospective application of Raman spectroscopy in
diagnosing normal, benign and malignant human breast tissue in freshly excised surgical
specimens. The NPV of our diagnostic algorithm in this prospective study was excellent,
indicating that the algorithm that was devised in laboratory calibration studies can be
applied successfully in clinical studies. Changes in disease prevalence and disease
spectrum in the prospective data set were found to significantly affect the PPV,
sensitivity and specificity of the diagnostic algorithm.
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4.4 In vivo study of margin assessment
The excellent results of the Raman spectroscopy in diagnosing breast cancer on
excised tissue led to the first ever in vivo study to use Raman for the assessment of the
status of margins during mastectomy and lumpectomy surgeries. The study was
performed at the operating room of the Cleveland Clinic Foundation. The clinical
protocol was approved by both the Massachusetts Institute of Technology Committee on
the Use of Humans as Experimental Subjects and the Institutional Review Board of the
Cleveland Clinic Foundation, in accordance with an assurance filed with and approved by
the Department of Health and Human Services. Informed consent was obtained from all
subjects before the surgical procedures [1].
4.4.1 Motivation
As described in Chapter 1, a surgeon removes not only the entire malignant
tumor, but a small margin (1-2 mm) of normal breast tissue surrounding the lesion during
mastectomy and lumpectomy. To verify that the surgeon has removed the entire
malignant lesion, a pathologist performs an assessment of the tissue margins to confirm
that no malignant cells are present within 1 to 2 mm of the border of the excised lesion. If
the margin is found to be positive (malignant cells are identified) during the pathology
review, then the patient has to undergo a second surgery (re-excisional surgery) in which
additional tissue is excised. A technique that can perform accurate, real-time in vivo
margin assessment would reduce the number of re-excisional procedures required to
achieve negative margins. In addition, it may also extend partial mastectomy to those
women who do not have a sufficiently small or localized breast cancer to qualify for
partial mastectomy by current standards.
4.4.2 Study protocol
The in vivo study was conducted in the operating room during partial mastectomy
surgery [1]. A total of 30 Raman spectra were collected from nine patients, 29 from
margins subsequently found to be negative on pathology examination and 1 spectrum
from a margin subsequently found to be positive on pathology examination. Of the 29
negative margins, 21 were composed of normal breast tissue and 8 were FCC. The one
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positive margin was diagnosed as high-grade DCIS. Two spectra were excluded from the
present analysis. The first, a benign papilloma, is a pathology not encountered in our
previous studies and thus our diagnostic algorithm does not encompass this type of
lesion. The second was a margin noted by the pathologist to demonstrate significant
cautery artifacts a result of the surgical procedure. This was the only specimen where
cautery artifacts of this degree were observed. We were able to accurately fit all 30
spectra with our previously developed spectral model of breast (Chapter 4.1) [17].
The experimental system was aligned and the probe was submitted for cold-gas
ethylene oxide sterilization prior to data acquisition. Just before surgery, the proximal
ends of the sterilized Raman probe were coupled to the experimental system. The distal
end of the probe was kept sterile and placed in gentle contact with the margin tissue while
spectra were acquired. All room and surgical lights were turned off during the
measurements. Raman spectra were collected from several of these margins before
excision and, thus, only tissue that would normally be excised during the procedure was
removed. Each spectrum was collected for a total of 1 second. A range of powers (82 to
125 mW) were used depending on the throughput of the probe used. The standard
practice of the surgeon in this study was to excise six samples from the margins of the
surgical cavity following removal of the main tumor specimen.
acquisition, a volume of tissue
corresponding roughly to that
probed by the spectroscopic
measurement was excised by
the surgeon. The margin
specimens were then fixed in
formalin, routinely processed,
and the histologic slides were
examined by an experienced
breast pathologist who was
blinded to the outcome of the
Raman spectroscopy analysis.
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Figure 4.5. Model fits and fit coefficients to Raman
spectra acquired from normal, fibrocystic change and
DCIS lesions.
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The data was analyzed in real-time as detailed in Chapter 4.2 and the spectral-based
diagnosis was displayed within 1 sec [18].
4.4.3 Results
Model fits to in vivo Raman spectra acquired from normal, benign, and malignant
breast tissue are shown in Fig 4.5. The difference between the measured spectrum and the
model fit, the residual, is shown below each spectrum. The lack of significant structure in
the residuals indicates that the model accounts for the majority of the spectroscopic
features observed and describes the data well.
As in the previous study, the fit coefficients of normal breast tissue exhibit a large
contribution from fat. There is more noise evident in spectra acquired from diseased
tissue; however, they still yielded excellent model fits. Differences in the SNR in the
spectra between normal breast tissue and malignant tissue may be explained by the
presence of a large amount of cytoplasmic fat (which also has a large Raman scattering
cross section compared to other model components) in a normal tissue. The margin site
characterized as FCC showed an increase in the fit coefficient for collagen, due to
fibrosis, and epithelial cell cytoplasm, as a consequence of adenosis. The positive margin
diagnosed as high-grade DCIS, also displayed an increase in the amount of epithelial cell
cytoplasm. In our studies, the spectroscopic variable characterizing the nucleus-to-
cytoplasm ratio was obtained by dividing the fit coefficient of the cell nucleus basis
spectrum by the fit coefficient of the epithelial cell cytoplasm basis spectrum. The
nucleus-to-cytoplasm ratio was much larger for the cancerous specimen than for any of
the FCC lesions encountered in this study, as shown in Fig. 4.5C, a histologic signature
of cancer is enlargement of cell nuclei, and thus a higher nucleus-to-cytoplasm ratio than
seen in benign conditions. In fact, the nucleus-to-cytoplasm ratio is a criterion routinely
used by pathologists in the diagnosis of breast cancer [19, 20].
Fig 4.6.displays a scatter plot of the fit coefficients for collagen and fat, FC (Coll)
and FC (Fat), respectively, for all data acquired in this study. The diagnostic algorithm
developed earlier (Chapter 4.2) was applied in prospective manner. Table 4.2. provides a
comparison between pathology diagnoses with those of the spectroscopic diagnoses for
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Figure 4.6. Performance of Raman diagnostic algorithm for the in vivo study. This figure
is taken from [1] and reprinted with the permission of the publisher.
our data set. The algorithm demonstrated a sensitivity for detecting carcinoma of 100%, a
specificity of 100%, and an overall accuracy of 93.3% (28 of 30). Note, although there is
only one malignant sample in the present data set, this algorithm has been previously
validated on 31 cancer specimens. The high-grade DCIS correctly identified by Raman
spectroscopy was grossly invisible. Upon pathologic review, the finding that this margin
was positive necessitated that the patient undergo a second surgery to excise the
remaining cancerous tissue. Had Raman spectroscopy been used in a real-time fashion to
guide excision during the initial surgery, the additional procedure could have been
avoided.
athology Normal Fibrocystic change Cancer
Raman (21 samples) (8 samples) (1 sample)
Normal 21 2 0
Fibrocystic change 0 6 0
Cancer 0 0 1
Table 4.2. Comparison between histopathology diagnoses and spectroscopic diagnoses of
breast lesions obtained during in vivo clinical study.
4.4.4 Significance of the study
This pilot study was the first use of Raman spectroscopy to examine breast cancer
in vivo. It clearly showed the feasibility of Raman spectroscopy as a clinical technique for
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real-time margin assessment during partial mastectomy surgery. The data provided a
good agreement with the previously developed spectral model and diagnostic algorithm.
4.5 Summary
The main goal of this work was to show that the Raman spectroscopy can be
successfully used in the clinical setting for diagnosing breast lesions. Through the years
of extensive research, Raman spectroscopy has moved from the laboratory setting into
the clinic. A Raman diagnostic algorithm was developed in an in vitro study for
classifying normal, FCC, fibroadenoma and IDC breast tissue based on fat and collagen
composition. We then prospectively applied this algorithm to another set of ex vivo data.
The sensitivity and specificity of the prospective study decreased slightly, reduced mostly
due to differences in the prevalence of the disease between two studies as well as
differences in the spread of disease spectrum. Most clinically important is that NPV of
the prospective study, described in Section 4.3, was 98%, which means that a surgeon can
be 98% confident that he/she is not leaving behind in the breast cancerous cells.
Real time application of the technology was proven in the first ever in vivo
clinical study for the assessment of the status of margins. Once again the performance
findings were in good agreement with the previously developed spectral model and
diagnostic algorithm. Using Raman spectroscopy, a grossly invisible cancer was correctly
identified via Raman spectroscopy and later diagnosed as DCIS by pathologist. Thus, it
was shown that the additional procedure could have been avoided if Raman spectroscopy
had been applied in the operating room to provide a real time feedback to surgeons.
Future Raman spectroscopy studies should be focused on the development of
additional algorithms to add other pathology diagnoses, such as ductal carcinoma in situ
(DCIS) and benign lesions other than FCC and fibroadenomas. Also, since the original
algorithm was developed using in vitro specimens it did not contain any calcified lesions.
Thus, a new diagnostic algorithm needs to be developed in order to classify these types of
lesions.
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Clinical DRS/IFS ex vivo study
Previous diffuse reflectance (DRS) and intrinsic fluorescence (IFS)
spectroscopy studies by our laboratory have shown promising results for the detection
of cervical dysplasia and oral cancer [1, 2]. The combination of DRS and IFS
provides a more complete biochemical and morphological profile than any of these
modalities individually. In this chapter we describe an ex vivo clinical study we
performed to test the potential of a combined DRS/IFS approach for the detection of
breast cancer. We used the clinical FastEEM instrument (Chapter 3) to collect data
from the same freshly excised breast tissue sites evaluated in the previous chapter
using the Raman clinical instrument. Using the physically meaningful parameters
extracted from the data, we developed a DRS/IFS diagnostic algorithm. A multimodal
spectroscopic algorithm, which included diagnostic parameters from DRS, IFS, and
Raman spectroscopy, was also constructed to determine whether this would lead to
further improvement in the overall diagnostic accuracy.
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5.1 Introduction
The ex vivo clinical study was conducted at the University Hospitals-Case
Medical Center (UHC) after being approved by the UHC Institutional Review Board
and the MIT Committee on the Use of Humans as Experimental Subjects. Data were
acquired using the FastEEM system over a period of 2 months from 17 consecutive
patients undergoing surgical biopsies. Data were acquired from the same tissue sites
and samples as were evaluated by the clinical Raman system in Chapter 4.
5.2 Data acquisition
Prior to data collection, calibration spectra were acquired as described in
Chapter 3. Spectra were collected in the frozen section room of the hospital from
freshly excised breast surgical specimens within 30 minutes of excisional biopsy
(n=16) and partial mastectomy (lumpectomy; n=1) procedures. Most of the 30 minute
delay was due to the gross examination, inking and sectioning of the specimen
performed as part of the routine pathology intraoperative consultation. Each surgical
specimen was interrogated at multiple sites of interest as indicated by the pathologist.
In addition, spectra were also acquired from the colloidal inks used to mark the
surgical margins of each specimen, after confirming that no artifacts were introduced
in the data as a result of this processing step. Two sets of DRS and IFS spectra were
taken at each site of interest to ensure that the spectra were free from artifacts.
Overall, 202 sets of DRS and IFS spectra from 104 sites were obtained from 17
patients, providing approximately 2 spectra per site.
Spectra that were unreliable or of poor quality were excluded from the
analysis according to a defined set of criteria. Specifically, DRS data in which the
overall reflectance was less than 1 percent were excluded. The low signal prevents the
reliable processing of the reflectance spectra, and thus extraction of information
needed to obtain the intrinsic fluorescence. Spectra from 11 sites failed to meet these
criteria as a result of contamination of the tissue surface by blood, which strongly
absorbs the reflected light. Additionally, specimens from patients with pre-operative
chemotherapy or who underwent re-excisional biopsy were excluded from analysis.
Sites classified into histological categories other than normal, fibrocystic change
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(FCC), fibroadenoma, and infiltrating ductal carcinoma (IDC) were also excluded
because their limited numbers precluded development of a robust diagnostic
algorithm. These included 2 sites diagnosed as ductal epithelial hyperplasia, 1 site
diagnosed as fat necrosis and 6 sites diagnosed as ductal carcinoma in situ (DCIS)
Following these exclusions, 202 IFS and DRS spectra acquired from a total of 104
breast tissue sites (1 and often 2 spectra per site) in specimens from 17 consecutive
patients remained and were used for spectroscopic analysis.
5.3 Pathology
After acquisition of the spectra, the exact site of probe placement was marked
with colloidal ink for correlation with histopathology. The breast specimens were
then fixed in formalin and submitted for routine pathology evaluation, performed by
an experienced breast pathologist blinded to the spectroscopy results. The
histopathology diagnoses for the 104 breast tissue sites were as follows: 31 normal,
55 fibrocystic change, 9 fibroadenomas and 9 invasive carcinomas (all infiltrating
ductal carcinoma) [5, 6]. The relative number of samples in each diagnostic category
in this data set closely resembles the typical prevalence for diseases of breast tissue
[7].
5.4 Development of a DRS/IFS diagnostic algorithm
We analyzed the DRS spectrum from each breast tissue site using a
mathematical model based on the diffusion approximation of light propagation in
tissue to determine the values of absorption coefficient, pa(X) and reduced scattering
coefficient, ps'(k) (Chapter 3) [8]. In order to extract the absorption coefficient, pLa,
two major absorbers, oxyhemoglobin and p-carotene, were used to model the
absorption of the tissue [9]. Because this study was performed ex vivo, the tissue was
exposed to room air and hemoglobin was fully oxygenated; therefore,
deoxyhemoglobin was not included. The wavelength-dependence of the reduced
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scattering coefficient, ps'(x), was modeled according to the following equation: Al-B
[10].
IFS spectra were extracted from the measured fluorescence spectra as
previously described in the Chapter 3 [11]. In a turbid medium such as tissue,
differences in the local chemical environment, may alter the shape of the measured
fluorescence from that of the pure components [12]. In contrast, the IFS spectrum is
composed of a linear combination of the spectra of the individual fluorophores
present in the tissue. Therefore, pure component spectra were fit to the intrinsic
fluorescence spectra. The fit coefficients for the individual fluorophores were
extracted using multivariate curve resolution (MCR), a standard chemometric method
[13].
5.4.1 Multivariate curve resolution (MCR)
MCR calculates basis spectra-MCR components- by minimizing the fitting
error of a given spectrum using an initial set of guess spectra as the input. For the
analysis, we extracted MCR basis spectra using spectra extracted from tissue
measurements as an initial guess [12]. Despite the original spectra being noisy, good
fits were obtained using MCR. Although, different initial guess basis spectra were
used for the MCR analysis, we confirmed that the MCR components extracted using
the various initial guess basis spectra overlapped. This suggests that minimization of
the fitting error does not rely heavily on the initial guess spectra. This is very
beneficial, as it is difficult to know the exact spectral shape of the various
fluorophores present in tissue due to variations in the tissue microenvironment.
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Figure 5.1. MCR from basis spectra for fitting mixture data: FAD, elastin: a) 1:2
concentrations; b) 1:3 concentrations, respectively. Data (blue), fit (red)
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In order to investigate the physical meaning and the reliability of the
parameters (e.g. fit coefficients) extracted from the intrinsic fluorescence, a chemical
study was performed in the Spectroscopy Laboratory using the FastEEM instrument.
Additional information can be found in [5]. The purpose of the study was to ensure
that the fit coefficients extracted using MCR have a physical basis. To test this
assumption, fluorescence spectra obtained from pure components (elastin and flavin
adenine dinucleotide (FAD)) were used to fit experimental data obtained from
mixtures of these pure components and linearity was confirmed using ordinary least
squares (OLS) fitting. After verifying that the system response was linearly dependent
on the concentration of the components, parameters obtained from MCR were used to
fit the experimental data collected from mixtures of pure components and the
resulting fit coefficients compared to expected values. Mixtures of FAD and elastin
were created in concentration ratios of 1:2 and 1:3 as is shown in Fig 5.1. As
expected, a linear combination of the spectra from the pure components fit the data
well, confirming system linearity.
The fit coefficients for a 1:2 ratio of FAD:elastin were 0.356 and 0.644,
respectively. The fit coefficients for a 1:3 ratio of FAD:elastin were 0.255 and 0.745,
respectively. In this case the error was no more than 7 percent. From this analysis we
concluded that in a simple system MCR provides reliable fit coefficients with a
physical meaning from spectra obtained from mixtures.
5.4.2 Choosing diagnostically-relevant wavelength
Based on the results of this study, we analyzed the IFS spectra from the ex
vivo tissue using two MCR components. The initial input spectra used for the MCR
analysis were the pure component spectra of fluorophores known to be present in
breast tissue, as described in Table 5.1 [12]. The maximum number of the initial input
spectra was not constrained; however, after analyzing the data, we found that only
two spectra were required to produce good fits to the data. The resulting MCR-
generated spectral components at 340 nm are shown in Figures 5.2a and 5.2b. The
combined basis spectra and fit to a representative IFS spectrum are shown in Figure
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5.2c. The MCR-generated spectral components are similar to the spectra of pure
NADH and collagen, respectively, but are broader and red-shifted, likely as a result of
the local properties of the tissue microenvironment [14].
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Figure 5.2. Comparison of pure component spectra(blue) and MCR basis spectra (red)
excited at 340 nm for a) NADH, and b) collagen; c)representative spectrum fit with a
linear combination of NADH (magenta) and collagen-like (green) basis spectra; data
(blue), fit (red), residual (black).
As was described previously in Chapter 3, the FastEEM instrument provides
emission spectra at 10 different excitation wavelengths. Collagen, NADH, elastin,
tryptophan, FAD, and porphyrins, the native fluorophores of breast tissue, have their
maximum emission at 308, 340, 360, and 425nm excitation wavelengths (Table 5.1)
[14]. Thus, these four fluorescence excitation wavelengths were employed in the
initial analysis.
Excitation Wavelength
308nm 340nm 360nm 425nm
NADH NADH NADH Collagen
Collagen Collagen Collagen Elastin
Fluorophores
Tryptophan Elastin FAD FAD
I _ I___I __ IPorphyrins 1
Table 5.1. Expected fluorophores for different excitation wavelengths.
However, it was found that not all of these fluorophores could be detected,
presumably because they were not present in our specimens at high enough
quantities. Undetected fluorophores included elastin (340 nm excitation) and FAD
and porphyrins (both excited at 360 nm). The absence of these fluorophores was
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confirmed by attempting to extract additional basis spectra using MCR and finding
that the contributions were negligible.
Of the measured fluorophores, only NADH and the collagen-like component
excited at 340 and 360 nm were required to obtain good fits to the IFS spectra. The
contributions of these two fluorophores at 340 and 360 nm, respectively, were very
similar, which is not surprising given the closeness of these two excitation
wavelengths. These excitation wavelengths associate with different penetration depth
of the light. However, this difference was estimated to be less than 5ptm and was not
sufficient enough to provide different parameters that could be diagnostically
DRS IFS excited at 340 nm
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Figure 5.3. Representative DRS and IFS spectra excited at 340 nm for a) normal tissue, b)
a lesion with fibrocystic changes, c) a fibroadenoma and d) infiltrating ductal carcinoma.
Data (blue), fit (red), residual (black). This figure is taken from [3] and reprinted with the
permission of the publisher.
significant. Averaging the information at these two wavelengths did not improve the
fits. Therefore, we opted to evaluate the contributions of NADH and the collagen-like
component excited at 340 nm for each tissue site, as this is the excitation wavelength
at which NADH emission is maximal. By analyzing a single wavelength we reduced
the complexity of the subsequent analyses. The additional benefit of this approach is
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that only a single UV source is required for future clinical instruments. Thus, the next
generation of the DRS/IFS instrument can be more compact, which is a significant
advantage in the clinical setting. Representative DRS and IFS spectra collected at 340
nm excitation are shown in Fig 5.3.
A total of six spectroscopy parameters were extracted from the spectra and
used to characterize the tissue-four DRS parameters (A, B, oxy-hemoglobin and,p-
carotene) and two IFS parameters (a collagen-like component and NADH).
5.4.3 Step-wise algorithm
All of the fit parameters except B were found to be diagnostically significant.
Boxplots of the diagnostic parameters as a function of lesion type are shown in Fig
5.4. (A boxplot is a graphical representation of the spread in a set of data, in which
the second and third quartiles are bounded by the box and the median for the data set
is indicated by the red center line. The inter-quartile range is defined as the distance
between the first and third quartiles. The extreme values are defined as 1.5 times the
inter-quartile range, measured from the median. Data points outside of this range are
defined as outliers and indicated by crosses. Depicting data using boxplots is useful
for visually examining the diagnostic capability of each parameter. For example, the
boxplot for the collagen-like component indicates that normal breast sites may be
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Figure 5.4. Boxplots of normal (Normal), fibrocystic change (FCC), fibroadenoma (FA),
and infiltrating ductal carcinoma (IDC) for diagnostically relevant parameters. This figure
is modified from [31 and reorinted with the oermission of the oublisher.
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distinguished from other lesions using this parameter because they demonstrate lower
contributions of this component. It is important to note that diagnostic parameters in
a particular tissue type may be correlated. Hence, one parameter may provide only
partial separation, but combining it with additional parameters may lead to an even
greater separation. The benefit of combining multiple parameters cannot be visualized
using boxplots.
In order to be clinically relevant, a spectroscopic diagnostic algorithm must be
able to classify tissue sites according to the following 4 histopathology diagnoses:
invasive breast cancer (in our case infiltrating ductal carcinoma (IDC)), benign breast
lesions (fibroadenoma and fibrocystic change (FCC)), and normal breast tissue. In
addition, it is important to distinguish different types of benign lesions from normal
tissue.
Because tissue from
different pathology categories are Nra
likely to be characterized by FlbroadenomN
different diagnostic parameters, we
performed the analysis in a step-
FCCC
wise fashion, as illustrated in Fig
5.5. In the first step, normal F
specimens are separated from the Figure 5.5. Step-wise diagnostic algorithm. This
figure is taken from [3] and reprinted with the
rest of the specimens. Following permission of the publisher.
this step, fibroadenomas are
separated from FCC and DC, and in the third and final step, DC is separated from
FCC. The diagnostic algorithm was developed using logistic regression and leave-
one-out cross validation. Histopathology diagnoses were used as the "gold" standard
against which the spectroscopic diagnoses were compared. Identification of the most
diagnostically important parameters was performed by optimizing the sensitivity at
each step in the algorithm. The diagnostic step-wise algorithm is presented in Fig 5.6.
In step 1, normal sites are classified using the collagen-like component and p-
carotene fit coefficients extracted from IFS and DRS, respectively (Fig 5.6a). In step
2, fibroadenoma sites are discriminated from FCC and IDC using the DRS scattering
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parameter A and the NADH fit coefficient extracted from IFS (Figure 5.6b). Finally,
in the third step, IDC sites are distinguished from FCC primarily based on
oxyhemoglobin, and to a lesser extent, the collagen-like component (Figure 5.6c).
5.4.4 Results
Table 5.2 compares the DRS/IFS spectral diagnoses and the histopathology
diagnoses. The diagnostic algorithm was successful in distinguishing normal, FCC,
fibroadenoma and IDC using physically-meaningful parameters extracted from
combination of DRS and IFS. All of the invasive carcinomas are correctly classified
Pathology Normal Fibrocystic Fibroadenoma Infiltrating
DRSaFS Change Ductal Carcinoma
(31 samples) (55 samples) (9 samples) (9 samples)
Normal 26 3 0 0
Fibrocystic Change 2 51 0 0
Fibroadenoma 0 0 9 0
Infiltrating Ductal Carcinoma 3 1 0 9
Table 5.2. Comparison of DRS/IFS classifications and histopathology diagnoses
and only 3 normal specimens and 1 fibrocystic change lesion were misclassified (both
as IDC). The total efficiency (overall accuracy) is 91% (95/104). The sensitivity and
specificity are 100% and 96%, respectively, with sensitivity defined as the fraction of
cancers correctly identified by the algorithm, and specificity defined as the fraction of
non-cancerous lesions correctly identified. The positive and negative predictive
values are 69% and 100%, respectively. PPV is the probability that a positive result is
accurate (i.e. that the patient actually has the specified disease). NPV is the
probability that a negative result is accurate [15]. NPV is the most important value
for our clinical work because it is more tolerable to excise normal or benign lesions
(as might occur when a technique has a low PPV) than to miss treating a cancerous
lesion (owing to a low NPV). Therefore, it is important that our technique have a
high NPV in order to be effective in clinical practice. As described in Chapter 4,
predictive values depend on the prevalence of disease. The prevalence for the lesions
in our data set is similar to the known prevalence encountered for clinical practice and
therefore the predictive values achieved by our technique are representative of what
would be observed if applied to the general population.
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In contrast to studies reported by other groups [16-18], we find that the DRS
parameters contribute the most to the distinction of benign from malignant lesions.
For example, using only the DRS parameters (A and the relative contributions of p-
carotene and oxyhemoglobin), we obtain a sensitivity, specificity, PPV, NPV, and
total efficiency of 100, 100, 100, 100, and 81 percent (85/104), respectively. All
malignant sites were correctly diagnosed, however some benign sites were
misclassified. A total of 6 normal and 1 fibroadenoma were misclassified as FCC, 8
FCC lesions were misclassified as normal and 4 FCC lesions were misclassified as
fibroadenomas. None of these are clinically significant misclassifications.
An accurate classification scheme could not be generated from IFS parameters
alone (relative contributions of NADH and the collagen-like component). Results for
the sensitivity, specificity, PPV, NPV and total efficiency were 89, 66, 20, 98, and 80
percent, respectively. It is important to note that although the inclusion of IFS
parameters into the combined algorithm does not improve the distinction of benign
from malignant lesions, IFS significantly improves the total efficiency (increase of 12
percent from the DRS algorithm alone). The total efficiency is the only metric that
considers the accuracy of the technique in subclassifying the benign lesions,
specifically normal, FCC and fibroadenoma.
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Figure 5.6. Step-wise DRS/FS diagnostic algorithm. a) Step 1 - identification of
normal tissue from rest of diagnoses; b) Step 2 - identification of fibroadenoma; c)
Step 3 - identification of FCC and IDC. This figure is taken from [4] and reprinted
with the permission of the publisher.
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5.4.5 Correlation with pathology
The DRS/IFS analysis accounts for physical changes in tissue composition
that contribute to changes in histopathology. Normal breast tissue consists mostly of
adipose tissue (fat). In contrast most breast lesions are characterized by an increase in
fibrous stroma, and thus an increase in the amount of collagen [7]. Therefore, in the
first stage of our diagnostic algorithm, we would expect normal tissue to be
distinguished from the three other types of breast lesions by the relative contributions
of the collagen-like component and p-carotene, a lipid-soluble marker of adipose
tissue. In the second stage of the algorithm, fibroadenomas are separated from FCC
and IDC based on NADH and A. By histopathology, FCC and IDC are both cellular
proliferative lesions, accounting for their relatively large contributions of NADH, a
product of cellular metabolism. The A parameter is representative of the density of
scatterers in the tissue [8]. We expect IDC to have a relatively high value of the A
parameter as a result of fragmentation and disorganization of the collagen fibers in
the stroma of invasive cancers due to the action of matrix metalloproteinases [19].
Finally, in the third stage of the algorithm, IDC is separated from FCC on the basis of
collagen-like component and oxyhemoglobin fit coefficients. As with most malignant
tumors, IDC is characterized by angiogenesis (increased vasculature) [7], therefore it
is not surprising that oxyhemoglobin is useful for separating IDC from FCC.
Interestingly, oxyhemoglobin is also a diagnostic parameter in diffuse optical
tomography imaging of breast cancer. It is not as clear why the collagen-like
component is useful in distinguishing IDC from FCC, as both demonstrate stromal
fibrosis. However, since there are differences in the types of collagen present in the
stroma of these two lesions [20], it is possible that the MCR collagen-like component
basis spectrum better reflects the type of collagen present in FCC. The number of
DCIS specimens was too small to develop a diagnostic algorithm. A larger clinical
study is needed to identify DCIS using our technique, as will be discussed in the
subsequent chapter.
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5.4.6 Significance of the study
The DRS/IFS spectroscopy study showed promising results in discriminating
breast lesions. This study is the first to show the benefit of combining diffuse
reflectance and fluorescence modalities. The step-wise diagnostic algorithm is based
on physically-meaningful parameters extracted from tissue spectra using a
mathematical model based on the diffusion approximation and multivariate curve
resolution. A diagnostic algorithm was developed based on A, p-carotene,
oxyhemoglobin, NADH and the collagen-like component using logistic regression
and a leave-one-out cross validation scheme. The diagnostic algorithm resulted in
100% sensitivity, 96% specificity, 69% positive predictive value, 100% negative
predictive value and 91% total efficiency. As our diagnostic algorithm was
constructed using an ex vivo data set and the prevalence of lesions in our study
closely reflect those observed in the general population, we expect the performance of
the algorithm to remain high in a larger study. As an important next step, our
diagnostic algorithm should be prospectively tested in an independent clinical study
with a larger number of patients. In Chapter 7 we present the results of a prospective
clinical trial we performed based on the successful findings of this ex vivo study.
5.5 Development of MMS diagnostic algorithm
So far we have presented the results of two individual studies to develop
diagnostic algorithms for breast cancer: Raman Spectroscopy (Chapter 4) and the
combination of DRS and IFS spectroscopy (Chapter 5.4). In these studies, the same
tissue sites were interrogated with DRS, IFS and Raman [21] spectroscopy.
Therefore, we investigated the possibility of further improving our diagnostic
capabilities by combining the respective information into one diagnostic algorithm.
Specifically, we would use diagnostic parameters from all three modalities to
construct a multimodal spectroscopic (MMS) diagnostic algorithm. In developing the
MMS algorithm, only parameters that were diagnostic in each of the individual
modalities were used: A, oxyhemoglobin, and p-carotene from DRS, NADH and
collagen from IFS, and the fit coefficients for fat and collagen from Raman
spectroscopy. Both IFS and Raman are sensitive to collagen. However, because each
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uses a different wavelength of light (830 nm for Raman and 340 nm for IFS), the
sampling depths are different. This fact explains why collagen fit coefficients
extracted via Raman spectroscopy do not strongly correlate with collagen fit
coefficients extracted using IFS.
5.5.1 Result and Significance of the study
In order to distinguish among each of the histopathology categories, leave-
one-out cross validation and logistic regression were performed after classifying the
tissue sites with the MMS diagnostic algorithm. As in the case of DRS/IFS diagnostic
algorithm, the MMS diagnostic algorithm was constructed in a sequential fashion. Fig
5.7 illustrates the MMS step-wise diagnostic algorithm. In the DRS/IFS diagnostic
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Figure 5.7. MMS step-wise algorithm
_" Pathology Normal Fibrocystic Fibroadenoma Invasive
MMS ______ Change ________Carcinoma
(32 samples) (55 samples) (9 samples) (9 samples)
Normal 30 4 0 0
Fibrocystic Change 2 49 0 0
Fibroadenoma 1 0 1 0 1 9 0
I nvasive Carcinoma 1 0 1 2 0 9
Table 5.3. Comparison of MMS discrimination and histopathology classification
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algorithm developed in the previous section, 2 normal tissue sites were misdiagnosed
as FCC and 3 normal tissue sites were misdiagnosed as IDC. By introducing the fit
coefficient of collagen obtained from the analysis of the Raman spectra to the first
step of the analysis (distinction of normal sites from lesions) we achieve a better
separation. Rather than 5 misclassifications, only two normal tissue sites were
misclassified (both as FCC, a benign condition). The results for the two subsequent
diagnosis steps were identical to those obtained in DRS/IFS diagnostic algorithm. In
the second step, all 9 fibroadenoma lesions were correctly diagnosed, while in the
third step both DRS/IFS and Raman misclassified the same two samples. The fact
that both modalities misclassified the same limited number of samples suggests a
possible registration error. Table 5.3 provides an overview of the MMS algorithm
performance. The MMS algorithm improved the number of sites correctly diagnosed
as normal and FCC over that from algorithms based on either DRS/IFS or Raman.
Additionally, fewer histopathology categories were misclassified as cancerous, which
is a major benefit in that it increases the sensitivity and overall accuracy of this
technique. The MMS algorithm resulted in sensitivity, specificity and overall
accuracy of 100%, 98%, 92%, respectively.
5.6 Summary
In the clinical ex vivo study presented in this Chapter, we first described the
development of a diagnostic algorithm based on physically-meaningful parameters
extracted from DRS and IFS. The DRS/IFS diagnostic algorithm was developed using
logistic regression and leave-one-out cross-validation. Using these two modalities to
classify the data we obtained a sensitivity, specificity and overall accuracy of 100%,
96% and 91% respectively. For comparison, we then constructed a MMS diagnostic
algorithm that combined spectroscopic data obtained from DRS, IFS and Raman
spectroscopy. All data were collected on the exact same tissue specimens. The MMS
algorithm showed a slight improvement over individual modalities and the DRS/IFS
algorithm, resulting in a sensitivity, specificity, and overall accuracy of 100%, 98%,
and 92%, respectively.
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This study showed the potential to improve the accuracy of spectroscopic
diagnostic algorithms by combining DRS, IFS and Raman spectroscopy as compared
to when any one technique is used. For this study it is important to note that two
different instruments and two different probes were used, thus there is some
uncertainty in whether the exact same tissue site was evaluated by each probe.
Therefore, to rigorously test the robustness of the MMS diagnostic algorithm a
multimodal spectroscopy instrument needs be constructed which can be tested in the
clinic. The development of such an instrument is described in Chapter 6.
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CHAPTER 6
Multimodal system: instrument and probe
This chapter describes the multimodal spectroscopy (MMS) instrument, which
combines Raman, diffuse reflectance and fluorescence modalities. The
(MMS) instrument is based on our previously described Raman and DRS/IFS
instruments; several key parts of the instrumentation, including hardware and
software, are presented in Chapter 3. One of the most challenging parts of the
MMS system development was the design and construction of the new MMS
front-viewing probe. This probe is capable of delivering and collecting both
visible and near infrared light. Differences in fitting data obtained with the
MMS and FastEEM probes are due to difference in probe geometry and are
explained further. Additional information on the MMS instrument can be
found in [1, 2].
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6.1 Motivation
In previous chapters (Chapters 4 and 6) it was shown that breast lesions were
successfully studied using two different instruments. Each of these instruments has its
own probe and software. The clinical Raman instrument [3] and probe [4] have been
developed for real-time clinical study of disease status of tissue, such as breast lesions
and atherosclerosis. The FastEEM instrument [5] has been used to extract DRS and
IFS spectra excited at several wavelengths within the range of 308 nm to 500 nm; and
it was used to study breast lesions, atherosclerosis, cervical dysplasia and oral cavity.
In the case of breast tissue, each of these techniques, Raman and the combination of
DRS and IFS, were able to correctly distinguish among four different pathology
diagnoses: normal tissue, two benign lesions - fibrocystic change (FCC) and
fibroadenoma, and a malignant lesion - infiltrating ductal carcinoma (IDC).
However, in order to apply spectroscopic techniques in a clinical setting to assess
status of margins during surgical excisions such as mastectomy and lumpectomy, the
spectroscopic technique would have to be able to diagnose ductal carcinoma in situ
(DCIS) as well. If the margin status is positive according to histopathology diagnosis,
most often it is due to the presence of DCIS. In our studies, Raman and DRS/IFS
individually are unable to distinguish DCIS from the other pathologies. Thus, the
combination of all three modalities - multimodal spectroscopy - has been explored.
6.1.1 Complementarity
Each of the spectroscopic modalities provides complementary information
about the biochemical state of biological tissue. As discussed in Chapter 3, diffuse
reflectance spectroscopy provides information about absorbers and scatterers such as
p-hemoglobin, oxy and deoxy-hemoglobin; fluorescence spectroscopy provides
information about autofluorophores such as collagen and NADH; and Raman
spectroscopy provides information about Raman active molecules found in the tissue
such as fat, collagen, calcium, and others.
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6.1.2 Elimination of the probe placement error
Development of a combined instrument should be done in parallel with
development of an efficient unitary probe that is able to simultaneously collect
spectra from all three modalities. Previously, when data was collected with two
different instruments, and thus two different probes, error between sampling sites of
each probe could have been introduced. Although great care was taken to place the
FastEEM probe in the same location as the Raman probe, the absolute precision and
accuracy of probe placement could not be guaranteed. The design and development
of the multimodal (MMS) probe will eliminate this sampling error.
6.1.3 Compact clinical system
Simultaneous usage of two clinical instruments is possible; however, clinical
settings are usually limited in space and already crowded with medical instruments.
Thus, it is desirable to have a single portable instrument that can be easily rolled in
and out of the operating room or radiology room. The system should be able to
provide diagnostically relevant information in real time and should be easy to operate.
This system will be used not only for research purposes, but if the MMS instrument
shows promising results, it will be given to the hospitals and will be operated by
nurses or technicians.
6.2 MMS instrument design
6.2.1 Instrument development
The clinical portable MMS instrument [1] (Figure 6.1) merges optimized
designs of the clinical Raman and FastEEM instruments. The MMS instrument
contains three excitation sources: an 830 nm diode laser (Process Instruments, Salt
Lake City, UT) used to excite Raman spectra; a Xe flash lamp (L7684, Hamamatsu
Corp., Bridgewater, NJ) used to obtain diffuse reflectance spectra (DRS); and a 337
nm N2 laser (NL100, Stanford Research Systems, Sunnyvale, CA) used to excite
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Figure 6.1. Diagram of the MMS instrument. LF - long pass filter, BF - bandpass
filter, FL - focusing lens, S - shutter, OF - optical fiber, FS - fiber switch, SP1 and
SP2 - visible and NIR spectrograph, respectively, iCCD and XTE CCD -
intensified and thermoelectrically cooled charge-coupled devices, respectively.
This figure is taken from [1] and reprinted with the permission of the publisher.
fluorescence. All of these sources are externally triggered via automated software.
The diode laser is capable of providing up to 500 mW of continuous-wave 830 nm
light, driven by a user-specified analog signal. The 830 nm laser light is filtered by an
830 nm bandpass filter (LLO1-830-12.5, Semrock, Rochester, NY) and gated by a
mechanical shutter (LS6ZM2, Vincent Associates, Rochester, NY) before being
focused into an optical fiber. The Xe lamp provides a 2.9 gs FWHM white light
pulse, 1 J/pulse max. The light from the Xe lamp passes through a 370 nm long pass
filter (LP02-364RS-25, Semrock, Rochester, NY) and is then focused into a fiber.
This long pass filter guarantees that the reflectance, collected over the range 370-740
nm is free of second order diffraction from the spectrograph grating. The N2 laser
provides externally triggered 3.5 ns FWHM pulses of 337 nm light, 170 pJ per pulse,
with a 10 Hz repetition rate. This light passes through a UV-coated lens and is
focused into an optical fiber.
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An optical fiber switch (FSM14, Piezo Jena, Germany) is used to sequentially
couple all three excitation sources into the MMS probe. An optical fiber switch is a
MEMS device that provides superior coupling of the individual sources and is
controlled by user-configurable binary code. This switch contains four optical fiber
inputs and a single optical fiber output with each fiber terminated by an SMA
connector. Thus it is possible to couple up to four sources into the output fiber. The
outputs of the Xe lamp, N2 laser, and diode laser are directly channeled into three
input fibers of the switch. The remaining input channel is left vacant for a possible
future light source. The output fiber of the switch is connected to the MMS probe by
means of an SMA-to-SMA connector that produces a reproducible and efficient
connection. The overall transmission efficiency of the switch is -60%, resulting from
an 80% switching efficiency and an 80% SMA-to-SMA coupling efficiency.
Detection of the collected light is performed with two spectrograph/CCD
modules, one optimized for NIR detection (Raman) and the other for visible
wavelengths (reflectance and fluorescence). The operation of both cameras is
controlled by modular LabVIEW drivers (R3 Software, Princeton, NJ).
The distal ends of the 10 collection fibers carrying the Raman light are aligned
in a linear array, serving as the entrance slit to the spectrograph (Holospec f/1.8i,
Kaiser Optical Systems), resulting in a -9 cm 1 spectral resolution. The fibers are
encased in a modified male FC connector to ensure highly reproducible alignment
with the connector plate of the spectrograph. Any spectral changes incurred by
disconnecting and reconnecting the linear array are found to be below the system's
spectral resolution. The numerical aperture of the collection fibers (NA=0.26) is
matched to the spectrograph (f/# = 1.8) to conserve throughput. The spectrograph
contains an 830 nm notch filter to further suppresses the elastically scattered Rayleigh
light, and a holographic grating to disperse the Raman scattered light onto a back-
illuminated, deep-depletion CCD detector with a 1024x256 array of pixels (Spec10
XTE, Princeton Instruments/Acton, Acton, MA). The CCD detector has a 16 bit
dynamic range and can be thermoelectrically cooled within minutes to -90'C, a
significant practical improvement over the older Raman system, which had a liquid
nitrogen cooled CCD that needed about 1.5 hours to be cooled to -120'C.
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The five remaining collection fibers that are used for reflectance and
fluorescence light are arranged vertically and coupled into a diffraction grating
spectrometer (Spectra Pro 150, Princeton Instruments/Acton, Acton, MA), resulting
in a -6 nm spectral resolution. The collection fibers have individual male SMA
adapters that connect to corresponding female SMA adapters mounted to a plate
adjacent to the spectrograph; this ensures easy reproducibility when the MMS probe
is disconnected from and reconnected to the system. The collected light is then
dispersed onto an intensified CCD detector (PIMAX, Princeton Instruments/Acton,
Acton, MA). The PIMAX CCD has a 16 bit dynamic range and is thermoelectrically
cooled to -20*C. The CCD is operated in a gated mode, where the intensifier is biased
on for only the short period of time (-30 ts) extending from immediately prior to
immediately after each laser/white light pulse. All spectra must be collected with
room lights off because the Raman signal is weak compared to ambient background
light.
Init System
a) START
Fiber switch #1
Laser shutte ON
Collect Raman spectra
Laser sutter OFF
# acq Fiber switch #2 Collect DRS
no
one Acq++ TriggerXe lamp
yes 
rairIC
Fiber switch #3 TrIger ICCD
no
one Acq++ Trigger N laser
yes
RT analysis
Figure 6.2. a) Flow-chart of the MMS software b) Front panel of the MMS instrument.
This figure is modified from [1] and reprinted with the permission of the publisher.
The MMS instrument is controlled by software developed in LabVIEW
(National Instruments, Austin, TX) and Matlab R2008b. The flow-chart of the
software of a single MMS acquisition is depicted in Fig. 6.2a, indicating periods of
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time required by each source and detector for data collection. Two data acquisition
cards (DAQ) (6062 and 6035E, National Instruments, Austin, TX) are used to trigger
sources and cameras. Figure 6.2b shows the front panel of the MMS software. User-
friendly software allows one to choose to acquire MMS data (all three modalities) or
separately Raman and the combination of DRS and IFS spectra. Exposure time and
number of spectra can be easily changed depending on the needs of the user and the
quality of the signal. All data is displayed in real time.
6.2.2 Instrument calibration and stability
Real-time data analysis and diagnosis depends on acquiring spectra for
calibration and background subtraction prior to data collection. The software allows
acquisition and storing of calibration spectra, which provides easy operation of
experimental and clinical data collection and instant feedback about the collected
spectra quality, fits, and diagnostic parameters.
The Raman-shift axis is calibrated using spectra acquired from 4-
acetamidophenol (Tylenol), with known peak positions. The fused silica Raman
background arising from the optical fiber probe is taken into account by acquisition
of a spectrum from roughened aluminum. The roughened aluminum provides enough
reflected light to record the Raman signal from the probe alone, which is later used in
fitting to experimental data. Finally, the spectral response of the Raman spectrograph
is obtained by collecting a spectrum of calibrated tungsten white-light source
diffusely scattered by a reflectance standard (BaSO4).
The wavelength of the reflectance and fluorescence spectra is calibrated by
obtaining a spectrum of a mercury lamp. In order to remove effects of CCD dark
current and stray light, a spectrum is acquired of deionized water contained in an
opaque cup. The amplitude of the reflectance signal is calibrated by collecting a
spectrum from a reflectance standard (20% reflectance standard, Labsphere Inc.,
North Sutton, NH). Finally, to normalize the fluorescence spectra, the output power
from the N2 laser is recorded on a daily bases via an energy meter.
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It is important to
operation. Based on
reconnecting the MMS
parameters and intensity
note that the MMS instrument must be stable for day-to-day
the design of the probe coupling, disconnecting and
probe to the instrument does not change the calibration
of the light delivered to the tissue.
6.2.3 Instrument layout
The MMS instrument has been designed to be used in a clinical setting in
which floor space is at a premium and ease of portability is essential. SolidWorks
software was used for designing the instrument cart and for optimal positioning of the
various components. The metal cart has dimensions 27"x27"x58" and can be wheeled
in and out of the operating or frozen section room for clinical data collection. The
final layout of the system and a photograph of the developed instrument are shown in
Fig 6.3.
Sw tch
Figure 6.3. The design layout of the MMS instrument and photo of the final MMS
instrument. This figure is modified from [1] and reprinted with the permission of the
publisher.
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6.2.4 Safety
The clinical MMS system must adhere to strict safety guidelines in the clinical
environment. The excitation laser energies cannot exceed predetermined maximum
values that are safeguarded prior to entering the operating room. The Xe flash lamp
and the N2 laser are pulsed sources, which are internally shuttered and controlled by
LabVIEW. The 830 nm diode laser delivers a continuous-wave laser beam that is
gated by an external high-speed shutter, which is also controlled by LabVIEW. The
shutters open immediately before data acquisition begins and closes immediately after
completion of data acquisition. The shutters remain closed until the system receives a
signal through LabVIEW for another data acquisition.
Importantly, all parts of the system that enter the sterile environment (directly
or indirectly comes in contact with a patient) must be kept sterile. In the case of the
MMS system, only the probe is near the patient. Sterilization of the MMS probe is
performed using cold-gas ethylene oxide.
6.3 MMS front-viewing probe design
The MMS instrument delivers light to and from the tissue via an optical fiber
probe. The MMS probe is based on the previously designed Raman probe. The MMS
probe design is modified to allow an efficient collection of DRS and IFS in the
UV/visible wavelength range and Raman in the NIR wavelength range.
6.3.1 Probe development
The schematic of the MMS front-viewing probe is provided in Fig 6.4. There
are several distinct differences between the MMS probe and the Raman probe: the
optical fibers that are used for delivery and collection; the filter characteristics of the
excitation rods and collection tubes; and the type of adhesives used to glue the
components in the probe tip.
The MMS probe's fibers must be optimized for the particular wavelength
range set by the spectroscopic modality it serves. The central excitation fiber, which
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collection fibers
excitation fibe
notch M
filter tube
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filter rod
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- 2 mm -+' ball lens QDRS/IFS QRaman
Figure 6.4. Schematic of the MMS front-viewing probe.
delivers light for all modalities, must efficiently transmit excitation light in the range
from 340 nm to 830 nm. The collection fibers must be divided to optimize
transmission of visible light and NIR light, respectively. Therefore, the material of the
collection fibers can be optimized based on the wavelength range of light they will be
transporting.
There are two primary materials used for the wavelength ranges of interest:
low-OH fused silica (trade name Anhydroguide) and high-OH fused silica (trade
name Superguide). Anhydroguide is best suited for long-wavelength light whereas
Superguide is best for short-wavelength light. Thus, Anhydroguide fibers (diameter
of 200ptm, NA = 0.26, Fiberguide Industries, Stirling, NJ) are used for NIR (Raman),
while Superguide fibers are used for the visible (DRS and IFS). The excitation fiber is
selected to be Superguide (diameter of 200 pm, NA = 0.22, Fiberguide Industries,
Stirling, NJ ) as it is the best compromise for both wavelength ranges.
The Raman signal is weaker than that of DRS or IFS and thus more fibers
need to be allocated for collection of NIR light. As a result, out of the 15 collection
fibers, 10 fibers are dedicated for Raman, while the remaining 5 fibers are dedicated
for DRS and IFS. This design allows a near equivalent signal collection with the
MMS probe as compared with the FastEEM and Raman probes used individually.
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Another very important change in the MMS probe from the Raman or
FastEEM probes are the filters. For the purposes of acquiring all three modalities, the
excitation and collection filters need to transmit visible light in the range of 300-800
nm.The excitation fiber rod contains a shortpass filter that transmits 300-830 nm light
and cuts off light with wavelength longer than 850 nm to limit fused silica Raman
signal. This shortpass filter is deposited onto a cylindrical rod with diameter of 0.5
mm and 1mm in length. In order to collect 300 - 800 nm light and 850 - 1000 nm
light while blocking light around the Raman excitation wavelength (800 - 850 nm),
the collection fiber filter is a notch filter. The collection fiber filter tube is donut-
shaped with inner diameter 0.7 mm, outer diameter 1.8 mm, and length 1 mm. The
filter characteristics are depicted in Fig 6.5. These filters are custom manufactured
(Barr Associates, Westford, MA) and deposited onto polished fused silica pieces.
Components of the fiber tip (rods and tubes) need to be glued to the fibers.
Ordinary epoxy is not optically clear in the UV wavelength range, thus a special
epoxy (Epo-tek 305, Epoxy Technology, Billerica, MA) is used for the MMS probe.
The sapphire ball lens that is used in the Raman probe is also appropriate for the
MMS probe as sapphire is optically clear in the range of 300-1000nm. The sapphire
100-
90
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E50 0aman
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Figure 6.5. The filter characteristics of the MMS probe. This figure is modified from [1]
and reprinted with the permission of the publisher.
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ball lens is held in place by a stainless steel retaining sleeve rather than epoxy in order
to minimize optical losses. In addition, the ball lens has an anti-reflection coating at
830 nm to substantially reduce reflection losses at the boundary between the fused
silica fiber and the ball lens. This is to increase the amount of Raman excitation light
on the tissue. Reflection losses at 337nm (-6%) are acceptable as fluorescence has
much higher signal strength than Raman.
6.3.2 Data modeling
The MMS probe has a similar geometry as the previously designed Raman probe;
however the inclusion of the sapphire ball lens and filter unit makes it substantially
different from the FastEEM probe. Previously, the geometry was such that the
excitation and collection spots on the sample were in the form of partially
overlapping circles. The diffuse reflectance spectral model developed by Zonios et al
[6] is dependent on this probe geometry. Now, in the MMS probe, the
excitation/collection geometry has changed by increasing the spatial overlap between
the excitation and collection regions and the angles collected as compare to the
FastEEM probe. The IFS modeling can be still done in the manner described by
Zhang et al [7] with modification of probe-specific parameters. Thus, modeling for
both DRS and IFS needs to be modified to account for the geometrical changes of the
MMS probe. In addition, each MMS probe must be calibrated individually to ensure
correct extraction of optical tissue parameters.
6.3.2.1 Raman modeling
Modeling of the Raman spectra remains the same for the MMS probe as its geometry
did not change for this modality. Modeling of Raman spectra is described in Chapter
3.
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6.3.2.2 DRS modeling
Farrell et al. [8] calculated the diffuse reflectance from a narrow beam of light
incident on the surface of a semi-infinite turbid medium in the diffusion
approximation. The Green's function for reflectance density, R(A, r), in units mm 2 , at
a distance r from the point of incidence, depends on tissue parameters: the
absorption coefficient pa (2), the reduced scattering coefficient pu (A), and A, a
diffusion model parameter that depends on the refractive index of the tissue, which is
assumed to be A-3.2 [6]. In order to calculate the calibrated reflectance collected by a
probe, R, (2), the Green's function must be integrated over the delivery and
collection areas, characterized by the radius of delivery, rd , and radius of collection,
r, and normalized by the delivery area, ;rr , to obtain the unitless quantity:
2xr re 27r rd
R,(2A) J d$, rdr Jdd b R(A, r - r)r'dr', 6.1
rd 0 0 0 0
where r - r specifies the distance between a point on the delivery area and a point
on the collection area. Eq. 6.1. can be evaluated numerically, but it can be further
simplified by making the approximation of point source delivery (rd<<1). With this
approximation, Zonios et al. obtained a closed form solution [6] for the reflectance
collected by a FastEEM probe, which is used for DRS modeling of the FastEEM
probe. As discussed below, this approach does not hold for the MMS probe.
The objective is to accurately extract p, (A) and pa(2) from the acquired
reflectance spectrum of tissue. To do this, r, and rc must be evaluated for a given
probe, which can be accomplished by the following calibration technique. First, a
calibration set of physical tissue models ("phantoms") is used to determine rd and r,;
then, these probe-specific parameters are used prospectively on tissue spectra for
accurate extraction of p, (A) and Pa (A) . Five physical tissue models ("phantoms")
were prepared to mimic breast tissue reflectance properties, as shown in Table 6.1.
Polystyrene beads with 1 pm diameter and 1% solids by volume (64030 Polysciences,
Warrington, PA) were used to simulate scattering. Absorption was simulated by using
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a solution of hemoglobin (16 mg/ml) created by dissolving 12 mg of dry hemoglobin
(H0267, Sigma-Aldrich, St. Louis, MO) with 1.5 ml of deionized H20. The five
phantoms included variations of scattering amplitude and hemoglobin concentration
similar to that found in normal breast tissue.
Table 6.1. Five phantoms used to calibrate DRS probe-specific parameters. Mixture 01
beads, hemoglobin and deionized water mimics optical properties of breast tissue.
400 500 600 700 400 500 600 700
Wavelength (nm) Wavelength (nm)
Figure 6.6. The p, (A) and , (A) values for the five phantoms used for calibration
probe-specific parameters.
The p'(A) values were calculated using a standard Mie code that evaluates
the total scattering cross section, o (A), as presented in Eq. 6.2. For biological tissue
in the visible region, p, (2) is dominated by hemoglobin absorption and can be
calculated using Eq 6.3.
y'() = y,(A)(1 - g)= poa(A)(1 - g) 6.2
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Phantom Beads (ml) Hb (ml) H20 (ml)
1 1.4 0.0 1.4
2 2.6 0.1 0.1
3 2.6 0.2 0.0
4 2.6 0.1 1.3
5 1.4 0.2 1.2
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ya A) = (109e1O)CHb(aEHb () + (1 - cEHb(A)) 6.3
The pa(A) parameter depends on the known extinction spectrum of
hemoglobin, eHb, the concentration of hemoglobin c H, and the oxygen saturation of
hemoglobin, a, which was taken to be 100% for the phantoms as the hemoglobin is
completely oxygenated. The resulting p (A) and pa(2) are shown in Fig 6.6.
The phantoms were mixed in small glass vials and thoroughly agitated to
prevent clumping of the beads. Diffuse reflectance spectra were then collected using
the MMS probe and instrument. The DRS spectra were obtained using the following
expression:
R r (2) = Reflectanc e (A) - Background (A)
p,observed (Spectralon (A) - Background (A)) / calibStd (A)
where Reflectanc e(A) is the recorded reflectance spectrum from the phantom,
Background (A) is the background spectrum collected deionized water contained in an
opaque cup, Spectralon (A) is the reflectance spectrum recorded from a calibrated
standard (20% reflectance standard, Labsphere Inc., North Sutton, NH), and
calibStd (A) is the manufacturer-specified response of the standard. In this way, the
Rpobserved (A) is expressed in calibrated reflectance units.
The probe-specific rd and rc values were calculated through an optimization
that minimized the residual (Rpobseved (A) - R, (A))2, where Rpobseved (A) was obtained
from Eq. 6.4 and R, (2) was calculated by numerically evaluating Eq. 6.1 with the
known and specified values of p (A) and p,, (A) for each phantom. Then the
measured DRS spectrum was compared to the spectra in the lookup table. The
spectrum from the lookup table that fitted the best also associated with the particular
set of r, and rc. The best fit spectra are shown in Fig 6.7. in red. This figure also
depicts the best fits (shown in black) obtained using the Zonios formulation. It is
clear from Fig 6.7 that fits obtained by the Zonios formulation do not accurately
model the experimental data, Rpobserved (A). Therefore, Eq. 6.1 should be used to model
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Figure 6.7. Experimental DRS spectra for five phantoms (blue), the best fits using a
lookup table with Eq. 6.1. (red), and best fits using Zonios approximation (black).
DRS data collected via the MMS probe. Although the optimal values of r, and r,
varied slightly across the five phantoms, we found for the particular probe used that
the intermediate values (rd = 0.45 mm and r, = 0.35 mm) can model well all five
phantoms. These average parameters also make physical sense, given the MMS probe
ball lens that specifies both delivery spot and also a range of reflected angles that can
couple into the collection.
The same operation was performed for all newly developed MMS probes. It is
noted that the values obtained were slightly different for different probes. Probe-
specific parameters were recorded for each MMS probe.
Once the calibrated values of rd and r, were obtained, we are able to
prospectively extract accurate values of the optical parameters of tissue, p3 (A)and
, (A), from an unknown tissue sample. In order to do so, a prospective lookup table
was used, in which DRS spectra are generated by numerically integrating Eq. 6.1 over
a range of values of p (A) and p,(A) with fixed values of the calibrated probe-
specific parameters rd and r. In this case, p,(A) was calculated by a power law,
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AA-B, with two free parameters A and B. As discussed above, p,(A) depends on the
concentrations of the particular absorbers present in the tissue (in this cause
hemoglobin) and their extinction coefficients.
An unknown tissue spectrum is then compared to the entries in the lookup
table to obtain the optimal values of A, B, cHb , and a, that in turn specify p(A)
and pa (A). To check the accuracy of the predictive lookup table, it was used to fit
spectra obtained from unknown phantoms, and the extracted spectral quantities
p (A) and pa(2) were compared to the known (measured) quantities. The
difference between the extracted and measured values was on average only a few
percent, which demonstrates the accuracy of the predictive fitting. In addition,
computation using the lookup table is fast and can be accomplished in real time.
6.3.2.3 IFS modeling
As discussed in Chapter 5, the raw tissue fluorescence spectrum contains
information about tissue autofluorophores, but the spectrum is distorted by the
presence of absorbers and scatterers found in tissue. Intrinsic fluorescence (IFS) is
defined as the spectrum free of these interferences and can thus be modeled as a
linear combination of fluorophores [9]. Zhang et al [7] presented a method based on
photon migration for extracting IFS spectra from turbid media, which built on the
previously developed model of Wu et al [10]. The IFS spectrum, f,, (A), is related to
the experimentally measured fluorescence spectrum, F,, (2), and the DRS spectrum,
R,,, (A), by means of Eq 6.5 [7]:
1 Ro:Ro,,(A) 1/2 R, R,(A) 6.5
p rl EX6,(A) RO rRom(A)
where R. is a constant obtained from Rpobseed(A) at the fluorescence excitation
wavelength, R0, is a constant similar to Rx but computed using Eq.6.1 by setting
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pl = 0 , Ro,, (A) is a spectrum evaluated from Rpobserved () for all fluorescence
emission wavelengths, and p, is evaluated at the fluorescence excitation wavelength
and is extracted from p, using the known value of anisotropy, g. Finally, , and
s,, (A) are evaluated at the excitation and all emission wavelengths, respectively,
using s = e' -1, with 8 = S -(1- g) , for a fixed parameter S and anisotropy g , and
1 is related to the optical thickness of the sample.
The parameters S and 1 are probe-specific and need to be calibrated for each
of the probes. This is done in a similar fashion as the DRS calibration to establish r,
and r,. First, a set of known phantoms using polystyrene beads, hemoglobin, and
furan for fluorescence, were used to calibrate the values of S and 1. In this step, it
was determined that the optimal values of these parameters for one particular MMS
probe were S = 0.7 and I = 40 pm. These probe-specific parameters were then held
fixed for the particular probe and plugged into Eq.6.5 to extract fx,, (A) prospectively
from unknown samples. Once the correct IFS spectrum is extracted, it can be fit using
least squares to a specific linear model of constituent spectra.
6.4 Summary
We have described the design and calibration of the MMS instrument and MMS
probes. This instrument is the first system that is capable of simultaneously collecting
reflectance, fluorescence, and Raman spectra from the same tissue site in less than 5
seconds. The outer diameter of the probe is approximately 2 mm and contains one
central delivery fiber surrounded by 15 collection fibers. Of the collection fibers, 5
fibers are designated for visible light collection and the remaining 10 fibers are
designated for NIR Raman light collection. All probe components are optimized for
their particular spectroscopic modality. Each of the 6 probes that were manufactured
for the clinical study in the following chapter were carefully calibrated to ensure an
accurate extraction of spectral and diagnostic parameters.
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CHAPTER 7
Ex vivo clinical application of the MMS
system
This chapter describes the data analysis of the first clinical study in which the MMS
system is used to diagnose breast lesions. Prospective validation of the previously
developed Raman and DRS/IFS diagnostic algorithms was performed on 99
consecutive patients during two ex vivo studies of tissue acquired from excisional
biopsy and needle biopsy procedures. Raman diagnostic algorithm was successfully
validated on the data set from the excisional biopsy, while its performance on the
needle biopsy was not as good. DRS/IFS algorithm had to be changed to distinguish
among different lesions. The last part of the chapter presents a new diagnostic
algorithm that was developed to enable the discrimination of two additional
pathology categories: ductal carcinoma in situ (DCIS) and infiltrating lobular
carcinoma (ILC).
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7.1 Motivation
The clinical studies described in the previous chapters of this thesis were
conducted using a separate Raman clinical system and DRS/IFS system demonstrated
that we could accurately classify four different types of breast lesions. Successful
development and testing of the MMS system provided a unique opportunity to
sequentially collect data from all three modalities within seconds at the exact the
same site on the lesion, thus eliminating registration errors caused by switching
probes in between measurements. The two major aims of this study were as follows:
1) To apply the previously developed Raman and DRS/IFS diagnostic algorithms
(Chapter 4 and 5, respectively) in a prospective manner to determine if the algorithms
are sufficiently robust to be applied to any set of breast specimens; 2) to construct a
new algorithm which is capable of distinguishing additional pathology categories,
including DCIS and ILC. Another very important aim of this project was to be able to
acquire data from calcified specimens along with non-calcified specimens.
Measurements from calcified specimens can only be acquired in the clinic and not
from ex vivo samples.
7.2 Study protocol
The clinical ex vivo study was carried out at the University Hospitals-Case
Medical Center (UH-CMC). The study was approved by the UH-CMC Institutional
Review Board and the Massachusetts Institute of Technology Committee On the Use
of Humans as Experimental Subjects. Data were collected either in the frozen section
room adjacent to the operating room where patients underwent surgical biopsy
(mastectomy or lumpectomy), or in the Mather Surgical Pavilion on patients
undergoing core needle biopsy (stereotactic and ultrasound). Measurements from both
sets of patients would yield samples from pathology categories that were not included
in the previously develop algorithms. In particular, DCIS is commonly associated
with the microcalcifications that are targeted during core needle biopsy. Pathology
categories which were most relevant for validating our diagnostic algorithms were
primarily collected from surgical patients. Informed consent was obtained from all
Page 1128
CHAPTER 7: Ex vivo clinical application of the MMS system
subjects prior to their surgical and biopsy procedures. During a period of 9 weeks,
data were acquired from 99 patients and consisted of patients undergoing ultrasound
core needle biopsy (n=40), stereotactic core needle biopsy (n=19), excisional
procedures (n=38), and re-excision procedures (n= 10).
Data were collected from breast specimens typically within 30 minutes of
excision. Before data acquisition, the surgical specimens were inked and sectioned
according to the standard pathology protocol, while breast cores from needle biopsy
procedures were simply placed in a petri dish. Depending on the region of interest
identified by pathologist, the number of MMS spectra acquired from each patient
varied. Several other pathologists and residents were working simultaneously on
different specimens in the frozen section room and we could not interrupt their work
by turning off the lights during our measurements. Therefore, each specimen was
placed inside a newly designed light tight box to prevent ambient light from entering
the probe and the spectrograph during data collection. During data acquisition in the
radiology room in the Mather Surgical Pavilion, the probe was placed in contact with
the region of interest and the room lights were turned off. Following data acquisition,
the breast specimens were marked with various colors of colloidal ink to uniquely
identify each site sampled, and then fixed in 10% neutral buffered formalin.
Pathology
The fixed tissue samples were routinely processed, paraffin embedded,
sectioned at the marked locations (5 ptm thick), and stained with H&E. The histology
slides were evaluated by an experienced breast pathologist who was blinded to the
outcome of the MMS spectroscopy analysis, and the results were used as the gold
standard against which the MMS findings were compared. .A total of 865 sets of
MMS spectra (each set of Raman, DRS and IFS spectra) were acquired from 99
patients: 476 spectra from core needle biopsy specimens and 389 from excisional
biopsy specimens. As will be discussed in Chapter 9, 9 gauge ATEC biopsy needles
were used during stereotactic while 12 gauge ATEC needles were used during
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ultrasound core needle biopsy procedures. The histopathology diagnoses are shown in
Table 7.1.
Histopathology Surgical Biopsy Needle Biopsy
Diagnosis Specimens Specimens
# spectra/patients # spectra/patients
Normal 98/ 37 204/52
FCC 91/27 152/40
Fibroadenoma 1/1 21/7
Lipoma 6/1 --
Healing Bx Cavity 21/12 -
Hemorrhage 12/7 -
Fat necrosis 14/9 --
DCIS 8/4 12/3
LCIS 3/1 --
IDC 23/5 18/7
ILC 21/3 --
Table 7.1. Distribution of histopathology diagnoses for the surgical
and core needle biopsy specimens, respectively.
As shown in Table 7.1, these data sets contained lesions with histopathology
diagnoses that we did not have in our previous studies. Healing biopsy cavity
(Healing Bx Cavity), hemorrhage and fat necrosis are all benign lesions, while lobular
carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS) and infiltrating lobular
carcinoma (ILC) are malignant breast lesions.
Several spectra had to be excluded from the analysis due to poor signal quality
of (n = 22), the presence of ambient light in the signal (Raman spectra; n = 15), and in
the case of DRS and IFS spectra, an overall reflectance of <1 % (n = 28). The latter
group of samples was excluded because when the reflectance values are low, we
cannot accurately extract the parameters necessary for calculating the intrinsic
fluorescence.
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7.2.1 Surgical biopsy specimens
Figure 7.1. Surgical biopsy specimen. a) original
specimen; b) one slice of specimen, 5mm thick; c)
placing specimen and acquiring data inside the black
box; d) inking exact sites with multicolor colloidal ink
Surgical specimens
were obtained from
excisional and re-excisional
surgical biopsy procedures
from 48 consecutive
patients within 30 min from
the procedure. The study
protocol was similar to one
described in Chapter 4.
Analysis of the data set
shows that the majority of
all lesions are found to be
normal or benign (FCC)
upon pathology evaluation.
In order to collect more data from malignant lesions, one has to acquire data from
more patients.
Surgical specimens, usually 5-7cm in diameter, were cut by a medical resident
or pathologist in 5mm thick sections. The sites of interest were identified by a
certified pathologist. However, it is impossible to turn lights of in the busy frozen
section room. So, the specimens were placed inside the light tight black box in order
to acquire MMS data. Once all of the spectra from one specimen were obtained, the
exact sites locations were marked with multicolored colloidal ink (see Fig 7.1) for
later identification/correlation of sites/MMS spectra. The power delivered to the
breast tissue was approximately 100mW over Imm2 spot. The acquisition time for all
three modalities was approximately 5 seconds, providing 10 spectra for each of the
modalities (for example, 10 Raman spectra of 0.5s acquisition time each) for
averaging and increasing signal-to-noise. In the few cases, for which the data was too
noisy, the acquisition time was increased to Is per spectrum.
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7.2.2 Core needle biopsy specimen
Because of the
geometry of the needle, the
breast biopsy cores obtained
during such procedures are ~
1.7mm x 20mm in
dimension. All of the cores
were originally placed inside
a petri dish, but once the
pathologist identified a core
Figure 7.2. Core needle biopsy specimen. a) biopsy of interest, it was placed on
cores; b) Data acquisition setup the aluminum block for data
collection. However, number of spectra were acquired from biopsy cores while they
were still placed inside a petri dish, see Fig 7.2. The power and acquisition time were
similar to the power and time during data collection from surgical biopsy specimens.
7.2.3 Data Analysis
All of the data were collected using the clinical MMS instrument and the
MMS optical fiber probe described in Chapter 6. On average, the excitation laser
power was 100 mW. Calibration spectra were obtained prior to data collection as
previously described (Chapter 3).
In addition, an increased contribution from cholesterol-like lipid deposits was
observed in this data set, possibly due to changes in the Raman scattering cross-
section of this component upon tissue freeze thaw in the in vitro study (Chapter 4.2),
and thus the cholesterol-like fit contribution was not included in the normalization.
The previously developed diagnostic algorithm (Chapter 4 and 5)
discriminated among four pathology categories: normal, fibroadenoma, FCC, and
IDC tissue. In the present study, we prospectively tested the algorithm only on data
measured from samples assigned to these same four categories.
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7.3 Results: Application of the DRS/IFS diagnostic
algorithm
7.3.1 Prospective application of DRS/IFS diagnostic algorithm
The previously developed DRS/IFS diagnostic algorithm (Chapter 5) was
applied to specimens classified as normal, FCC, fibroadenoma and IDC in the current
data set. Data collection was performed using 4 different MMS probes that were
previously tested as described in Chapter 6. For each probe we had generated a
different lookup table for fitting procedures of DRS, as rd and rc were slightly
different for each MMS probe. Fig. 7.3 shows a boxplot of values of A, concentration
of p-carotene and oxyhemoglobin, as well as relative concentration of collagen and
NADH.
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Figure 7.3. Boxplots of normal (Normal), fibrocystic change (FCC), fibroadenoma (FA),
and infiltrating ductal carcinoma (IDC) for diagnostically relevant parameters of excisional
biopsy specimens.
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As in the previous study, the amount of p-carotene is much higher and the
contribution of collagen-like is smaller in normal lesions as compared to other
lesions. Thus the first step of the step-wise algorithm is based on the combination of
p-carotene and collagen-like component (Fig 7.4a). Step II was not needed for this
particular data set, as there was only one FA specimen. Step III, in which we separate
FCC from IDC lesions was based on the contribution of hemoglobin and the
collagen-like component (Fig.7.4.b). In the previous study we noted an increase in the
value of oxyhemoglobin in malignant lesions compared to FCC samples. This is
consistent with the fact that most malignant tumors are characterized by angiogenesis
(increase in vasculature), which should result in a larger contribution of hemoglobin.
However, in the data set on excisional biopsy specimens, the difference in the value
of oxyhemoglobin between FCC and IDC samples is insignificant. The distinction
between these two pathology groups based on concentration of oxyhemoglobin and
collagen-like was not as good as in the previous study. Eight of the 23 IDC specimens
were incorrectly classified as FCC, and the decision line had to be changed to
minimize the number of misclassified IDC samples. The reason for the low
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Figure 7.4. Prospective performance of DRS/IFS algorithm in excisional biopsy
specimens. a) Step I; b) Step III.
contribution of hemoglobin in malignant specimens in this study is unclear. Thus, it
resulted in a sensitivity, specificity, PPV, NPV, and overall accuracy of 43%, 91%,
37%, 93%, and 79%, respectively.
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The performance of the DRS/IFS algorithm for the data set acquired from core
needle biopsy specimens is shown in Fig. 7.5. The plot for Step I of the algorithm
(Fig.7.5a) shows that the contribution of P-carotene is more significant in normal
lesions than in abnormal lesions (both benign and malignant). The plot for Step II of
the algorithm (Fig.7.5b) shows that the contribution of NADH is smaller in FA
specimens than in FCC and IDC. However, as seen for excisional biopsy specimens,
the contribution of oxyhemoglobin does not provide a good separation between IDC
and FCC, as 8 IDC specimens are incorrectly classified as FCC. Thus, it resulted in a
sensitivity, specificity, PPV, NPV, and overall accuracy of 44%, 98%, 57%, 97%, and
87%, respectively.
:OO 10 ODD C) D
a) b) - .t-i-
C00 31
0 0 02 0040C.6 0 .215 . . 01
p.caroten. A Hb
Figure 7.5. DRS/IFS step-wise algorithm applied prospectively on core needle biopsy
specimens. a) step I; b) step II; c) step III.
7.3.2 A new DRS/IFS diagnostic algorithm
Careful examination of physical parameters obtained from DRS and IFS (see
Fig. 7.5) showed, that A parameter can be used to separate IDC specimens from FCC
both in excisional biopsy and core needle biopsy data sets. Thus, a new DRS/IFS
algorithm was constructed for these data sets. The new algorithms are depicted in Fig.
7.6 and Fig. 7.7 respectively.
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Figure 7.6. New DRSIFS diagnostic algorithm for excisional biopsy specimens
The new algorithm is also a step-wise algorithm. We can separate Normal
from the rest of the diagnoses using the concentration of P-carotene and collagen-like
(the same two parameters as before). In order to separate IDC from FCC lesions, we
use A parameter and relative concentration of collagen-like. The change in the last
step increases the diagnostic performance of DRS/IFS technique, as only 3 IDC are
a) b) 1W ( C) IDC
x Apcatne700.
1%660%, 9 a
e400 d T r t a tlg . n hZ ls a ci
0oxyhemoglobin 1l1as t 25 3 3 ID as 1C A sensiivit
p.carotene A A
Figure 7.7. New DRS/IFS diagnostic algorithm for core needle biopsy specimens
classified as FCC. A sensitivity, specificity, PPV, NPV, and overall accuracy of 78%,
91%, 60%, 97%, and 85%, respectively were obtained.
The same parameters were used to classify specimens from the core needle
biopsy data set. The first two steps remained the same as in the original DRS/IFS
algorithm. In the last step, the use of A parameter instead of concentration of
oxyhemoglobin, resulted in misclassification of only 3 IDC as FCC. A sensitivity,
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specificity, PPV, NPV, and overall accuracy of 78%, 97%, 54%, 99%, and 87%
respectively was obtained.
7.4 Results: Application of the Raman diagnostic
algorithm
7.4.1 Prospective application of Raman diagnostic algorithm
For the excisional
0.7biopsy data set, as
* Normal
6CC shown in Fig. 7.8.,
* FA
IDC we have successfully
0.5
FCC prospectively
0.4
~04 validated the Raman
.IDC 
*
S03 * . diagnostic algorithm
a a
012 00%N on 48 new patients,
01 *.* *which resulted in a02
sensitivity,
S 0. 1 0.2 0.3 0.4 05 0.86. specificity, PPV
FC(FaD ra
LNPV and overall
Figure 7.8. Prospective application of Raman diagnostic algorithm accuracy of 78%,
on excisional biopsy specimens
98%, 82%, 98%. and
86%, respectively. Two IDC specimens were incorrectly diagnosed as FCC, and two
were incorrectly classified as normal. In the case of the samples classified as normal,
we found that only a few malignant cells were present and the sample consisted
almost entirely of adipose tissue. The presence of even a few malignant cells would
classify this specimen to be malignant by pathology; however, Raman spectroscopy
was not sensitive enough to detect such a small number of malignant cells. Thus,
there are some limitations in the use of spectroscopy to diagnose lesions.
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Figure 7.9. Prospective application of Raman diagnostic samples are much
algorithm on core needle biopsy specimens
smaller in size than
specimens from excisional biopsies. Application of the Raman diagnostic algorithm
yielded a 50% sensitivity, 83% specificity, and 68% overall efficiency. The PPV was
13%, and the NPV was 97%. These values are almost equivalent to those observed in
the in vitro study.
It is clearly seen that the contribution of fat and collagen is reduced in a large
number of FCC specimens, and that this resulted in FCCs samples being misclassified
as IDC and normal. There are several reasons why this may occur. First, the impact of
the specimen size needs to be studied further. Second, the spread in the samples
diagnosed as FCC diagnosis could contribute to number of misclassified lesions. As
discussed in Chapter 2, specimens classified as FCC may be predominately
characterized by fibrosis, adenosis, ducts or any combination of these features. We
further analyzed FCC specimens to determine whether there was any correlation
between the predominant feature and Raman findings. It was found that 38 of the 44
misclassified specimens had adenosis (19), microcalcifications (11) or duct cysts (8).
These are all space occupying lesions, where the proliferating ducts (adenosis),
microcalcifications or duct cysts occupy space that would otherwise be occupied by
collagen-rich stroma. As a result of this, they have less collagen (and lower collagen
fit contributions) than FCCs that lack adenosis, microcalcifications and duct cysts.
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Thus, the increase number of FCC lesions with features of adenosis,
microcalcifications and duct cysts accounts for most of the misclassified FCC lesions.
Pathology Normal Fibrocystic Change Fibroadenoma Infiltrating Ductal Carcinoma
(204 samples) (152 samples) (21 samples) (18 samples)
Normal 185 29 2 5
Fibrocystic Change 12 72 6 4
Fibroadenoma 1 6 1 0
Infiltrating Ductal Carcinoma 6 45 12 9
Table. 7.2. Comparison of histopathology diagnoses and Raman spectroscopic
classification of breast disease for core biopsy specimens
7.4.2 A new 3D Raman diagnostic algorithm
As previously mentioned, the current data set from the excisional biopsy
contains malignant lesions that were not seen before in previous data sets (in vitro and
ex vivo previous study), such as DCIS and ILC. The previously developed Raman
diagnostic algorithm did not perform well on needle biopsy specimens. Thus, there
was a need to develop a new diagnostic algorithm that can be used for needle biopsy
procedures, and it should be able to correctly classify DCIS and ILC.
Careful analysis of the parameters from all three spectroscopic modalities
(Raman, DRS, and IFS), lead to development of the new diagnostic algorithm. As it is
shown in Fig. 7.10 and Fig. 7.11, the new algorithm employs three fit coefficients
obtained from Raman spectroscopy: fat, collagen and a sum of cell nucleus and cell
cytoplasm.
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Figure 7.10. 3D Raman diagnostic algorithm applied on excisional biopsy specimens.
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Figure 7.11. 3D Raman diagnostic algorithm applied on needle
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biopsy specimens.
Table 7.3 and Table 7.4 provide information on the performance of the 3D
(three dimensional) Raman algorithm applied on the excisional and needle biopsy
specimens, respectively. The sensitivity (malignant lesions vs. non-malignant
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lesions), specificity, PPV and NPV were 88%, 92%, 75%, and 97% for excisional
biopsy specimens; and 82%, 91%, 41%, and 98% for needle biopsy specimens.
Normal Fibrocystic Cancer
Pathology Change Ductal Infitrating Infsitrating
Carcinoma Ductal Lobular
Raman In s Carcinoma carcinoma
(98 samples) (91 samples) (8 samples) (23 samples) (21 samples)
Normal 96 0 0 0 0
Fibrocystic Change 0 78 2 1 3
Ductal CarcinomaIn Sltu 0 0 6
Cancer Infiltrating Ductal Carcinoma 2 13 22
Infiltrating Lobular Carcinoma 0 0 18
[able 7.3. Performance of the 3D Raman diagnostic algorithm on excisional biopsy
.pecimens
Normal Fibrocystic Cancer
Pathology Change Ductal Carcinoma Infiltrating Ductal
InSiM Carcinoma
Raman (204 samples) (152 samples) (12 samples) (18 samples)
Normal 199 5 0 2
Fibrocystic Change 119 2 3
Ductal Carcinoma In Situ 10
Cancer Infiltrating Ductal Carcinoma 5 28 13
Table 7.4. Performance of the 3D
specimens.
Raman diagnostic algorithm on needle biopsy
7.5 Discussion
The previously developed Raman diagnostic algorithm were successfully
tested on data from excisional biopsy resulting in sensitivity, specificity, overall
accuracy, PPV, and NPV of 78%, 98%, 86%, 82%, and 98%, respectively. Note, that
the original study on in vitro specimens has resulted in sensitivity, specificity, overall
accuracy, PPV and NPV of 94%, 96%, 86%, 88%, 98%, respectively. The difference
in the performance of the algorithm is a result of the difference in prevalence of
malignancy (IDC). In the original study the prevalence was 25% (31/126), while for
this study the prevalence was 10% (23/236). Also, as stated above, Raman
spectroscopy resulted in the incorrect diagnosis of two IDC sites as normal tissue,
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because only a few malignant cells were present in those specimens. The performance
of the Raman algorithm on core needle biopsy specimens was not as good, yielding a
sensitivity, specificity, overall accuracy, PPV and NPV of 50%, 83%, 68%, 13%,
97%, respectively. The most clinically significant value, NPV, remained virtually
unchanged from that obtained in the original study (-97-98%). The difference in
performance between the two types of specimens may be related to the fact that the
algorithm was developed using excisional biopsy specimens. We first determined
whether this difference resulted from the type of material on which the sample was
placed (paper in the Petri dish versus aluminum). However, we found that the
contribution of the Raman signal arising from the paper was insignificant, and that
accounting for this signal did not improve the classification of core biopsy specimens.
In addition, we compared the performance of the algorithm on specimens from
ultrasound guided biopsy versus stereotactic core needle biopsy. The specimens from
stereotactic core needle biopsies were usually bloodier and larger in size because a
9G biopsy needle, rather than the 12G needle used for ultrasound guided biopsy. The
performance of the algorithm was approximately the same for both types of core
needle biopsy, as 21 FCC sites out of total 90 FCC were incorrectly diagnosed as IDC
in the case of stereotactic core needle biopsy, while 24 FCC specimens out of 62 FCC
were incorrectly classified as IDC in case of ultrasound core needle biopsy. The
DRS/IFS diagnostic algorithm was tested on the same data set.
The need to diagnose additional types of malignant lesions led to the
development of a new 3D Raman diagnostic algorithm based on the fit coefficients of
fat, collagen and sum of cell cytoplasm and cell nucleus. Note, that the fit coefficients
of fat and collagen were used in the original Raman diagnostic algorithm. The
diagnostic components makes sense from the anatomy, that cancer cells have larger
cell cytoplasm and cell nucleus compare to normal cells. The new algorithm is more
powerful due its ability to diagnose two cancerous lesions (DCIS and ILC), in
addition to IDC lesions.
Page 1142
CHAPTER 7: Ex vivo clinical application of the MMS system
7.6 Microcalcification study
7.6.1 Results of the study
During data collection from stereotactic core needle biopsy specimens,
additional study was performed to investigate the feasibility of Raman spectroscopy
to detect microcalcifications. The data set contained 31 calcified sites and 97 non-
calcified.
In this study the approximate location of the microcalcifications within the
tissue core was determined via comparison with the corresponding radiograph of the
specimen. Raman spectra were obtained in several locations of the core: in the
approximate location of the targeted microcalcifications, as well as in adjacent non-
calcified areas of the same tissue core. The Raman spectra were then analyzed in real
time (Chapter 3).
b
0.6
A 0.Fit coefficients
Calcium 1.3
r02 Fat 70.6
Collagen 0.0
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-0.4600 Boo 1000 120 14o 600 1000m-
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Figure 7.12. a) Specimen radiograph of strereotactic needle biopsy of the breast with
microcalcifications (circled); b) Raman spectrum from normal region of the core indicated
in blue arrow; c) Raman spectrum from calcified region of the core indicated in red arrow;
d) histopathology slide indicating microcalcifications (red arrow) in the area corresponding
to the Raman spectrum in Fig. 7.12.c, and fatty tissue in the area corresponding to the
spectrum in Fig. 7.12.b.
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Real time analysis of Raman spectra allowed to locate the exact position of
the microcalcifications within the tissue cores, as illustrated in Fig. 7.12. Figure
7.12a presents a specimen radiograph of a biopsy tissue core that contained
microcalcifications (circled). By translating the probe along the biopsy specimen and
examining the values of fit coefficients of calcium oxalate dehydrate and calcium
hydroxyapatite at various locations, we were able to identify the exact location of the
microcalcifications. The difference between Raman spectra acquired from calcified
and non-calcified sites can be clearly seen in Fig. 7.12b (non-calcified site) and Fig
7.12c (calcified site). The large contribution of calcium salts (the sum of calcium
hydroxyapatite and calcium oxalate) of 45.7% indicates the presence of
microcalcifications, which was later confirmed by histopathology, shown in Fig.
7.12d. When the probe was placed on the site indicated with the blue arrow of the
core (Fig. 7.12b), the contribution of calcium salts was 1.3%, indicating that it was a
non-calcified lesions, later confirmed by histopathology (Fig. 7.12d blue arrow).
Similar results were found in [1].
0.35 Great success
0 Noncal
0.3- LL !ali with this small study,
i2 lead us to another proof-
of-principle study:
e 0.2-
separation calcified
lesions from non-
0.i 0 Ecalcified lesions. For this
0.0 0 0 0 Estudy we used data
00 0> collected from patients
0 0.02 0.04 0.06 0.08 0.1 0.12 0.14 0.16whuneet
FC (Calcium Oxalate Dihydrate)underwent
Figure 7.13. Classification of calcified vs. non-calcified stereotactic core needle
lesions. Data from stereotactic core needle biopsy.
biopsy procedure.
Overall we acquired data from 97 non-calcified lesions, including 58 normal and 39
FCC lesions; also we collected data from 31 calcified lesions: 29 FCC and 2
fibroadenoma. Fig. 7.13 shows that we are able to distinguish between calcified and
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non-calcified lesions using Raman fit coefficients of Calcium oxalate dihydrate and
calcium hydroxyapatite. We were able to correctly identify 81% (25/31) calcified
lesions 82% (80/97) non-calcified lesions. This is a preliminary result as more data
has to be collected in order to see the feasibility of this algorithm. Also, it might be
important to create a separate diagnostic algorithm for calcified lesions. However, at
the present state it is impossible, as the data set does not have enough data (only 31
calcified lesions) to construct a robust diagnostic algorithm.
7.6.2 Significance of the microcalcification study
The ex vivo studies using front-viewing optical fiber probes demonstrate the
potential of Raman spectroscopy to detect and precisely localize microcalcifications
in breast needle biopsies using real-time spectroscopic feedback. The capability of
our spectroscopic system to provide a real time feedback allowed us to perform this
study.
7.7 Summary
This study showed the first application of MMS system during ex vivo study.
The previously developed algorithms were tested during two types of biopsy
procedures: excisional biopsy and core needle biopsy. The Raman diagnostic
algorithm was successfully tested in a prospective manner for excisional biopsy
specimens. However, we observed a smaller contribution of collagen and fat in FCC
lesions of the needle biopsy specimens, which resulted in a poorer sensitivity and
specificity in this lesions. The DRS/IFS algorithm was also applied to the same two
data sets, and we observed a smaller contribution of oxyhemoglobin in malignant
cells, thus the algorithm had to be revised to include A parameter in addition to
relative concentration of collagen-like. Based on these two parameters all IDC
specimens could be correctly classified.
Finally, we developed an algorithm to classify additional types of lesions. A
new 3D Raman diagnostic algorithm was constructed. Two fit coefficients, fat and
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collagen, were the same as in the original Raman diagnostic algorithm. With the
addition of the third component, sum of cell cytoplasm and cell nucleus, we were able
to correctly diagnose DCIS and ILC specimens.
Additionally, we studied the feasibility of Raman spectroscopy to indicate
location of microcalcifications in the core biopsy specimens. We correlated the
presence of microcalcifications with contribution of calcium hydroxyapatite and
calcium oxalate dihydrate. This study showed that Raman spectroscopy could be used
for guidance of core needle biopsy to correctly target microcalcifications, which will
be described in Chapter 9.
7.8 References
1. Haka, A.S., et al., Identifying Microcalcifications in Benign and Malignant
Breast Lesions by Probing Differences in their Chemical Composition Using
Raman Spectroscopy. Cancer Res, 2002. 62: p. 5375-5380.
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CHAPTER 8
New prognostic algorithms
The objective of the study presented in this chapter was to establish the feasibility of using
Raman spectroscopy to predict prognosis or outcomes for patients with breast cancer. Raman
spectra were measured ex vivo from breast tissue specimens obtained from excisional
biopsies. As in previous chapters, the extracted spectroscopic parameters were correlated
with the histopathology results for the lesions. In addition, the spectroscopic parameters were
correlated with conventional clinicopathologic indicators of prognosis and response to
therapy, including malignancy grade, and the expression of the estrogen receptors (ER) and
the progesterone receptors (PR). Diagnostic algorithms were developed to differentiate
among malignancy tumor grade (grade I, II and III) and ER and PR status. The findings of
this study are presented in this chapter.
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8.1 Motivation
In order to determine the patient's prognosis, pathologists assign a histologic grade to
the cancerous breast tumor. Chapter 2 described the Scarff-Bloom-Richardson system that is
used to determine malignancy grade. Grade of the malignancy is a significant predictor of
patients' survival, as well as the possibility of local recurrence and metastasis, as described in
the Table 2.3.
Currently, the American Society of Clinical Oncology guidelines recommend routine testing
of all invasive breast cancers for only three tumors markers with established-- albeit modest--
prognostic value, ER, PR and Her 2 neu. ER and PR are ligand-activated transcription
factors belonging to the family of nuclear hormone receptors. ER protein is expressed by 50-
70 % of invasive breast cancers; PR is less frequently expressed.
In 1975 Rosen et al. [1] first determined the existence of correlations between ER /
PR expression and the histopathology of breast carcinoma. The expression of PR is estrogen
regulated, thus most PR-positive carcinomas are ER-positive as well. Less than 10% of
carcinomas are ER-negative and PR-positive [2]. Patients with ER-positive and PR-positive
carcinomas have a longer disease-free survival than women with ER/PR-negative tumors [3].
Estrogen stimulates cell proliferation. In order to block estrogen from binding to estrogen
receptors, "antiestrogen" drugs were developed that allow antiestrogens to bind to estrogen
receptors. As seen in Chapter 2, Tamoxifen is commonly used to bind to estrogen receptors
of breast cells. By interfering with estrogen receptors, tamoxifen blocks the ability of
estrogen to stimulate the proliferation of breast cells. The status of the ER is an important
predictor of patient's response to hormone therapy in patients with recurrent carcinoma [4,
5]. Patients with ER-positive tumors tend to have a lower recurrence and significantly
improved survival rate. Positive expression of estrogen and progesterone receptors indicate
and increased likelihood that hormonal therapy will be effective in treating the cancerous
tumor.
The motivation of the present study is to explore the potential of Raman spectroscopy to
not only diagnose lesions, but also to predict of prognosis and response to therapy. This study
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may reveal spectroscopic signatures predictive of clinical outcome that can be used for in
vivo prediction of clinical outcome, independently of current clinic-pathologic indicators,
which are subjective.
8.2 Protocol of the study
A subset of the data acquired during the prior
ex vivo clinical study of excisional breast biopsies
(Chapter 7.1) was used in the present analysis. The
details of the data collection protocol are also
described in Chapter 7.1. Spectroscopic data acquired
from malignant lesions were used to create diagnostic
algorithms for distinguishing lesions by tumor grades
and the absence or present of estrogen and
progesterone receptor expression. Overall 40
malignant lesions were evaluated in the study,
including 23 IDC and 17 ILC. A summary of the data
set is presented in Table 8.1.
In order to distinguish among
tumor grades, specific features that are
characteristic for each grade must be
identified. Grade I represents an early
stage of cancer, which is not always
caught on time, and stage III tumor
represents the latest and most aggressive
malignancy. Most women receive
treatment before the tumor has
progressed to grade III.
0.
I 10
Grade II 20
III 10
Negative 14
ER
Positive 26
Negative 26
PR
Positive 14
Table 8.1. Data set for Raman analysis
600 800 1000 1200 1400 1600 1800
Raman Shift (cm- )
Figure 8.1. Average spectra of tumors with grade I
(blue solid), grade II (green, dashed), grade III (red,
dashed-point)
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8.3 Data analysis
8.3.1 Tumor grades
The average spectra for lesions from each tumor grade are depicted in Fig 8.1. The most
prominent differences among the average spectra for the various grades were observed in the
regions of 750 - 100cm~1 and 1500 - 1600cm~'. Spectra from all 40 malignant sites were
analyzed using a linear combination of the Raman components previously described in
Chapter 3. Spectral differences among comparison groups become more apparent using
difference spectra, such as the plots of the residuals we use to assess spectral model fits.
The Raman spectra of all cancers with the same grade were averaged, and difference spectra
calculated by subtracting the average spectrum of one group from that of another. The results
are shown in Fig. 8.2.There are significant spectral differences at ~750, -950 and -1550cm~'.
Goad. I minus Goad. M Goad. H1 minus Goads, 11 God. I minus Goad., 11705 025
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03 02
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~~~~~~~0Q~~~~ low Nom low 1" ta a 3o m lm 12510 001ma am tm 1400 low
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Figure 8.2. Differences between the average spectra of different tumor grades.
Comparison of the differences spectra with our existing chemical and morphologic basis
spectra shows that only the basis spectra of epithelial cell nuclei and purified DNA (Fig 8.3.)
have prominent bands at -750 cm-1, suggesting that the spectral differences noted between
grade I and grade III cancers in the region may be due to difference in the DNA of the
malignant epithelial cells. The origin of the spectral differences noted at -950 and -1550 cm~
1 is less clear, as the basis spectra of several of our Raman components have bands in these
regions.
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Figure 8.4. shows plots comparing
the fit coefficients of all eight basis spectra
for each tumor grade. Trends in the fit b
coefficients for several components are
clearly visible among different tumor
grades, including for calcium oxalate
dehydrate, cholesterol-like, cell cytoplasm,
and cell nucleus. Using logistic regression Rain.a Shift (cm-)
and cross-validation, we found that for this Figure 8.3. Spectra of cellular components. a)DNA, b) cell nucleus, c) actin and d) epithelial
particular data set, fit coefficients of cell cytoplasm.
calcium oxalate dehydrate and the
cholesterol-like component are the most diagnostically significant spectroscopic parameters.
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Figure 8.4. Boxplot of all fit coefficients for different tumor grades
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Figure 8.5. Diagnostic Raman algorithm for discriminating among tumor grades
Fig. 8.5. shows the decision plot that separates all grades using these two fit
coefficients. All grade III specimens are characterized by a small contribution of the
cholesterol-like component and a large contribution of calcium oxalate dehydrate. Grade II
specimens tend to have a smaller contribution of cholesterol-like component compared to the
grade I. The spectroscopic diagnostic algorithm correctly predicts the tumor grade for 9 out
of 10 grade I specimens, 13 out of 20 specimens with grade II, and all 10 grade III
specimens.
8.3.2 Biomarker
An analysis procedure similar to that used to distinguish among tumor grades was
used to evaluate negative (absence) or positive (presence) ER and PR expression. The most
significant differences between positive and negative ER expression were found in the fit
coefficients for P-carotene and cell nucleus (Fig. 8.6).
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Figure 8.6. Decision plot for distinguishing between
positive and negative ER statuses
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A decision line (y=1.34x-0.0615) based
on these two components, correctly
separated 38 of the 40 specimens based
on their ER status. The ROC curve for
this separation is shown in Figure 8.7.
A sensitivity of 100% and specificity of
92.3% was achieved in discriminating
between ER-positive and ER-negative
specimens.
A similar analysis was performed to
distinguish between positive and
negative PR status.
However, in case of PR the trends among
the fit coefficients were not as
pronounced as for ER status. The most
diagnostically relevant fit components
were P-carotene and calcium oxalate
dehydrate. The decision line
y=4.06x+0.05 separates two clusters, as
is shown in Fig. 8.8a. Figure 8.8b depicts
the ROC curve for the Raman algorithm
.9 / + PRner
a) / S PpOO*i
0/
CHAPTER 8: New diagnostic algorithms
to distinguish between PR positive and negative specimens. A sensitivity of 76% and
specificity of 78.6%, was obtained for this separation.
8.4 Significance of the study
This is the first study, to our knowledge, that utilizes Raman spectroscopy to predict
tumor grade and status of ER and PR receptors. The results clearly indicate that Raman
spectroscopy can potentially contribute to the evaluation of the prognosis and outcome of
breast lesions. Additional larger scale studies need to be performed to fully assess use of
Raman spectroscopy for this application.
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CHAPTER 9
Apparatus for guiding core needle biopsy
This chapter describes the design of a side-viewing Raman probe that will be used in the
future study of targeting microcalcifications during core needle biopsy. The goal of this
project is to design a probe that can be easily incorporated into an ATEC 9 gauge needle
device, provided by Hologic company, which is used during stereotactic breast biopsy
procedures at the University Hospitals Case Medical Center. In order to design an
optimal fiber optic probe, a design strategy was implemented to fully utilize system
throughput by characterizing the distribution of Raman signal from tissue. Monte Carlo
simulations were used to estimate the interaction of light with tissue. Zemax simulations
were carried out to develop the optimal probe geometry to maximize the Raman signal
intensity.
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9.1 Motivation
It is estimated that more than 1.5 million breast needle biopsies are performed in
the U.S. annually [Preventive Services Task Force 2002]. Vacuum-assisted needle biopsy
is a safe, reliable alternative for patients who wish to avoid surgical biopsy of suspicious
microcalcifications discovered at mammography. Vacuum-assisted breast biopsies for
non-palpable lesions, including microcalcifications, are typically done under stereotactic
mammographic guidance.
The complete diagnostic work up of mammographically suspect
microcalcifications may take days to weeks and include multiple biopsies and extensive
pathology evaluation. For the patient, the biopsy and wait for a diagnosis is a traumatic
experience both physically and mentally. In a small but significant number of cases the
resulting biopsy will be either non-diagnostic or yield false negative results despite all
precautions. There is a clinical need for a technology that can provide real-time feedback
to the radiologist during stereotactic biopsy and detect microcalcifications in the tissue.
Such a clinical tool would have a number of benefits. First, it would enable the
radiologist to be better informed when deciding whether the needle should be re-
positioned, without the need to wait for a specimen radiograph. Second, it could also
minimize the procedure time, and thus the radiation exposure, risk of intra-procedural
hemorrhage and patient anxiety/distress. Third, by significantly improving retrieval of
microcalcifications, both the number of non-diagnostic/false-negative breast needle
biopsies for microcalcifications and the need for follow up surgical biopsy should be
reduced. Finally, the number of tissue cores removed would also be reduced because only
targeted biopsies would be taken. The tool should be able to interrogate a large volume of
breast tissue in a short period of time.
9.1.1 Stereotactic core needle biopsy
In current medical practice, a core needle biopsy is performed under stereotactic
mammographic guidance in order to diagnose a non-palpable lesion. During the
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stereotactic breast needle biopsy for microcalcifications, small cores of tissue are
removed from the breast using a hollow needle, which is precisely guided to the correct
location using x-ray mammography and computer-automated stereotaxis. In a vacuum-
assisted needle biopsy, the patient lies in the prone position on the biopsy table, with the
breast protruding through an opening in the table. The patient and table are elevated and
the radiologist positioned underneath the table (Fig 9.1.a) (this figure obtained from
Hologic website: www.hologic.com/womens-health/lbs). The skin of the breast is
manually incised under local anesthesia and a 9 or 1 IG needle containing a circular blade
(or cutting canula) is advanced to the lesion position as identified by digital spot view
mammography. Accurate 3-D
localization of the
microcalcifications and placement
of the needle requires at least two
planar digital spot x-ray views. The
Hologic console (also shown in Fig
9.1 .a) is necessary to operate www.hologic.com/
womens-health/ibs/
biopsy needle device. When suction b)
is applied, the breast tissue is drawn
into a side-viewing port in the
needle and the blade incises the c)
trapped tissue (Fig 9.1.b). The
suction also draws out the incised
breast tissue cores, which are
passed through the hollow lumen of Figure 9.1. a) Stereotactic Biopsy Procedure
using Hologic equipment; b) ATEC 9G needle
the needle and into a collection with biopsy aperture; c) ATEC vacuum-assisted
basket. Successive biopsies can be needle biopsy device.
performed over 3600 around the axis of the needle without any need to withdraw the
needle between biopsies. In the majority of cases, twelve cores of tissue are removed and
in some cases, the entire lesion may be excised. However, recent studies have
documented the failure of this technique to retrieve microcalcifications in up to 15% of
needle biopsies [1]. In these cases, a larger number of digital spot views (sometimes more
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than 20) must be taken. This was the case for one of the 19 patients undergoing vacuum-
assisted needle biopsy for microcalcifications in our most recent pre-clinical study
(Chapter 7 and 8). Upon removal, tissue cores are radiographed to confirm that
microcalcifications are present in the tissue to be submitted for microscopic examination
by a pathologist. While the radiograph of the specimen is being processed, the needle
remains in position in the patient's breast and the patient must remain still in order to
keep the needle in place. Additional tissue cores may be removed if microcalcifications
are seen in the radiograph of the specimen. This significantly increases procedure time
and the risk of biopsy site hemorrhage, which in turn decreases the likelihood of
microcalcification retrieval [2]. Failure to retrieve microcalcifications is most common in
patients with dense breasts [1]. Therefore, optical techniques such as Raman
spectroscopy may have an advantage over conventional x-ray imaging techniques like
mammography. A follow-up surgical biopsy is indicated if no microcalcifications are
retrieved. If microcalcifications are seen on the radiograph, great care is taken on
pathology examination of the needle biopsy to ensure that the breast lesion associated
with the microcalcifications is found. Overall, the biopsy procedure takes at least an hour
and often lasts much longer. In patients with multiple foci of suspicious
microcalcifications, it must be repeated for each focus. At the completion of the
procedure, a small metallic clip may be deployed through the needle to mark the biopsy
site in case surgery and/or radiation therapy needs to be performed later for invasive
cancer.
9.1.2 Microcalcifications
Mammography is
currently the standard method for
detecting small, non-palpable,
highly curable breast cancers [3]. Figure 9.2. Breast microcalcifications. A) In clinical
X-ray mammography is a non- mammogram (circled); b) Type I in duct cyst (arrows;
clear crystals; H&E; 40X; 50 micron bar); c) Type I in
duct cyst (arrows; birefringence under polarized light;
rays to create images of breast H&E; 40 X; 50 micron bar); d) Type II in DCIS (arrow;
basophilic concretion; H&E; 40X; 50 micron bar).
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tissue. Microcalcifications are deposits of calcium mineral salts [4]. They strongly
absorb x-rays and, thus, have a distinctive (white) appearance on mammography.
Microcalcifications geographically target the location of the most clinically significant
abnormality within the breast and are a key feature that radiologists look for during
mammography [5]. Over 350,000 screening mammograms are performed in the U.S.
annually [Breast Cancer Surveillance Consortium], 10% of which are interpreted as
abnormal using the Breast Imaging and Reporting and Data (Bi-Rad) System [6] and
referred for diagnostic mammography and potentially biopsy [7]. Roughly 10% of all
abnormal mammograms are interpreted as such because of the presence of suspicious
microcalcifications [8].
Microcalcifications are classified into two types based on their chemical
composition and histologic appearance. Type I microcalcifications are composed of
calcium oxalate, while type II microcalcifications are composed of calcium phosphates,
mainly calcium hydroxyapatite. Type I microcalcifications appear as colorless crystals
on light microscopic examination of hematoxylin and eosin (H&E) stained tissue sections
and are birefringent under polarized light (see Fig 9.2.b and c) whereas type II
microcalcifications appear as basophilic concretions on H&E stained tissue sections and
are non-birefringent as shown in Fig 9.2.d.
Microcalcification type appears to correlate with disease state [9]. Type I
microcalcifications are seen almost exclusively in benign duct cysts and are rarely found
in foci of breast cancer, while type II microcalcifications are most often seen in
proliferative lesions, including invasive and in situ cancer. This is consistent with the
hypothesis that type I microcalcifications (calcium oxalate) are a product of degradation
of secretions in the breast ducts, whereas type II microcalcifications (calcium
hydroxyapatite) result from cellular degradation or necrosis. Type II microcalcifications
occur 2-3 times more frequently than type I [10], and therefore account for the majority
of microcalcifications seen on mammography. There is no reliable way to distinguish
between type I and type II microcalcifications in a clinical mammogram [11-14].
Therefore, patients with suspicious microcalcifications on mammography must undergo
breast biopsy for diagnosis.
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9.2 Side-viewing probe design
9.2.1 Why Raman?
Raman spectroscopy is an ideal candidate technology to improve stereotactic core
needle biopsy by precisely targeting microcalcifications and providing diagnostically
valuable information in real-time. Raman spectroscopy can be obtained in a non-
destructive manner via an optical fiber probe that is compatible with needle biopsy
devices, such as the ATEC needle. Raman spectroscopy is extremely sensitive to the
presence of calcium mineral salts and can thus be used to detect and localize
microcalcifications and provide real-time feedback to the radiologist to improve retrieval
of microcalcifications during vacuum-assisted stereotactic needle biopsy. Because Raman
spectroscopy can be performed in real-time, a large number of tissue sites can be
interrogated in a short time span, potentially minimizing the amount of excised tissue.
Calcium salts like calcium oxalate, calcium hydroxyapatite and calcium
carbonate, undergo symmetric molecular stretching and thus have large Raman cross
sections-- several orders of magnitude larger than those of other breast tissue
constituents. They are therefore easily detected and differentiated in breast tissue using
Raman spectroscopy. Figure 5.3 shows the distinctive Raman spectra of a type I breast
microcalcification (in red), with a
prominent C-O symmetric CalciumOxalate Dihydrate -Type
1.27 - Calcium Hydroxyapatite - Type 11
stretching band at 1477cm' due to
calcium oxalate. Type II breast 0.8
microcalcifications have a M .I
It
prominent phosphate symmetric C
stretching band at 960cm 1 due to 0.2
calcium hydroxyapatite. The 0
ability to detect calcium mineral 800 100 0 1 20 1400 1600 1800
salts, and therefore Raman Shift (cm')
Figure 9.3. Raman spectra of a type I
microcalcifications, is a distinct microcalcification (blue), with a prominent band at
1477 cm' due to calcium oxalate (arrow), and a type II
advantage of Raman spectroscopy microcalcification (red) with a prominent band at 960
over other optical spectroscopy cm '(arrow) due to calcium hydroxyapatite.
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techniques that have been explored in breast, such as diffuse reflectance and fluorescence
spectroscopy.
9.2.2 Probe constraints
In order to develop a spectroscopic system that will be used in a clinical setting,
the Raman instrument and probe should be optimized to work in conjunction with the
Automated Tissue Excision and Collection (ATEC) System (Suros Surgical Systems,
Inc., Indianapolis, IN), which is the commercial vacuum-assisted stereotactic needle
biopsy system used in the UHC-CMC Breast Center. Because ATEC needle devise has
only a side-viewing port in which tissue is pulled by vacuum and subsequently excised,
the fiber optic probe has to be able to acquire spectroscopic data from the side of the
probe and not from the front of it. That is why, the new probe has to have a side-viewing
geometry and still be able to collect good quality of data that will be useful for diagnosis.
In order to develop a system with high sensitivity the following steps were
undertaken: 1) the efficiency of each component of the system was determined to
maximize Raman collection; 2) the delivery geometry of the excitation beam was chosen
to confine the radiance distribution of the Raman signal to a small area at the tissue
surface; and 3) the sample damage threshold was considered owing to the focused
excitation beam and potential for tissue damage. The optimal collection spot size and
collection angle were considered in determining the collection geometry based on
conservation of radiance.
9.2.3 Throughput estimation
The conservation of radiance is the optical principle used in designing new optical
systems. The conservation of radiance theorem is based on Abbe's sine condition in
optical systems and states that the radiance of a source cannot be increased by
instrumentation. Therefore the radiance of an image cannot exceed that of the object.
Thus, for an optical system the radiance at the output is at most equal to the input
radiance
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ni sin 1h, =n 2 sin 0 2h2  9.1
where n is the index of refraction,
0 is the ray angle with respect to
the optical axis, and h is the height nn
of the source, as shown in Figure h, 2
9.4. h2
From the conservation of
Figure 9.4. Diagram of Abbe's sine condition
radiance theorem we can derive the
throughput theorem that states that throughput at the source plane is equal to the
throughput at the image plane. The throughput (0, or etendue) of an optical system is
given by the product of its collection area (A) and its solid angle (fl).
E = A,(r)Q,(0,) 9.2
where r, is the collection radius, and 0, is collection angle. The conservation of
throughput implies that these two parameters cannot be independently selected, as there
is a trade-off between collection area, Ac(re), and collection solid angle, QO(6c).
Diffuse scattering in tissue results in emission of Raman light over an area and
solid angle of a particular distribution. Optimization of signal collection requires
consideration of two parameters. First, the distribution of the Raman light emerging from
the turbid medium (tissue) must be estimated. This distribution defines the potential
light-collection efficiency for a given Raman source as the area or angle of collection is
varied for particular throughput constraints. Second, the overall throughput of an optical
system is determined by the optical element with the lowest throughput. In spectroscopic
systems, the spectrograph is often the element of the lowest throughput; therefore we
want to use the spectrograph with the highest possible throughput.
The current clinical Raman system has a Holospec f/1.8i, Kaiser Optical Systems
spectrograph. Our f/1.8i spectrograph provides a numerical aperture (NA) =0.278 (f/# =
1/2NA). The spectrograph contains an 830 nm notch filter that suppresses the elastically
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scattered Rayleigh light and a holographic grating to disperse the Raman scattered light
onto a back-illuminated, deep-depletion CCD detector with a 1024x256 array of pixels
(PIXIS: 256, Princeton Instruments/Acton, Acton, MA). The pixel size is 26x26 pm,
giving a CCD height of 6.7 mm. The height of the array of collection fibers cannot be
larger than the height of the CCD, otherwise substantial light loss will occur. Collection
fibers that are under consideration are low-OH fibers (AFSH200-2407) with a core
diameter 200pm, cladding diameter of 220pm surrounded by the jacket with diameter of
250pm. The product of the number of fibers and their maximum diameter should be less
than or equal to 6.7mm. Thus, the maximum number of fibers with core diameter 200pm
is 26. Stripping off the jacket would permit a greater number of fibers in the probe,
however, the probe would be too fragile for practical use.
The optics in the distal end of the optical fiber probe must also be designed to
transform the Raman light for efficient coupling into the collection fibers. The collection
fibers must have the same NA as the spectrograph, assuming a 1:1 imaging system. In
addition, to optimize signal collection it is necessary to maximize the cross-sectional area
of the collection fibers in the distal probe tip. This can be achieved by using a single
excitation fiber surrounded by closely-packed rings of collection fibers. As determined
above, the maximum number of fibers that can be accommodated by the spectrograph-
CCD unit is 26. Moreover, the probe that is under construction will be incorporated into a
9 gauge ATEC needle device, which has an inner diameter of 2.7mm. Thus, at the distal
end of the probe, the outer diameter of the optical fiber probe should be less than 2.7mm,
thereby limiting the number of fibers.
0 = Ac(r )Qc(O) = #fibers *dcore . . (r . NA2 =#fibers ,. NA 9.3
Eq. 9.3 describes the relationship between the number of collection fibers and the
throughput of the system. The throughput linearly increases with increasing number of
fibers up to 26 fibers. The throughput of the system that uses 26 fibers is 0.1 87mm 2sr.
However, according to a Zemax simulation the maximum number of fibers that can be
packed in the optical probe with an outer diameter of less than 2.7mm is 15. The
Page 1165
CHAPTER 9: Apparatus for guiding core needle biopsy
throughput of the system that uses 15 fibers is 0.1079mm 2sr, thus utilizing 58% of the
maximum throughput of the system.
To maximize throughput it is also crucial to select the proper excitation optics.
While it is important to match the NA of the collection fibers to that of the spectrograph,
it is desirable to choose an excitation fiber of low NA. This is because the intensity of
the unwanted Raman background generated in the fibers is proportional to the square of
the NA and relatively independent of the core diameter. A smaller NA results in smaller
beam divergence at the distal end, which improves the performance of the short-pass
filter. Previous studies in our laboratory have shown that fibers of very low NA (<0.12)
exhibit substantially increased fiber background associated with the doping material used
in the cladding. Thus, an excitation fiber NA of 0.22 is optimal.
Finally, the excitation diameter must be chosen to ensure safe illumination fluence
at the tissue while confining the spot size to provide efficient collection of Raman signal.
While a tighter focus spot enhances Raman signal collection, it also increases the
deposited thermal energy leading to sample damage.
9.3 Optimization with Zemax
We estimated the distribution of Raman light from the tissue in order to determine
the optimal collection geometry. The total power of Raman scattered light that can be
collected from the tissue can be calculated using the following equation
Panan = fJB(r,9)dAdQ ~ B, (r)dA / B2(r) dQ = P,.P0 9.4
where dA = (2nr)dr, dK = 2nsin(0)dn, and Pr and Po are the integral radial and angular
distributions, respectively. It is also assumed that B(r, 0) is separable.
The excitation radiant power is independent of the collection geometry and is
derived as follows:
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(90d
rB, (r)dr fsin(9)B 2 (6)dO
R (rc ,0,c) ~Z r/ 1(rc ) -r/(0 )=0 ~4 ./-2
frB2(r)dr Jsin(O)B 2(9)d9
r=O 0=0
9.5
where ri1 and 112 are radial and angular efficiency, respectively. By using throughput
conservation theory we established the relationship between collection angle and radius
of the collection spot.
c,0.
.2
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Figure 9.5. The collection angle, Q, as a
function of the radius of the collection spot, r,
in an optical system with a throughput of
0.3248mm2sr limited by the throughput of
spectrograph-CCD.
) = A,(r,)K2,(0, #)=ib#e,.d,,2 . ( r
Thus, the throughput of this system is
Angular efficiency, 12(0), can be
calculated as a function of radius, Eq
5.6. Thus, a linear array of collection
fibers with core diameter 200pm is used
as the input slit to the spectrograph.
However, if we use the entire slit height
that is available, the limiting collection
area would be 1.34mm2 , and the
limiting collection solid angle for the
f/1.8 spectrograph would be 0.2424.
-NA2)=#fibersr dcore NA 2
E = An = 1.34mm 2 .0.2424sr = 0.3248mm2 sr
9.6
9.7
As seen from Eq 9.7, the maximum signal intensity can be obtained represents a trade-off
between the collection area and the collection angle. Thus, the collection angle within
the system throughput can be calculated: n = 0.3248 /A. The collection angle cannot be
greater than 90, therefore the throughput is not conserved when a collection spot radius
is less than 0.17mm due to the geometric constraint as shown in Fig. 9.5. The data is then
integrated and normalized to determine angular collection efficiency, 12, depicted in Fig.
9.6.
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Raman source radius (mm)
Figure 9.6. The angular collection efficiency
9.3.1 Monte Carlo simulations
7010
4C
0 05 1 1.5 2 25
Radius (mm)
Figure 9.7. Radial distribution of Raman signal
from tissue
It is crucial to understand the
effect of scattering and absorption in
breast tissue in order to study the
generation of the Raman signal inside
the sample and its distribution and
intensity at the surface. Monte Carlo
simulations were used to model Raman
scattering light in turbid media.
As discussed in Chapter 3, light propagation in tissue is subject to elastic
scattering and absorption of photons in the tissue. Tissue is characterized by several
optical properties, including absorption coefficient, pa, scattering coefficient, ps,, and the
anisotropy factor, g. The Monte Carlo simulation method is a probabilistic model for
photon propagation. The accuracy of a simulation result from Monte Carlo depends on
the probability density function. A large number of photons are necessary to correctly
simulate the distribution of light.
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Figure 9.8. Monte Carlo simulation of side-
viewing Raman probe sampling volume
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Figure 9.9. Radial collection efficiency of
Raman signal
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Figure 9.10. Potential probe collection efficiency
The sampling volume is difficult to measure
experimentally, thus Monte Carlo modeling
was implemented to obtain a good
approximation of depth of penetration. The
Monte Carlo simulation depicted in Fig. 9.8
provides an estimate of the depth penetration
profile of 830 nm light in breast tissue. The
sampling depth, 6. , can be defined as:
1
9.8j43 p(Pa + P,,
where Sex and 6 em are the penetration depth
of the excitation and emission light,
respectively. Using this equation, it was
estimated that the sampling depth for our
current prototype Raman probe is 1.27mm.
The Monte Carlo simulation was
performed with the following parameters: 1)
the geometry of the sample was a semi-
nfinite medium; 2) the excitation beam was
i 200im collimated beam with Gaussian
profile; 3) parameters of normal breast
tissue were used: pta = 0.05cm-1, pS =
90cm~1, and g=0.9 [15]; and 4) one
million photons were used for the
simulation.
Light emitted from tissue has a
Lambertion distribution. The geometry
was assumed to be independent of the
azimuthal angle, thus measuring the
spatial distribution from a single scan
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was sufficient enough to describe the distribution over the entire surface. The distribution
of the Raman signal on the surface is plotted in Fig. 9.7.
The data is then integrated and normalized to determine the radial collection
efficiency pi(r) depicted in the Fig. 9.9. According to Eq 9.5, the potential collection
efficiency, 9, was determined by the product of i1(r) and 712(r(0)). The optimal efficiency
of 13.6% occurs at a collection radius of 1.05mm and a corresponding 900 angle.
According to Fig. 9.10, it is desirable to collect the full angular range of Raman light
from the most intense area of illumination, rather than collecting a smaller range of
angles while radially expanding to the
weaker tails in the edge of the distribution
The throughput of the system is 7
subsequently reduced from 0.3248mm2 sr to
___2a Collection E~ff cin
0. 1079mm2sr due to the restriction of the
number of fibers to fit within the allotted 0
0
diameter and the dead space between the 32
fibers caused by the cladding and jackets.
The reduced throughput results in a potential 0 0.1 0.2 03 7 0.8 01 1
collection efficiency of 7.82% as shown in Figure 9.11. Potential total collection
Figure9.11.efficiency of the probe.Fiuri911urtetil otl.olecio
9.3.2 Half ball lens design
In order to apply our Raman spectroscopic technique in real time in the clinical
setting during stereotactic core needle biopsy, we have designed and fabricated a
prototype side-viewing probe that is capable of delivering and collecting light from the
tissue in a lateral geometry as required by the commercial vacuum-assisted needle biopsy
systems. A photograph of the side-viewing probe inserted into the biopsy aperture of a
9G ATEC vacuum-assisted biopsy needle is shown in Fig. 9.12. As shown in the figure,
we can place our probe inside the needle and align the side-viewing window of the probe
with the side-viewing biopsy aperture of the needle. A schematic diagram of the probe is
depicted in Fig. 9.13.
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Our designed side-viewing probe
has an outer diameter of 2.4 mm,
with one central delivery fiber and 9
surrounding collection fibers [16].
The distal tip of the probe is
terminated by a half-ball lens
mounted on a 450 mirror, to direct
the excitation light (shown in
orange) laterally through a sapphire
window. The half-ball lens also
greatly improves collection
efficiency, which is critically
important for Raman spectroscopy
where the signals of interest are
weak. The side-viewing probe has
the same set of filters as the front-
viewing probe.
Figure 9.12. Side-viewing Raman probe inside
biopsy aperture of 9G ATEC biopsy needle. Half
ball lens design
irror ball lens
Figure 9.13. Schematic of the side-viewing Raman
probe with a half ball lens design
9.3.2.1 Collection efficiency and probe manufacturing
The prototype was recently been successfully tested in surgically excised breast
tissue, see Chapter 5.5, but has not yet been implemented in a clinical setting. This probe
has identical collection capabilities to a similarly designed front-viewing probe, with
collection efficiencies of 3.5% and 1.7% for air and tissue interfaces, respectively. Even
though this probe was not optimized to work with the ATEC 9 gauge needle, it can easily
fit inside it as demonstrated in Fig. 9.12. However, it is unknown if this probe design will
support a stainless sheath of 55cm that is necessary to add to the probe to ensure proper
alignment of the probe with respect to the needle and good connection between the probe
and breast tissue in anticipated in vivo clinical studies. This probe design can be
manufactured in-house at the G.R. Harrison Spectroscopy Laboratory, while all other
designs given in this chapter must be manufactured elsewhere, providing additional
complexity to the process of moving this project to the clinic.
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9.3.3 Parabolic mirror design
Zemax software was utilized to further improve the efficiency of the side-viewing
probe. As before, simulations were performed using a semi-infinite medium that has the
same optical parameters as normal breast tissue [15]. The largest difference between this
design and the half ball lens design is that the geometry of the side-viewing piece was
optimized to support 15 fibers and therefore an increase in Raman signal.
delivery fiber collection fiber
parabolic mirror
filter
OO 00 15 collection around 1 excitation0 fiber core diameter: 0.2 mm
filter size: 0.5 mm, 1.9 mm
parabolic mirror: r=2mm
collection fiber delivery fiber f-silica block: d=2mm, 1=2.5mm
Figure 9.14. Side-viewing Raman probe design with solid-state, gold-coated parabolic mirror.
This new probe design has solid state imaging optics and has several advantages
over the current prototype design which improve collection efficiency. The new design
(Fig. 9.14) has an outer diameter of 2.4 mm, which is the maximum allowed by the inner
diameter of the ATEC needle. The distal tip now terminates in a gold-coated parabolic
mirror etched on a sapphire or fused silica block, which Zemax ray tracing (Fig. 9.15)
revealed to be the geometry with maximal collection efficiency. This has several
advantages. First, it makes use of imaging optics, which has inherently higher collection
efficiency than the non-imaging optics used in the prototype probe. Second, it has a solid
state design. This eliminates air space between the optical components and thus the need
for the sapphire window, which (due to fabrication constraints) extended laterally beyond
the fiber bundle. This unwanted feature added 200-300 um to the probe outer diameter
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and thus limited the
number of fibers that
could be accommodated
within the allowable
probe outer diameter. Figure 9.15. Zemax simulation of light collection of Raman
Zemax simulations probe with gold-coated parabolic mirror.
show that, using solid state optics, we can now accommodate 15 (rather than 9)
collection fibers surrounding the excitation fiber, which further improves collection
efficiency. Overall, the collection efficiency of this second probe design utilizing the
parabolic mirror etched into a solid sapphire or fused silica block is 4.7% for the Raman
distribution source discussed above, a factor of 3 improvement over that of the current
prototype Raman probe.
This second probe design is more efficient than the probe with the half ball lens
design and will be optimal for usage in clinical studies. However, due to its small size,
the gold-coated parabolic mirror will be challenging to manufacture. In fact, a number of
manufacturing companies have been contacted and none of them can manufacture the
small parabolic piece. Therefore, we have worked on another design that should be easier
to implement than the parabolic mirror design while still remaining more efficient than
the half ball lens design.
9.3.4 Three-cut design
In the three-cut design, the sapphire orfilica block
distal tip of the probe terminates in a
half ball lens similar to that in the first
prototype, but the lens is now mounted
on a sapphire or fused silica block, the
distal surface of which is cut at several
filter half ball lens coated with gold
angles optimized using Zemax42. 48
simulations, see Fig. 9.16. Figure 9.16. Schematic of Side-viewing Raman
This design will result in a collection probe design with the three-cut design.
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efficiency of 2.2%, a 30% improvement over that of the half ball lens Raman probe.
9.4 Side-viewing probe and ATEC needle
As was discussed in the beginning of the chapter, the final goal of this part of the
project is to be able to provide diagnostic information about tissue composition in real-
time during core needle biopsy by acquiring Raman data. In order to do so, one has to
adopt Raman side-viewing probe to the currently used vacuum-assisted biopsy needle.
ATEC biopsy devices manufactured by Hologic company were used in this study,
because these devices are exclusively used at University Hospitals of Cleveland (our
clinical collaborators) on a daily basis.
9.4.1 Adaptor
a)
-~ ---- - - LRY3IJV
Figure 9.17. Adapter for the ATEC biopsy needle. a) Layout; b) Photo of
the final version of the adapter.
The primary need for an adaptor is threefold. We need to be able to: 1) secure the
Raman probe to the ATEC needle; 2) withdraw the probe throughout the side-viewing
port of the needle in a very controlled manner; 3) provide vacuum and saline flush with
the probe in place within the needle.
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A standard ATEC 9-gauge needle has a side-viewing port of 20mm, while a side-viewing
probe can acquire Raman spectrum from a 1mm 2 area. Thus, the Raman probe has to be
withdrawn from the needle in 1mm increments along the length of the 20mm port in
order to cover the entire area (and volume) of the biopsy cores. Figure 9.17a depicts a
schematic of parts of the adapter, while Figure 9.17b shows the final version of the
adapter. All parts of the adapter are made of stainless steel (#316), which is necessary for
medical devices. The adapter was designed using emachineshop software.
Figure 9.18a-b shows the configuration of ATEC needle, the tissue collector and
adapter that connects the needle and the tissue collector. Fig. 9.18c shows two ports of
the adapter, where one is used to place a probe and another one is used to apply a
vacuum, which is necessary for biopsy. Fig 9.18d-e shows the Raman side-viewing probe
inside the ATEC needle. The adapter allows the user to withdraw the probe in 1mm
increments without rotating the probe. When the needle is rotated during the biopsy
procedure, the probe will rotate simultaneously with the needle, as it is secured by the
adapter.
Figure 9.18. a) Combining ATEC needle, adapter and a tissue collector; b) Detailed view of
adapter connected to tissue collector; c) end-view of the adapter; d) side-viewing probe at the
tip of the needle; e) side-viewing probe is moved by 3mm inside the aperture.
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Using Suros console we were able to apply a vacuum while the probe was placed inside
the ATEC needle and secured using the adapter. This is a necessity to make sure the
proper prober/tissue contact. Due to the fact that central port of the adapter is used for
probe placement, the vacuum port is off centered. The tissue collector is connected to the
vacuum port (Fig 9.18b). The adapter and the probe have to be removed from the needle
prior of removing biopsy cores. The adapter has to be further modified to allow collection
of cores without detaching the adapter.
9.4.2 Side-viewing probe
Due to the difficulties of manufacturing the parabolic mirror, the half ball lens
design (Section 9.3.2) was chosen for the second-generation version of the Raman side-
viewing probe. The second-generation probe has approximately 50cm of rigid stainless
steel tubing that is 20tm smaller than the inner diameter of the cutting tube of the ATEC
needle. That allows enough space to apply a vacuum.
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Figure 9.19. Raman spectra of sapphire components of the side-viewing probe
The probe has a sapphire half ball lens, a sapphire tube that is used to facilitate the
probe's manufacturing, and a sapphire side-viewing window that is used for index
matching that preventing contact between optical parts of the probe and blood or tissue.
Figure 9.19 illustrates Raman spectra of all sapphire parts used in the probe. The top
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spectrum is that of the pure sapphire that
0.71 a was used in the model for fitting data
collected from breast specimens, see
Chapter 3. The next four plots are the
Raman spectra of actual components
7used in the probe. The flat side of the half
700 800 900 10001100 1200 1300 1400 15001600 17001800 ball lens has a gold coating. Data was
Raman Shift (crm)
Oft acquired from the sapphire side of the
,11 b) ---
sball lens ("ball top") and from the gold
side of the ball lens ("ball gold"). These
spectra have additional Raman features
that are not seen in the pure sapphire
-A-
spectrum. In order to fit data acquired by
Raman Shif (cm-)
Figure 9.20. Raman spectra and fit using the side-viewing probe ("breast"
a) pure sapphire spectrum; b) spectrum of spectrum), we have to include the
sapphire side-viewing window
spectrum of the side-viewing window
into the model, as this spectrum has the most Raman features out of all sapphire
components in the probe. Figure 9.20 shows a side-by-side comparison of fits to the data
using: a) pure sapphire; and b) sapphire used in the side-viewing window; for fitting
Raman data. Fitting the data with the sapphire spectrum of the side-viewing window
results in the least amount of structure in the residual spectrum .The difference between
these two sapphire spectra is still under study. Impurities in the material used in the side-
viewing window could be the source of the additional Raman peaks.
9.5 Ex vivo study with side-viewing probe
An in vitro proof-of-principle study has been conducted, in which spectra were
collected for the first time through a biopsy needle, using our second generation side-
viewing Raman probe, from frozen-thawed normal breast tissues obtained from a breast
reduction specimen (Fig. 9.21). A 9-gauge ATEC vacuum-assisted biopsy needle was
inserted into the breast tissue, and then the side-viewing Raman probe was inserted into
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Figure 9.21. Ex vivo study. a) ATEC needle is inserted into a breast specimen; b) The probe
is inserted into ATEC needle, and needle is placed inside breast tissue in order to acquire
Raman spectra; c) adapter, side-viewing probe and needle used in the study
the needle until it made contact with the breast tissue in the biopsy aperture. Raman
spectra with excellent SNR were obtained from the breast tissue in 0.5s without
application of a vacuum (Fig. 9.21 b). The probe was moved throughout the length of the
needle's aperture in 1mm increments in order to collect Raman spectra over the entire
length of the tissue core. Finally, the Raman diagnostic algorithm developed using the
front-viewing probe was applied to these data, Fig. 9.22. All of the breast samples were
0.7
0.6
0.5-
0.4. FCC
0
Ii. IDC0.2-
Fibroadenoma 0- Norma
0 0.2 0.4 e.6 I
FC (Fat
Figure 9.22. Side-viewing probe experiment: breast lesion diagnosis using Raman algorithm.
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correctly diagnosed as normal tissue. This indicates that the fitting procedure and the
diagnostic algorithm designed for data collected via the front-viewing probe may be able
to be used in future studies with the side-viewing probe.
9.6 Summary
Two potential Raman side-viewing probe designs have been developed based on
Zemax and Monte Carlo simulations. We have developed both instrumentation and data
analysis techniques for the clinical application of Raman spectroscopy for the diagnosis
of breast disease. The ex vivo study using one of the side-viewing optical fiber probes
(first design) demonstrated that it is feasible to collect Raman spectra of high S/N in a
clinically-relevant time frame through the biopsy aperture of a commercial vacuum-
assisted needle biopsy device. A previously developed Raman diagnostic algorithm for a
front-viewing Raman probe was successfully applied to data acquired using the side-
viewing probe. These are important capabilities in developing Raman spectroscopy as a
clinical tool to provide real-time feedback to the radiologist to improve retrieval of
microcalcifications during stereotactic biopsy procedures. The ability to identify and
localize microcalcifications as the optical fiber probe is scanned (pulled back) along the
biopsy aperture in the stereotactic biopsy needle, and obtain information on the type of
microcalcification and breast lesion associated with the microcalcification, will allow the
radiologist to make better informed decisions as to whether to biopsy and how many
biopsy tissue cores to remove at a particular needle location. This should result in
improved retrieval of microcalcifications during stereotactic needle biopsies.
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CHAPTER 10
Accomplishments and future directions
The first part of this chapter, we summarize the accomplishments of the work
presented in this thesis and critically discuss the strengths and weaknesses of the
spectroscopic techniques. In the second part of the chapter, we discuss potential
future directions for the breast project.
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10.1 Accomplishments of the thesis
10.1.1 Development of a DRS/IFS diagnostic algorithm
The diagnostic potential of a combined approach utilizing DRS and IFS was
shown via a pilot ex vivo study. Physical parameters extracted from these
spectroscopic modalities were used to develop a step-wise algorithm for
distinguishing among breast tissue diagnosed as either normal, fibroadenoma, FCC,
or IDC by histopathology. Raman spectra were collected from the same location on
the tissue using a second instrument; therefore, we were able to assess the diagnostic
potential of MMS - a combination of all three modalities. The diagnostic algorithm
based on DRS/IFS successfully distinguished malignant from non-malignant lesions,
as well as benign lesions (FCC and fibroadenoma) from normal tissue. The results of
the study demonstrated a sensitivity, specificity, PPV, NPV, and total efficiency of
100%, 96%, 69%, 100% and 91%, respectively. By combining Raman with DRS/IFS,
we were able to correctly diagnose 4 normal sites previously misdiagnosed by the
algorithm based on DRS/IFS, and improve the overall accuracy to 92%. The
promising results from this study supported the further development of an integrated
MMS probe and instrument to rigorously evaluate the MMS approach.
10.1.2 Prospective application of the Raman and DRS/IFS diagnostic algorithms
A Raman diagnostic algorithm which was previously developed was
prospectively validated on a large data set from two subsequent ex vivo studies. The
NPV, the most clinically important value, remained -98% in all studies. The
sensitivity and specificity decreased slightly in the present study, which is likely due
to differences in the disease prevalence and disease spectrum. To our knowledge this
is the first spectroscopy study to date which evaluates a diagnostic algorithm for
breast lesions in prospective manner. This is very significant step in bringing our
technology to the clinic, where it can aid physicians with tissue diagnosis.
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10.1.3 Development of the MMS clinical instrument
We designed and developed a compact, a novel portable clinical MMS system
capable of acquiring and analyzing reflectance, fluorescence and Raman
spectroscopic data and providing a diagnosis in -2-3 seconds. The MMS instrument
was tested in the clinic in an ex vivo study involving 99 patients. Future
improvements of the instrument may include the use of a single spectrograph/CCD
unit for both visible and near infrared light (once this technology becomes available)
to further reduce the size of the system
10.1.4 Clinical implementation and evaluation of MMS
A clinical ex vivo study was performed at the UH-CMC using the MMS
instrument. Spectroscopic data were collected from 99 patients undergoing both
excisional and core needle biopsies. The system collected reproducible and reliable
data. The difference in performance of DRS and IFS is still under investigation. One
of the possible reasons is the difference in the sample volume associated with
different spectroscopic modalities. The data set included several lesions that were not
seen during previous investigations, including malignant (DCIS and ILC) lesions. We
developed a new diagnostic algorithm which enabled the identification of these
additional lesion types.
10.1.5 Development of new Raman algorithm to predict patients' outcome
In addition to relating the spectroscopic parameters to histopathology
categories, we evaluated the potential of spectroscopy to predict the outcomes of
patients with malignant lesions. We developed a Raman algorithm to distinguish
among different tumor grades and the status of estrogen and progesterone receptors.
We found that the Raman fit coefficients from calcium oxalate dehydrate and
cholesterol-like can distinguish among tumor grades. The combination of the fit
coefficients from n-carotene and cell nucleus distinguished between ER negative and
ER positive statuses, misclassifying two ER positive sites. Fit coefficients of calcium
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oxalate dehydrate and p-carotene were the most promising in identifying PR status.
The findings from this study demonstrated that Raman spectroscopy may provide
information which is relevant for determining the treatment course.
10.1.6 Development of a mini-Raman clinical system for guidance of core needle
biopsy
Finally, we developed a mini-Raman clinical system to guide the clinician
when performing stereotactic core needle biopsies by identifying microcalcifications.
A side-viewing probe geometry was developed that enabled the probe to be inserted
into a 9G ATEC biopsy needle device. Several different prospective side-viewing
probes were designed to maximize collection of the Raman signal. However, due to
the manufacturing constraints a sub-optimal design was used in the initial proof-of-
principle study. The findings from this study revealed that the diagnostic algorithm
developed for the front-viewing Raman probe could be successfully applied to data
collected using the side-viewing probe. This study demonstrated that it is possible to
collect high quality Raman signals in this geometry and has led to collaboration
between the G.R. Harrison Spectroscopy laboratory and Hologic Inc., a commercial
company that is a leading developer and manufacturer of diagnostic products related
to the healthcare needs of women.
10.2 Future directions
The future of this project may involve following:
10.2.1 Improved instrumentation
The current design of the side-viewing optical fiber Raman can be further
optimized for clinical use. Replacing the half-ball lens with a parabolic mirror
(Chapter 9.3) would result in a more sensitive fiber probe that can collect good
quality Raman spectra in less time than current probe. Decreasing the acquisition time
required per site ultimately decreases the time data collection adds to the core needle
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biopsy procedures. It would be extremely beneficial to redesign the current adapter
used to incorporate the side-viewing Raman probe into the ATEC needle such that
tissue cores can be extracted without completely removing the probe from the needle.
This change would also minimize procedure time, thus making Raman spectroscopy
more attractive to clinicians as a tool for identifying sites of microcalcifications that
should be targeted for biopsy.
A future in vivo study is being planned to evaluate the use of the Raman system to
guide core needle biopsy. The first pilot study will involve a small number of patients
(~10). The aim of this study is to optimize the study protocol and answer the
following questions: 1) How many Raman spectra should be taken from each core in
order to provide clinically relevant information? 2) Is vacuum necessary for good
probe-tissue contact? and 3) Where should the Raman instrument be located in the
radiology room? The results of this pilot study will also address whether there is a
need to change the adapter or to modify the instrument because of space constraints in
the radiology room.
10.2.2 Development of new algorithms
As we described in Chapter 7, current data obtained from 48 patients
undergoing excisional biopsy provided 36 number of calcified lesions. Based on this
data set, we had found correlations between the Raman spectroscopy results and
histopathology diagnoses. The algorithm for distinguishing calcified from non-
calcified lesions should be prospectively validated on a larger data set and modified
as necessary. We were unable to construct a diagnostic algorithm to distinguish
between calcified lesions, because of the limited data set. Thus, the algorithm needs
to be designed and tested on a larger data set to test its reliability for this distinction.
In addition, a larger data set should provide us with enough data to distinguish
between type I and type II microcalcifications. The data required to develop and
assess algorithms for these applications will be acquired during the large in vivo study
in which Raman spectroscopic is used to identify microcalcifications (10.2.1).
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10.2.3 Raman basis spectra
The Raman basis spectra used in the studies described in this thesis were
obtained several years ago and have not been updated. The fits to the measured
Raman spectra are generated based on a linear combination of all Raman basis
spectra- each of which is related to a chemical or morphological component within
breast tissue (Chapter 3). Although the residuals from the fits to the Raman spectra
are generally featureless, it would be important to collect the basis spectra once more
for the following reason: as described in Chapter 7, IDC lesions have large
contribution of the sum of cell cytoplasm and cell nucleus compared to other lesions.
This finding is consistent with histopathology. These features are particularly
important to note when the pathologist making a diagnosis. In order to provide better
algorithm based on fit coefficient of cell cytoplasm and cell nucleus, we may need to
add additional basis spectra to the breast model, such as Raman spectra of cytoplasm
and nucleus from stroma (currently we have spectra of epithelial cells, only). This
would require a Raman confocal microscope setup.
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Performance Matrix
Condition (gold
standard=pathology)
True False
normalTrue False
Positive Positive -
(TP) (FP)
+ 0 False True
4 Negative Negative -
(FN) (TN)
cancer
-PPV
+N1'PV TN FN kFP TP
Sensitivity Specificity
Figure A.1. Binary classifier plot. Visual definition of sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV)
Sensitivity and specificity are two statistical measurements of diagnostic
performance most often reported in the medical literature. The sensitivity of a test is a
measure of how well the classification test identifies a condition, i.e. proportion of
true positives of all malignant lesions in the data set. The specificity of a test is a
measure of how well the classification test identifies the negative case or the absence
of a condition, i.e. the proportion of true negatives of all the non-malignant lesions.
The positive predictive value (PPV) is a posterior measure that shows the proportion
of data points with a positive test outcome that are correctly classified. The negative
predictive value (NPV) is a posterior measure that specified the proportion of data
points with a negative test outcome that are correctly classified. These parameters can
be calculated as follow (p is the prevalence of disease):
TP
sensitivity = se Pr {test positive I condition true) = TP + FN A. 1
T N
specif icity = sp Pr {test negative I condition f alse} =TN A.2TN +FPA2
TP p-sePPV = Pr{condition true Itest positive) = = - sp
TP+FP (1-p)-(1-sp) A.3
NPV = Pr{condition false Itest negative) = TN (1 - p) - spTN+FN (1-p)-sp+p-(1-se) A.4
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High sensitivity is wanted in the case of serious and treatable disease, which
should not be missed; and false positive results do not have serious adverse
consequences for the patient. In this situation, one wants to identify every single
patient with the disease for further clinical evaluation and treatment, even at the cost
of misdiagnosing few healthy patients as diseased [1].
High specificity is wanted in the case of serious but not treatable disease; and
false positive results may have serious adverse consequences for the patient. In this
situation, one wants to correctly identify every single non-diseased or healthy patient,
even at the cost of misclassifying some diseased patients as healthy.
High PPV is wanted in the case of a serious and treatable disease, which
should not be missed; and false positive results may have serious adverse
consequences for the patient. In this situation, one wants to be certain that every
patient with positive test has the disease in question, even at the risk of missing some
diseased patients.
High NPV is wanted in the case of serious but not treatable disease; and false
negative results will not have serious adverse consequences for the patient.
Overall efficiency is defined as the ration of the total number of correct test
results to the total number of tests performed. High overall efficiency is wanted when
the disease is serious and treatable; and false positive and false negative results are
equally serious or potentially injurious to the patient. In this situation, one wants to be
certain that the test result is accurate whether it is positive or negative.
1. Fitzmaurice, M., Principles and pitfalls of diagnostic test development:
implications for spectroscopic tissue diagnosis. J Biomed Opt, 2000. 5(2): p. 119-
30.
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1. OVERVIEW
Raman scattering provides chemical information from a sample based on the
specific spectral shifts that result from molecular vibrations. Since Raman scattering can
occur without damaging the sample, it can serve to be an effective tool for extracting
chemical and morphological information in a non-invasive manner [1]. Early Raman
spectroscopy studies have used excised and cadaver tissues, and whole blood samples
for the examination of atherosclerosis, detection of cancer, and the measurement of
blood analytes [2, 3, 4, 5]. With the development of flexible and high-throughput
optical fiber probes [6], as well as compact and improved spectroscopic devices, it has
become possible to apply Raman spectroscopic techniques in the clinic in vivo [7, 8].
The ability to rapidly collect Raman information, and provide immediate
feedback to the physician during a clinical procedure has the potential to greatly
improve patient care by facilitating real-time disease management, improving diagnostic
accuracy, and allowing early disease diagnosis as well as long-term monitoring of
therapy. The Raman clinical instrument described in this manual serves to be a
necessary step towards achieving these goals. The manual will explain each portion of
the Raman clinical instrument and describe the operating procedures. It will also
provide some useful troubleshooting steps, as well as basic analytical techniques for
Raman spectroscopy.
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2. INSTRUMENTATION
A. Overall setup
A schematic of the Raman clinical instrument is shown in Figure 1. The Raman
clinical instrument consists of the following optical components: an 830nm diode laser
(500mW maximum power, Process Instruments, Salt Lake City, UT) for excitation light
source, an optical fiber probe [1] for delivering excitation light and collecting Raman
scattered light from the tissue, a spectrograph (Holospec f/1.8i, Kaiser Optical Systems),
and a thermoelectrically cooled CCD camera (PIXIS 256, 26x26pm pixels, 1024x256 array,
Princeton Instruments) for spectrum analysis and detection, and various optics.
Shufter
Focusing Ilens Bandpass fter
Ram Probe
Holographic
Figure 1 A schematic diagram of the portable Raman clinical instrument.
-3-
NO . . .......
Figure 2 Major components and instruments fixed on the cart optical breadboard
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In addition to these optical components, the Raman clinical instrument also
includes a computer for instrument control and data collection. Specifically, the
computer monitors and controls the diode laser power and CCD temperature,
opens/closes the laser shutter (Uniblitz, Vincent Associates) and collects data from the
CCD. Data transfer to and from the instrument is achieved by PCI (peripheral
component interconnect) and USB (universal serial bus) connections located at the
bottom of the computer. The white box under the laser shown in Figure 2 encloses the
adapter that connects the laser and the control card in the computer.
B. Laser light delivery alignment
COUPLING LENS UNT
SHUTTER
BANDPASS FILTER LASER
Figure 3 Laser light delivery components. The 830 nm beam from the laser is filtered
through a bandpass filter and is gated by a computer-controlled shutter. The
beam is then focused and collimated through a lens unit to be coupled to the
optical fiber probe.
-5-
Figure 3 shows the components used for excitation light delivery. The beam
from the 830 nm diode laser is filtered through a bandpass filter and it is gated by a
computer-controlled shutter. The beam is then focused and collimated through a lens,
and coupled to the excitation light delivery fiber of the optical fiber probe.
Figure 4 shows a close-up view of the coupling lens unit and the optical fiber
probe. The laser, bandpass filter, shutter, coupling lens unit and the delivery fiber are
carefully aligned to minimize losses in laser power. The power of the laser can be
controlled by the Labview software, as described later in Figure 12. The "Set Power"
setting should not exceed 1.26V, at which approximately 440mW is delivered from the
laser output. With 440mW at the laser output, the power after passing through the
bandpass filter, the shutter, and the coupling lens unit should be no less than 380mW.
Usually, the most significant power loss occurs between the coupling lens unit and the
optical fiber. If correctly aligned, the power of the excitation light measured at the
distal tip of the optical fiber should be about 130mW with 440mW at the laser output.
However, for typical spectroscopic measurements, the power measured at the tip of the
optical fiber should be at 100mW. Before measurements, adjust the "Set Power"
setting to reach this power level. Laser power greater than 100mW should not be used
on human subjects, as it may induce tissue damage. The ANSI (American National
Standards Institute) maximal permissible exposure to continuous wave near infrared
laser light for 10 seconds is 0.36 W/cm 2, which is an extremely conservative standard [2].
An 830nm light excitation power of 100mW over a 200tm diameter spot corresponds to
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irradiance of 318 W/cm 2, which is clearly above the ANSI standards, but comparable to
what is currently being used safely by many research labs including our own [3-9].
Figure 4 A: Front view of the coupling lens unit.
B : Excitation light delivery fiber coupled to the lens unit.
C. Optical fiber probe, spectrograph, and CCD
The optical fiber probe serves dual functions of delivering excitation light to the
target tissue as well as collecting Raman scattered light from the target tissue. The
probe (Figure 5) has a central excitation fiber (multimode, 200pm core, 0.22 NA) with an
aluminum jacket for optical isolation to prevent cross-talk with the 15 collection fibers
(multimode, 200pm core, 0.27 NA). [1]
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Figure 5 Schematic of the Raman probe tip. [1]
A : Longitudinal view, B : Transverse cross section at the fiber-filter interface.
The distal tip of the probe has a ball lens mounted inside the metal sleeve to
enhance light collection (Figures 5, 6). When collecting Raman spectra, the probe
should be in gentle contact with the sample. At the proximal end, the collection fibers
are aligned in a column to form the slit of the spectrograph (Figure 6A). When coupling
to the spectrograph, the column of fibers must be in a vertical position so that the
column of light spots can be evenly dispersed by the spectrograph. This alignment can
be achieved by monitoring the optical fiber patterns through the CCD camera under
WinSpec (section 3B(i)).
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Figure 6 A: Column of collection fibers lighting up on the optical fiber probe connector
B : Distal tip of the optical fiber probe
References:
1. J. T. Motz, M. Hunter, L. H. Galindo, J. A. Gardecki, J. R. Kramer, R. R. Dasari, and
M. S. Feld, "Optical fiber probe for biomedical Raman spectroscopy," Applied
Optics. 43(3), 542-554, (2004).
2. ANSI.Z136-1 (2000). Safe Use of Lasers, American National Standards Institute.
3. M. G. Shim, B. C. Wilson, "Development of an in vivo Raman spectroscopic
system for diagnostic applications," Journal of Raman Spectroscopy 28. 131-142,
(1997).
4. P. J. Caspers, G. W. Lucassen, E. A. Carter, H. A. Bruining and G. J. Puppels, "in
vivo confocal Raman microspectroscopy of the Skin: noninvasive determination
of molecular concentration profiles," Journal of Investigative Dermatology 116.
434-442, (2001).
5. J. T. Motz, S. J. Gandhi, 0. R. Scepanovic, A. S. Haka, J. R. Kramer, R. R. Dasari,
and M. S. Feld, "Real-time Raman system for in vivo disease diagnosis," J.
Biomed. Opt. 10(3). 031113, 1-7, (2005).
-9-
6. H. P. Buschman, E. T. Marple, M. L. Wach, B. Bennett, T. C. B. Schut, H. A.
Bruining, A. V. Bruschke, A. van der Laarse and G. J. Puppels. "In vivo
determination of the molecular composition of artery wall by intravascular
Raman spectroscopy," Analytical Chemistry, 72(16):3771-3775, (2000).
7. 0. R. Scepanovic, Z. Volynskaya, C.-R. Kong, L. H. Galindo, R. R. Dasari, and M. S.
Feld, "A multimodal spectroscopy system for real-time disease diagnosis," Rev.
Sci. Instrum. 80(4). 043103, 1-9, (2009).
8. A. S. Haka, Z. Volynskaya, J. A. Gardecki, J. Nazemi, J. Lyons, D. Hicks, M.
Fitzmaurice, R. R. Dasari, J. P. Crowe, and M. S. Feld, "In vivo margin assessment
during partial mastectomy breast surgery using Raman spectroscopy," Cancer
Research, 66, 3317-3322, (2006).
9. 1. V. Ermakov, R. W. McClane, W. Gellermann and P. S. Bernstein. "Resonant
Raman detection of macular pigment levels in the living human retina," Optics
Letters, 26(4): 202-204, (2001).
- 10 -
3. OPERATING INSTRUCTIONS
A. Hardware operations
The first step of initializing the Raman clinical instrument is to power up the
hardware. The next step is to turn on the computer and the laser. The computer power
switch is located on the lower back of the computer, and the laser is switched on by
turning the key clockwise, as shown in Figure 7.
Figure 7 The 830 nm diode laser is switched on by turning the key.
Next, the shutter controller must be turned on to enable gating of the laser. The
shutter controller power switch is located on the back of the controller. For proper
operations, the shutter controller settings should be set as follows :
Mode turn key = "STD"; Normally closed ("N.C."); "REMOTE"
These controller settings are shown in Figure 8.
- 11 -
Figure 8 The shutter controller power switch and control settings
If the optical fiber probe is not attached already, attach the delivery fiber to the
coupling lens unit and the modified SMA connector to the spectrograph. As described in
the "Instrumentation" section, make sure that the bandpass filter, shutter, coupling lens
unit and delivery fiber are properly aligned so that approximately 100mW is delivered at
the distal tip of the probe. To enable laser light delivery, use the Labview software to
open the laser shutter remotely from the computer, as described later (Figure 20). For
troubleshooting, the shutter can also be opened without the computer by adjusting the
shutter control setting to normally open "N.O.". However, leave the setting to "N.C."
for normal operations (Figure 8). The laser power is controlled remotely from the
computer software with maximum allowable setting at 1.26V (Figure 19). For
-12-
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troubleshooting, the power can also be adjusted locally by removing the cable
connection to the computer and turning the power adjust knob on the laser (Figure 9).
Figure 9 Power adjustment knob of the diode laser
B. Software operations
Three major software packages are used in the operation of the Raman clinical
instrument. The first is WinSpec, which is used for troubleshooting steps and
determining the region of interest of the CCD. The second is Labview virtual instrument
(VI) software "Ramanmain.vi", which is the main software used in the normal
operation of instrument control and data acquisition. These two software packages
should not be run simultaneously, as it would create conflicts in software and freeze the
computer. If this happens by mistake, restart the computer. The third is Matlab, which
is utilized by Labview during operation.
- 13 -
Figure 10 WinSpec initialization screen
(i) WinSpec Software
a. First, determine the region of interest of the CCD by using the WinSpec software.
Locate the WinSpec icon from the Start menu and run it (Figure 10). If the software
shows an error message about not being able to find the camera, check the USB and
power connections. Next, open the "Setup" menu and click on "Detector
Temperature". Set the target temperature to -700 C.
b. Before acquiring Raman spectra, turn off the room light. Go to the "Acquisition"
menu and select "Experimental Setup" (Figure 11).
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Figure 11 Locating "Experimental Setup" command under "Acquisition" menu.
c. Select exposure time, starting from shorter exposure times (e.g. 0.25 s) to prevent
CCD saturation (Figure 12).
Figure 12 "Experimental Setup" setting window
d. Obtain a Tylenol (4-acetamidophenol) calibration sample, turn on the laser, turn
off the room light, and execute "Easy Bin" under the "Acquisition" menu (Figure 13).
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Figure 13 Locating "Easy Bin" command under "Acquisition" menu
e. While the probe is properly positioned over the Tylenol sample (Figure 26A), click
on "Acquire Full image" (Figure 14). The acquired image should show several
vertical columns of light spots, with high intensity areas corresponding to the Tylenol
Raman peaks. By either dragging the pointer on the image or directly entering the
pixel numbers, choose the starting and ending pixel numbers so that the red lines
cover just enough of the CCD area that contains the spectral data (Figure 14).
Fil E&t V"e w it Calbratia To*l Dhspla Specrogaph Proes eu WV indow He
Figure 14 Using the "Easy Bin" function to define binning pixel ranges (boxed).
- 16 -
Note these starting and ending pixel numbers, and enter them into the region of
interest settings when later using the Labview software (Figure 21).
f. Click on "OK", and click on "acquire" to produce the Raman spectrum of Tylenol,
as shown in Figure 15 (in original colors), and in Figure 16 (colors modified for better
visibility).
(Note: During WinSpec's normal acquisition and focus operation, the spectroscopy
mode can also be achieved by navigating to "Acquisition" menu -> "Experimental
Setup" -> "ROI Setup" and selecting "Spectroscopy mode".)
Fe Edt View Aq tOn Cairatin Tools Dspay p Pro s SetUP Windo Hel
7iL A~ 441 4 0 00' 14 23 1
Figure 15 Raman spectrum of Tylenol obtained by "Easy Bin" process.
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Figure 16 Raman spectrum of Tylenol obtained by "Easy Bin" process, with colors in
black and white for visibility.
If the spectrograph is properly aligned and focused, the 834.5cm 1 Tylenol peak should
be clearly distinguishable from its neighboring peaks (arrow, Figures 33, 16). If this is
not the case, adjust the spectrograph focus by turning the camera focus and slit focus
knobs located on the outside of the spectrograph.
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(ii) Labview Software
a. Make sure the WinSpec software is not running. To initiate the main Labview
software, open the shortcut to "Raman_main.vi" on the Desktop and run the code.
The main software screen should initially be as shown in Figure 17.
b. Upon initialization, the software will immediately show the current CCD
temperature on the upper left corner of the screen (Figure 17, circle) and will initiate
cooling to the target temperature.
-19-
Figure 17 The main Raman spectroscopy software initial screen. Red circle indicates
CCD temperature readings, and arrow points to the textbox for entering the
target temperature.
The target temperature can be set by typing in the desired temperature at the "Set
Raman Temp." box (Figure 17, arrow). Set the target temperature to -700 C. When
the target temperature is reached, the green box on the upper left of the screen will
light up and it will read "Raman Locked" next to the box (Figure 18).
Figure 18 Raman CCD temperature locked to the target temperature
c. Next, the laser should be turned on by clicking on the "Raman laser" switch (Figure
19, arrow). The power level can be controlled by adjusting the "Set Power" setting
(Figure 19). This setting should not exceed 1.26V (-440mW at laser output).
Figure 19 Turning on and setting the power of the laser.
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Figure 20 Controlling the laser shutter.
d. For alignment purposes, the laser shutter can be manually opened and closed by
clicking on the "Raman Shutter" switch (Figure 20).
e. Also, the CCD exposure time, number of frames acquired, and the region of interest
(i.e., starting and ending vertical CCD pixel numbers) can be specified (Figure 21).
Exposure time may vary depending on the application and the sample under study.
For typical artery and breast tissue measurements, start from exposure time of 0.5 sec
and increase as necessary. Enter the starting and ending pixel numbers obtained
previously with WinSpec (Figure 14).
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Figure 21 Specifying region of interest, exposure time, and number of frames.
f. To enable saving data, turn on the "Save" option (Figure 22, left). Next, the directory
path for storing the data is specified by clicking on the folder button (Figure 22).
Navigate to the desired directory and click on "Current Folder" (Figure 22, right).
Specify the name of the data files to be stored by changing the content of the "Name"
textbox. Each data file will have a date and time stamp in its filename.
Figure 22 Specifying directory for data storage and selecting save option.
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g. To acquire data, click on the orange "Acquire Raman" button. (Figure 23, right,
arrow). When collecting Raman spectra, the probe should be in gentle contact with
the sample. Keep the "Raman Mode" setting on "Acquire", so that clicking on the
"Acquire Raman" button would acquire spectral data at the specified exposure time
and number of frames.
Figure 23 Selecting "Acquire" mode and initiating data collection.
h. The Labview software is also used for calibration measurements and real-time
analysis. These are described in the following sections (iii) and (iv), respectively.
(iii) Calibration measurements
In order to correct for background Raman scattered light from the optical fiber
probe and to accurately measure the Raman shifts, several calibration measurements
need to be made. For this purpose, barium sulfate (BaSO4), aluminum and Tylenol
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samples, as well as a tungsten halogen lamp light source are required (Figure 24). To
help with the calibration measurements, the Labview software has a "calibration" menu
with each type of calibration to be selected before taking each measurement (Figure 25).
Figure 24 A: BaSO 4, aluminum and Tylenol samples B : Tungsten halogen lamp
Figure 25 Selecting type of calibration under "Calibration" menu
First, select "Tylenol" under the calibration menu (Figure 25) and collect the Tylenol
Raman spectrum with the probe in gentle contact with the sample (Figure 26). If the
tallest peak has less than 20,000 intensity counts, increase the exposure time. Since
Tylenol has a well known Raman spectrum with clearly defined peaks (Figure 23), its
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Raman spectrum will serve as a standard for calibrating the Raman shift (wavenumber)
axis of the spectrum. Next, select "Aluminum" under the calibration menu and collect
the aluminum Raman spectrum with the probe in gentle contact with the sample. If the
intensity count is less than 8,000, increase the exposure time. The aluminum spectrum
will serve as a background spectrum, which will later be subtracted from the Raman
spectra collected from the tissue samples. Finally, select "White" under the calibration
menu and collect the white light response with the Raman probe approximately 1cm
above the BaSO 4 sample, while it is illuminated by a tungsten halogen lamp (Figure 28).
Figure 26 Measuring Raman calibration spectra. A: Tylenol, B: Aluminum.
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Figure 27 Typical Tylenol and aluminum calibration spectra.
Care must be taken not to saturate the CCD while measuring the white light response.
Vary the distance between the probe and the sample until the white light response has
an intensity count of about 50,000. For consistent measurements, a probe holder
should be used to hold the probe in a vertical position, as shown in Figure 28.
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Figure 28 Measuring white light response with a tungsten halogen lamp (upper left)
illuminating the BaSO 4 sample, and the Raman probe ~1cm above the sample.
Figure 29 Typical white light response.
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(iv) Real-time Analysis
To use the real-time analysis feature of the Raman clinical instrument software,
obtain calibration spectra as described in section (iii). Next, load the calibration spectra
by choosing "Load" under "Calibration" menu (Figure 25). Select the figure of Tylenol
spectrum, and move the mouse pointer over the figure. A crosshair will appear on the
figure to help locate the pointer. Choose the calibration pixel points by clicking on the
Figure 30 Selecting Tylenol peaks for calibration.
figure from right to left with a mouse, so that 13 Tylenol peaks are selected as described
in section 4A. It is important that these 13 peaks are selected in the proper order of
high to low wavenumbers (right to left).
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Next, choose between "Breast" and "Artery" model, and enable real-time
analysis (Figure 31).
A B
Figure 31 A: Choosing analysis models, B: Enabling real-time analysis
When "RT Analysis" is enabled, the software will generate the analysis
information based on the model of choice (Figure 32).
Figure 32 Real-time analysis display.
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4. DATA ANALYSIS
A. Extracting Raman spectrum from acquired data
The raw data obtained and stored by the Raman clinical instrument can be
processed and analyzed in many different ways. This section describes the data
processing methods used by the Raman clinical instrument during its real-time analysis
process (section 3(iv)). In order to obtain an accurate representation of the sample's
Raman spectrum, the acquired raw spectrum data must first be corrected for the
background response. This can be done by dividing the acquired spectrum by the white
light response calibration spectrum, which is collected by using the same instrument
and probe (section 3(iii)). In addition, the acquired spectrum should also be corrected
for probe background. This is achieved by subtracting the aluminum Raman calibration
spectrum from the acquired spectrum.
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Figure 33 Raman spectrum of Tylenol.
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The next step is to remove the fluorescence background in the spectrum, which
is achieved by removing a best-fit 6th order polynomial. Finally, the well-known peak
locations of the Tylenol calibration Raman spectrum are used to calibrate the Raman
shift (wavenumber) axis for displaying the processed Raman spectrum in the proper
form (Figure 34 B). This is achieved by using the Matlab codes "calibrateTylenol.m" and
"tylenol-ccf.m" (Appendix B), where the appropriate pixel locations corresponding to
the following 13 Tylenol peaks in the calibration Raman spectrum are selected from high
to low wavenumbers (cm1) :
1648.4,1561.6, 1371.5,1323.9,1236.8,1168.5,1105.5, 968.7, 857.9, 834.5, 797.2, 710.8, 651.6
A Raw Raman Data B Processed Raman Spectrum
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Figure 34 A: Raw Raman spectrum of a calcified artery tissue.
B: The same Raman spectrum after spectral response correction, fiber background
removal, tissue autofluorescence removal, and Raman shift axis calibration.
After these data processing steps, the raw tissue Raman data (Figure 34 A) is
represented in the proper form of Raman spectrum (Figure 34 B). The data processing
steps mentioned in this section are described in detail in the commented Matlab files
"analysis.m", "calibrateTylenol.m", "tylenol_ccf.m", and "RamanloadFile.m" (Appendix
B).
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B. Fitting the Raman spectrum
This section describes the ordinary least squares (OLS) analysis method used by the
Raman clinical instrument during its real-time analysis process (section 3(iv)). It should
be noted, however, that there are many other ways to analyze the Raman spectrum
data, such as principal component analysis (PCA) [1] and partial least squares (PLS) [2].
In the OLS analysis, the tissue Raman spectrum is fitted with linear combinations of
Raman spectra collected from tissue constituents [3, 4, 5]. The combination of
morphological basis spectra fit coefficients that provide the best fit to the acquired
Raman spectrum is a good representation of the tissue composition. In order to
generate such fits to the Raman spectrum, the OLS algorithm searches for the best
linear combination of fit coefficients with the least amount of error. Figure 35 shows
the morphological basis spectra of components known to be present in the artery tissue,
and the result of fitting these components into the Raman spectrum of a calcified artery.
The detailed analysis steps for Raman spectrum fitting are described in the commented
Matlab files "'analysis.m", "ffitRaman.m", "nnfit.m", "chopfit.m", and "calibrate2.m" in
Appendix B.
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Figure 35 (Left column) Components of artery morphological basis spectra. CF: collagen
fibers, CC: cholesterol crystals, CM: calcium mineralization, EL: elastin, AA: adventitial
adipocytes, FC/NC: foam cells / necrotic core, b-CC: beta carotene, SMC: smooth muscle
cells, Hb : hemoglobin. (Right) Raman spectrum of calcified artery tissue fitted with
artery morphological model. The bottom trace is the residual between the Raman
spectrum ("Data") and the morphological model ("Fit").
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5. TROUBLESHOOTING
1. Problem : When attempting to run the Labview program, it displays a message that
Matlab license has expired.
Solution : Renew the Matlab license. If the Matlab license expires, running the
Labview code will generate an error message. The Labview code used in the Raman
clinical instrument also requires Matlab to be operational.
2. Problem : Laser shutter does not respond to control software.
Solution : Check if the shutter control box is turned on. Also, check the back of the
shutter control box and make sure the pulse input cable is properly connected to the
control box pulse input. Finally, make sure that the shutter control box settings are as
described in section 3A and Figure 8 :,
Mode turn key = "STD"; Normally closed ("N.C."); "REMOTE"
3. Problem : No laser power, or laser power is not high enough.
Solution : Check if the shutter is open and the laser power key is switched on. As
described in section 3A and 3B, the laser shutter can be opened by clicking on the
"Raman laser" button in the Labview control software, and the power is controlled by
changing the "Set power(V) 1 settings, up to a maximum of 1.26 V (Figure 19). If this
does not work, check that the control signal (RS-232 serial) cable is properly
connected between the computer and laser. If this does not work either, open the
shutter manually by switching the shutter control box setting from "N.C." to "N.O.",
disconnect the laser control signal cable from the computer and laser, and manually
vary the laser power adjustment knob (Figure 9) to confirm that the laser itself is
functioning properly.
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As described in section 2 and 3A, make sure that the bandpass filter, shutter,
coupling lens unit and delivery fiber are properly aligned so that approximately
100mW is delivered at the distal tip of the probe. If necessary, increase the laser
power by increasing the value under the "Set power(V)" setting to no more than
1.26V in the Labview control software (Figure 19).
4. Problem : No Raman spectrum data is saved.
Solution : Check that the "Save" option is turned on (Figure 22).
5. Problem : Raman spectrum intensity is low.
Solution : Check that at least 100mW is delivered at the distal tip of the probe. If not,
refer to troubleshooting number 3. If the problem persists despite proper laser
power, try increasing the acquisition exposure time (Figure 21).
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APPENDIX A
LABVIEW
Labview VI for Raman spectrum acquisition
A-1
. . ...... --------
APPENDIX B
MATLAB
The following pages in Appendix B describe the Matlab codes used in data acquisition,
processing and analysis. These files are created by the researchers at the MIT Spectroscopy
Laboratory, and they cannot be found in commercial Matlab packages. Consult with the MIT
Spectroscopy Laboratory before distributing in public. Each code can be interpreted with
the help of the comments which follow the "%" sign and are shown in green.
File: analysis.m
% Specify location of data directory
root = '..\your data_directory\;
global alum
global data
global white
global minpix
global maxpix
%%%%%%%%%%% LOAD Calibration Spectra %%%%%%%%%%%%
if exist('wn') ~=1,
[wn] = calibrateTylenol(root);
end
%%%%%%%%%%%%% LOAD data %%%%%%%%%%%%%%%%%
tempRam = dir(strcat(root, '\*your data_file_name*.xis'));
for i1 :length(tempRam),
[Ram(,:)]=Raman loadFIle(root,tempRam(i).name(1:end-4));
end
%%%%%%%%%%%%%% ANALYZE Data %%%%%%%%%%%%%%
% calculate Raman
RamanWn = [686:2:1788];
scallinglin = [48];
for 1=1:size(Ram,1),
if scalinglin(i)~=-1,
[Raman(i,:), FC, morphFC, Fits, Resids, FullDev] = fitRaman(1, Ram(i,:),
scalingin(l));
else
[Raman(i,:), FC, morphFC, Fits, Resids, FullDev] = fitRaman(1,
Ram(i,:));
end
end
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File: calibrateTylenol.m
function [wn] = calibrateTylenol(path);
% This script creates calibrations for clinical Raman data.
% The output is the wavenumber file which is cut to usable range: ("wn")
% The input is the directory where the calibration files are stored: ("path")
% Global variables:
% wn (wavenumber)
% alum (aluminum spectrum)
% white (white light spectrum)
% minpix, maxpix (minimum and maximum pixel numbers)
cf
global wn
wn=D;
acet=D;
global alum
alum=[];
global white
white=D;
global minpix
minpix=D;
global maxpix
maxpix=0];
% Create wavenumber calibration
acetname = dir(strcat(path,'\* Tylenol *.xis'));
acet=load(strcat(path,'\',acetname(11 ).name))';
alumname~dir(strcat(path,'\*Aluminum*.xis'));
alum=load(strcat(path,'\',alumname(1,1).name))';
% Load white light spectrum
whitename~dir(strcat(path,'\*White*.xis'));
white=load(strcat(path,'\',whitename(1,1).name))';
if size(acet,1) > 1,
acet = mean(acet);
end
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if size(alum,1) > 1,
alum = mean(alum);
end
if size(white,1) > 1,
white = mean(white);
end
% Convert 1024 pixels to 1340 pixels
acet_1340 resample (acet, 335, 256);
alum_1340 = resample (alum, 335, 256);
white_1340 = resample (white, 335, 256);
acet_1024 = acet;
alum_1024= alum;
white_1024= white;
acet = acet_1340;
alum = alum_1340;
white = white_1340;
%%%%%%%%%%%%%%%%%%%%
[wn]= tylenol-ccf(acet-alum);
plot(wn,acet-alum);
% Cut wavenumber calibration to usable range
minplx=max(flnd(wn<680));
maxplx=min(find(wn>1800));
if lsempty(maxpix)
maxpix = length(wn);
end
wnzwn(minpix:maxpix);
wn=wn';
% Cut white light and aluminmum spectra
alum=alum(minpix:maxpix);
whitemwhite(minpix:maxpix);
% Normalize and correct data for spectral response
whlte=white/max(white);
alum=alum./white;
alum=alum/max(alum);
alum=smooth(smooth(smooth(smooth(alum))));
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File : tylenolccf.m
function [wn] = tylenol ccf(tyl)
% This program allows one to create tylenol calibration using matlab.
% The input is the Tylenol spectrum: ("tyl")
% The program will ask you to input sixteen peak regions.
% The program will look for the maximum in each region.
% Use the mouse to click on the graph and input the regions.
% Proceed from high to low wavenumbers, in order.
% It is important to make sure there are no cosmic rays in the spectrum.
% The output is a single column of wavenumbers : ("wn")
for i=1:size(tyl,2),
pixels(i)=;
end;
spectrum=[pixels;tyl]';
plot(spectrum(:,1),spectrum(:,2));
[x,y]=ginput(13);
zE";
wzround(x);
%find maxima in peak regions
for i=1:13,
[z(i,2),out]=max(spectrum(w()-5:w(i)+5,2));
z(I,1)=w()+out-6;
end;
c=[1648.4;1561.6;1371.5;1323.9;1236.8;1168.5;1105.5;968.7;857.9;834.5;79
7.2;710.8;651.6];
P=polyfit(z(:,1),c,5);
wn=polyval(P,spectrum(:,1));
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File: RamanloadFile.m
function [data allFrames] = RamanloadFile(masterPath, savename,
varargin);
% This program loads data from in vivo Raman procedures.
% It should be preceded by 'calibrateTylenol.m'
% It averages the data from all frames of a given acquisition.
% Then corrects the data for white light spectral response and cuts
% the data into the usable range. It also normalizes the data by
% the maximum intensity.
global data
global minpix
global maxpix
global white
% Load data
data=load(fullfile(masterPath,strcat(savename,'.xis')));
data = data';
% Convert 1024 pixels to 1340 pixels
data_1340 = resample (data, 335, 256);
data_1024 = data;
data = data 1340;
% Average the data
if Isempty(varargin)
if size(data,1)>1
allFrames = data(1:size(data,1),minpix:maxpix);
data = mean(data(1:size(data,1),minpix:maxpix));
else
data = data(1,minpix:maxpix);
end
else
data = mean(data(varargin(1):varargin(2),minpix:maxpix));
end
% White light division
data~data.Iwhite;
% Normalize data
data=data/max(data);
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File : fitRaman.m
function [allini, FC, morphFC, Fits, Resids, FullDev] = fitRaman(modelType,
data, varargin);
% This program fits the Raman spectrum with the morphological
% basis spectra using OLS, and outputs the fit coefficients, fit spectrum
% and the residual after fitting to the original Raman spectrum data.
global wn
global alum
% Initialize variables
FC=[];
morphFC=D;
Fits=[;
Resids=[;
FullDev=f;
meanFC=;
stdFC=D;
P=D;
callbwn=D;
callbP=D;
devP=D;
normallFC=D;
allFits=D;
allResids=0;
x=1;
y=D;
iter = 100;
%Subtract various weightings of the aluminum background
if isempty(varargin),
for J=1:Iter,
P(J,:)=data-alum*(100-j)/100;
end
else
P = data - alum*(100-varargin(1))/100;
end
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%Remove the fluorescence background
P=chopflt(P,6,1);
%Calibrate the data matrix
if modelType,
load arterymodel.mat;
Model = arterymodel;
[callbP,callbwn]=callbrate2(P, wn, 686, 1788, 2);
else
load breastmodel.mat;
Model = breastmodel;
[calibP,callbwn]=callbrate2(P, wn, 686, 1780, 2);
end
%Renormalize the data
for j=1:slze(calibP,1),
callbP(J,:)=callbP(J,:)/max(calibP(J,:));
end
%Calulate the fit coefficients
FC=nnfit(callbP, Model);
%Correct for oversubtraction of the sapphire spectrum,
oversub = find(FC(:,12) == 0);
Model2 = Model;
if -isempty(oversub),
Model2(12,:)=-Model(12,:);
%recalculate fit coefficients with inverted sapphire spectrum
FC(oversub,:)=nnfit(calibP(oversub,:), Model2);
end
%Caluculate the fits
allFlts=FC*Model;
allFits(oversub,:) = FC(oversub,:)*Model2;
%Calculate residuals
allResids=calibP-allFits;
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%Calculate the standard deviation of the residuals
for J=1:slze(allReslds,1),
devPU)=std(allResds,:));
end
FullDev=devP;
%Find the smallest residual for each exposure
[c,x]=min(devP);
[x, c]
%Normalize the all fit coefficients
normallFC=FC(x,:);
clear FC
for J=1:12,
FC)=100*normallFC(j)/sum(normallFC);
end
if sum(x == oversub) == 0
y = 1;
else
y = -1;
end;
FC(12)=y*FC(12);
%Normalize the morphological model fit coefficients
for j=1:8,
morphFCU)=100*FCU)/sum(FC(1:8));
end
clear allini
alliniucallbP(x,:);
Fits=allFits(x,:);
Reslds=allResids(x,:);
%Plot the data
set(0,'DefaultFigureUnits','normalized');
set(0,'DefaultFigureposition',[0.5 0.4 0.5 0.5]);
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figure(1);
cif
subplot(1,1,1);
plot(callbwn, allini, b');
hold
plot(callbwn, Fits,'r');
plot(callbwn, Reslds+2*min(alllni),'k');
axis([680 1800 min(Resids)+2*min(allini) max(allini)]);
set(gca,'YTick',-1:.25:1);
set(gca,'YTick',-1:.25:1);
xlabel('Raman Shift (cmA{-1))', 'fontsize', 12);
ylabel('Intensity (a.u.)', "fontsize', 12);
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File : nnfit.m
function C = nnfit(SP)
%Uses improved algorithm for non-negative least-squares fitting.
%Based on MATLAB's Isqnonneg command.
%C refers to "concentration", P is the pure spectrum, and S is the mixture
spectrum.
ltnum=size(S,1);
for i=1:ltnum,
CC(:,i)=Isqnonneg(P',S(I,:)');
end;
C=CC';
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File : chopfit.m
function [outspectrum,fit] = chopfit(S, Pnum, Itnum)
% This function chopfits a spectrum S, returning a spectrum output,
% "outspectrum".
% Pnum = order of polynomial
% Itnum = number of passes through the algorithm
% get size of spectrum
NumofPixels = size(S,2);
% generate polynomial
P = poly2(Pnum, NumofPixels);
PP = P'*Inv(P*P')*P;
oldS = S;
for 1=1:ltnum,
fit = S*PP;
% create residual
resid = S - fit;
outspectrum = oldS -fit; %for plotting
% flatten residual; get rid of *positives*
temp = -resid;
temp = setzero(temp);
resid = -temp;
% add fit to the flattened residual; call it S
S = fit + resid;
end;
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File: calibrate2.m
function [S2, wavenums2] = calibrate2(S, wavenums, wn-start, wn-end,
binsize)
% This function takes spectral data S and redistributes
% the signal counts into bins of equal wavenumber spacing.
% (This is useful for our CCDs because the dispersion is
% not linear in wavenumber, yet we sometimes want to compare
% data taken at different excitations. In order to compare two
% such spectra quantitatively, we need to give them a common
% set of bins; otherwise, the data points don't perfectly
% overlap.
% Inputs: spectra: S (each spectrum occupying a ROW)
% associated wavenumber calibration: wavenums
% starting wavenumber for output: wn start
% ending wavenumber for output: wnend
% bin size (in cm-1): binsize
% Outputs: spectra S2
% associated wavenumbers : wavenums2
% We need to repartition the data into integral wavenumber bins
% of reasonable size and do it in a logical way so the lineshapes aren't
% altered.
% Calculate the width, in wavenumbers, of each pixel:
% Use the convention that the wavenumbers listed in
% 'wavenums' are at (near) the MIDDLE of each bin;
% i.e, the wavenumber bin i extends from
% wavenums(i)-Widths(i-1)/2 to wavenums(i)+Widths(i)/2,
% except for the first one, which extends from
% wavenums(1) +/- Widths(1)/2, and the last one, which extends from
% wavenums(N) +/- Widths(N-I)/2.
sz-size(wavenums,2);
Widths = wavenums(2:sz)-wavenums(1:sz-1);
%% note: for N pixels, there are N-1 widths
%% --first pixel:
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PixelWidth = Widths(1);
LeftEdgeValue = wavenums(1)-Widths(1)/2;
%% --middle pixels:
PlxelWIdth = [PixelWidth, Widths(2:sz-1)/2 + Widths(1:sz-2)/2];
LeftEdgeValue = [LeftEdgeValue, wavenums(2:sz-1)-Widths(1:sz-2)/2];
%% --end pixel
PixelWidth = [PixelWidth, Widths(sz-1)];
LeftEdgeValue = [LeftEdgeValue, wavenums(sz) + Widths(sz-1)/2];
NumofSpectra = size(S,1);
%% set up a loop to create the output spectra
I = 0;
S2 = ];
for CenterValue = wnstart:binsize:wnend,
I = 1+1; % index for writing new arrays
LeftValue = CenterValue - binsize/2;
RightValue =CenterValue + binsize/2;
%% use the whichbin.m function to do the finding of left and right bin....
LeftBin = whichbin(LeftEdgeValue, LeftValue);
RightBin= whichbin(LeftEdgeValue,RightValue);
%% Are the left and right bins the same?
if LeftBin=RightBin
Counts = (S(:,LeftBin)/PIxeIWIdth(LeftBin)) * binsize;
%% If not, sum left fraction, right fraction, and any middle bins
else
LeftBinFraction = LeftEdgeValue(LeftBin+1) - LeftValue;
Counts = (S(:,LeftBin)/PixelWidth(LeftBin)) * LeftBinFraction;
RightBinFraction = RightValue - LeftEdgeValue(RightBin);
Counts = Counts + (S(:,RlghtBin)/PlxelWidth(RightBin)) * RightBinFraction;
for MiddleBin = LeftBin+1:RightBin - 1,
Counts = Counts + S(:,MiddleBin);
end; % of for loop
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end; % of if/else statement
%% append Counts to the reconstituted spectral matrix
82 = [S2, Counts];
%% loop back
if (rem(,30)=0)
fprintf('\nStill working; Nu = %.1f', CenterValue');
end; %of if statement for user update info
end; %of for CenterValue loop
%% create the corresponding wavenumber calibration for these data
wavenums2 = wnstart:binsize:wnend;
%% output of this should be the spectral matrix S2, binned according to
%% the desired wavenumber spacing, and the corresponding wavenumber
%% calibration 'wavenums'.
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Matlab files needed for running Raman clinical
instrument Labview program
File: MMSRamanSpectraProcessing.m (Used by Labview)
%This program specifies the date and time stamps used in the filenames
% where data is saved.
data = dataRaw;
Indices = [";
for I=1:size(data,1),
if data(i,:) ~= zeros(1,size(data,2)),
indices = [indices, 1];
end
end
data = data(indices,:)';
% dataMean = mean(data')';
% dataStd = std(data')';
if ((saveFile || RT) && acquire),
savename = strcat(datestr(now,'mm.dd.yyyy.HH.MM.SS'),',filename);
save(fullfile(masterPath,strcat(savename,'.xis')),'data','-ascii','-tabs');
% save(fullfile(masterPath,strcat(savename,'_Stdev.xis')),'dataStd','-
ascii','-tabs');
End
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File: RamanloadFile.m (Used by Labview)
function [data allFrames] = RamanloadFile(masterPath, savename,
varargin);
%This program loads data from in vivo Raman procedures.
%It should be preceeded by calibrateTylenol.m
%It averages the data from all frames of a given acquisition.
%Then corrects the data for white light spectral response and cuts
%the data into the usable range. It also normalizes the data by
%the maximum intensity.
global data
global minpix
global maxpix
global white
%Load in vivo data
data=load(fulfile(masterPath,strcat(savename,'.xis")));
data = data';
%Average the data
if isempty(varargin)
if size(data,1)>1
allFrames = data(1 :size(data,1),minpix:maxpix);
datamean(data(1:slze(data,1),minpix:maxpix));
else
data=data(1,minpix:maxplx);
end
else
data=mean(data(varargin(1):varargin(2),minpix:maxpix));
end
%White light devision
data=data./white;
%Normalize data
data=data/max(data);
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File: Ramanclinfit.m (Used by Labview)
% This function applies the diagnostic algorithm to the fit coefficients
function [allini, FC, morphFC, Fits, Resids, FullDev] =
Raman_clinfit(modelType);
global wn
global alum
global data
FC=D;
morphFC=D;
Fits=D;
Resids=D;
FullDev=D;
meanFC=D;
stdFC=[;
P=D;
callbwn=[];
callbP=[;
devP=D;
normallFC=f;
allFits=0;
allResids=D;
x=D;
y=D;
iter = 100;
%Subtract various weightings of the aluminum background
for j=1:iter,
P(j,:)=data-alum/(2*0.1 *j);
end;
%Remove the fluorescence background
Pzchopfit(P,6,1);
%Calibrate the data matrix
if modelType,
load arterymodel.mat;
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Model = arterymodel;
[callbP,callbwn]=calibrate2(P, wn, 686, 1788, 2);
else
load breastmodel.mat;
Model = breastmodel;
[callbP,callbwn]=callbrate2(P, wn, 686, 1780, 2);
end
%Renormalize the data
for J.1:Iter,
calibPU,:)=callbP,:)/max(callbP,:));
end
%Calulate the fit coefficients
FC=nnfit(callbP, Model);
%Correct for oversubtraction of the sapphire spectrum,
if FC(:,12)=0
Model(12,:)=-Model(12,:);
y=-1;
%recalculate fit coefficients with inverted sapphire spectrum
FC=nnfit(callbP, Model);
else
y=1 ;
end
%Caluculate the fits
allFits= FC*Model;
%Calculate residuals
allResids=callbP-allFits;
%Calculate the standard deviation of the residuals
for j=1:iter
devP)=std(allResids,:));
end
FullDevdevP;
%Find the smallest residual for each exposure
x=flnd(devP==mln(devP));
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%Normalize the all fit coefficients
normallFC=FC(x,:);
clear FC
for j=1:12,
FCU)=100*normallFC)/sum(normallFC);
end
FC(12)=y*FC(12);
%Normalize the morphological model fit coefficients
for j=1:8,
morphFC)=100*normallFCU)/sum(normallFC(1:8));
end
clear allini
aillnl=calbP(x,:);
Flts~allFts(x,:);
Resids=allResids(x,:);
%Plot the data
set(O,'DefaultFigureUnits','normalized");
set(0,'DefaultFigureposition',[0.5 0.4 0.5 0.5]);
figure(1);
clf;
subplot(1,1,1);
plot(calibwn, allini, 'b');
hold
plot(calibwn, Fits,'r);
plot(callbwn, Resids+2*min(allinl),'k');
axis([680 1800 min(Resids)+2*min(allini) max(allini)]);
set(gca,'YTick',-1:.25:1);
set(gca,'YTick',-1:.25:1);
xlabel('Raman Shift (cmA{1))", 'fontsize', 12);
ylabel('Intensity (a.u.)', 'fontsize', 12);
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File: Ramandiagnose.m (Used by Labview)
function D = Raman.diagnose(FC, modelType)
if modelType,
sgdlagnose heme(FC);
else
diagnose-breast(FC);
end
File: sgdiagnoseheme.m (Used by Labview)
function f = sgdlagnosebheme(FC);
% This function applies the diagnostic algorithm to the fit coefficients
morphFC=D;
morphFC=[FC(1:8)1;
morphFC=100*(morphFC/sum(morphFC));
nobetaFC=D;
nocmFC=D;
%Remover beta Carotene and re-normalize the fit coefficients.
nobetaFC=[morphFC(1:6),morphFC(8)];
nobetaFC=nobetaFC/sum(nobetaFC);
%Extract calcium mineralization.
cm=nobetaFC(3);
%Remove calcification and re-normalize the fit coefficients.
nocmFC=[nobetaFC(1:2),nobetaFC(4:7)];
nocmFC=nocmFC/sum(nocmFC);
%Extract cholesterol crystal + foam cell/nacrotic core.
ccfc~nocmFC(2)+nocmFC(5);
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%Plot
set(O,'DefaultFigureUnits','normalized');
set(O,'DefaultFigureposition',[0.01 0.4 0.47 0.5]);
figure(2);
clf;
%Plot the normal or calcified vs. non-calcified plaque line.
plot([(0.07/0.30) 1]J,[0 0.23]);
hold;
%Plot the normal vs. calcified plaque line.
plot([(0.24/0.79) 01,[(0.17-0.48*(0.24/0.79)) 0.17]);
%Plot diagnosis.
plot(ccfc,cm,'rd','MarkerSize',12,'MarkerFaceColor','r');
if cm<(-0.07+0.30*ccfc)
tltle('Diagnosis: Non-Calcified Plaque','fontsize', 14);
elseif cm<(0.17-0.48*ccfc)
title('Diagnosis: Non-Atherosclerotic Tissue','fontsize', 14);
else
title('Diagnosis: Calcified Plaque','fontsize', 14);
end
axis([0 1 0 1]);
xiabel('Cholesterol+FCNC', 'fontsize', 12);
ylabel('Calcification', 'fontsize', 12);
%Display fit coefficients
set(0,'DefaultFigureUnits','normalized');
set(0,'DefaultFigureposition',[0.5 0.03 0.49 0.15]);
figure(3);
clf;
axis([0 1 0 1]);
axis off;
text(0,1 ,['Collagen Fibers:' '' num2str(morphFC(1))],'fontsize',12);
text(0,0.75,['Cholesterol Crystals:"' num2str(morphFC(2))],'fontsize',12);
text(0,0.5j'Calcified Minerals:" ' num2str(morphFC(3))],'fontsize',12);
text(0,0.25,['Elastic Lamina:' ' ' num2str(morphFC(4))],'fontsize',12);
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text(0.5,1,['Adventitial Adipocytes:' ' num2str(morphFC(5))],'fontsize',12);
text(O.5,0.75,['Foam Cells/Necrotic Core:"'
num2str(morphFC(6))],'fontsize',12);
text(0.5,0.5,['Beta Carotene:' ' ' num2str(morphFC(7))],'fontsize',1 2);
text(O.5,0.25,['Smooth Muscle Cells:' ' ' num2str(morphFC(8))],'fontsize',12);
text(0,0,['Hemoglobin:' ' ' num2str(FC(9))],'fontsize',1 2);
set(O,'DefaultFigureUnits','normalized');
set(O,'DefaultFigureposition',[O.5 0.4 0.5 0.5]);
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File: diagnosebreast.m (Used by Labview)
function f = diagnose breast(FC);
%Function applies the diagnostic algorithm to the fit coefficients
% and displays the diagnosis on the screen.
morphFC = FC(1:9);
morphFC = morphFC/sum(morphFC);
%Plot
set(0,'DefaultFigureUnits','normalized');
set(O,'DefaultFigureposition',[0.01 0.4 0.47 0.5]);
figure(2);
clf;
%FC(Col)=-0.70*FC(Fat)+0.55
plot([O 0.55/.7],[0.55 0]);
hold on;
%FC(Coll)-0.06*FC(Fat)+0.10
plot([0.45/.64 I],[-.06*.45/.64+.1 -.06+.1]);
%FC(Fat)=0.2
plot([0.02 0.02J0 -.70*.02+.55])
%Plot diagnosis.
plot(morphFC(6),morphFC(7),'rd','MarkerSize',12,'MarkerFaceColor','r);
if FC(6)<0.02
x=0;
else
x=1;
end
if FC(7)<(-0.06*FC(6)+0.10)
y=0;
else
y=I;
end
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if FC(7)<(-0.70*FC(6)+0.55)
z=O;
else
Z=1;
end
%checking where point lies on graph relative to all-in-one diagnostic
%algorithm lines
%if point is in fibroendoma region
if and((x=0),(z==0))==1
title('Diagnosis: Fibroendoma','fontsize', 14);
end
%if point is in fibrocystic region
if and(y,z)=1
title('Diagnosis: Fibrocystic Disease','fontsize', 14);
end
%if point is in normal region
if and((y==O),(z==1))==1,
title('Diagnosis: Normal','fontsize', 14);
end
%if point is in infiltrating carcinoma region
if and((x==1),(z==0))==1,
title('Diagnosis: Infiltrating Carcinoma,'fontsize',14);
end
axis([O 1 0 1]);
xlabel('Fat', 'fontsize', 12);
ylabel('Collagen', 'fontsize', 12);
%Display fit coefficients
set(O,'DefaultFigureUnits','normalized');
set(0,'DefaultFigureposition',[0.5 0.03 0.49 0.15]);
figure(3);
clf;
morphFC = morphFC *100;
axis([0 1 0 1]);
axis off;
text(0,1,['Calcium Oxalate:' num2str(morphFC(1 ))],'fontsize',12);
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text(O.75,['Calcium Hydroxyapatite:'
num2str(morphFC(2))],'fontsize',12);
text(0,0.5,['Cholesterol-like:' ' ' num2str(morphFC(3))],'fontsize',12);
text(0,0.25,['Water.' 'num2str(morphFC(4))],'fontsize',12);
text(O.65,1,['Beta-Carotene:' ' ' num2str(morphFC(5))],'fontsize',12);
text(O.65,0.75,['Fat: ' num2str(morphFC(6))],'fontsize',12);
text(O.65,0.5,['Collagen:" "' num2str(morphFC(7))],'fontsize',12);
text(O.65,0.25,['Cell Nucleus:' ' num2str(morphFC(8))],'fontsize',12);
text(0,0,['Epithelial Cell Cytoplasm:' ' ' num2str(morphFC(9))],'fontsize",12);
set(O,'DefaultFigureUnits','normalized');
set(O,'DefaultFigureposition',[O.5 0.4 0.5 0.5]);
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